UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended		~~September 30, 2019~~March 31, 2020
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 001-14956

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)



British Columbia	,	Canada	98-0448205
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant’s telephone number, including area code)



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, No Par Value	BHC	New York Stock Exchange	,	Toronto Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐	Smaller reporting company	☐	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common shares, no par value — ~~352,431,217~~354,727,444 shares outstanding as of ~~October 31, 2019.~~April 30, 2020.

BAUSCH HEALTH COMPANIES INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER 30, 2019~~MARCH 31, 2020

INDEX



Part I.	Financial Information
Item 1.	Consolidated Financial Statements (unaudited)
	Consolidated Balance Sheets as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019	1
	Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	2
	Consolidated Statements of Comprehensive Loss for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	3
	Consolidated Statements of Shareholders' Equity for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	4
	Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	5
	Notes to the Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4239
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	8777
Item 4.	Controls and Procedures	8878
Part II.	Other Information
Item 1.	Legal Proceedings	8979
Item 1A.	Risk Factors	8979
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	8980
Item 3.	Defaults Upon Senior Securities	8980
Item 4.	Mine Safety Disclosures	8980
Item 5.	Other Information	8980
Item 6.	Exhibits	8981
Signatures		9082

BAUSCH HEALTH COMPANIES INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER 30, 2019~~MARCH 31, 2020

Introductory Note

Except where the context otherwise requires, all references in this Quarterly Report on Form 10-Q for the quarterly period ended ~~September 30, 2019~~March 31, 2020 (this “Form 10-Q”) to the “Company”, “we”, “us”, “our” or similar words or phrases are to Bausch Health Companies Inc. and its subsidiaries, taken together. In this Form 10-Q, references to “$” are to United States (“U.S.”) dollars and references to “€” are to euros. Unless otherwise indicated, the statistical and financial data contained in this Form 10-Q are presented as of ~~September 30, 2019.~~March 31, 2020.

Forward-Looking Statements

Caution regarding forward-looking information and statements and “Safe-Harbor” statements under the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws:

To the extent any statements made in this Form 10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, “forward-looking statements”).

These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our ~~products, including the Significant Seven;~~products; anticipated growth in our Ortho Dermatologics business; expected research and development ("R&D") and marketing ~~spend, including in connection with the promotion of the Significant Seven;~~spend; our expected primary cash and working capital requirements for ~~2019~~2020 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement (the "Restated Credit Agreement"), and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; ~~and~~ our impairment assessments, including the assumptions used therein and the results ~~thereof.~~thereof; and the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and the Company’s planned actions and responses to this pandemic.

Forward-looking statements can generally be identified by the use of words such as “believe”, “anticipate”, “expect”, “intend”, “estimate”, “plan”, “continue”, “will”, “may”, “could”, “would”, “should”, “target”, “potential”, “opportunity”, “designed”, “create”, “predict”, “project”, “forecast”, “seek”, “strive”, “ongoing” or “increase” and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form 10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the following:

but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);

the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including pending investigations by the U.S. Attorney's Office for the District of Massachusetts and the U.S. Attorney's Office for the Southern District of New York, the pending investigations by the U.S. Securities and Exchange Commission (the “SEC”) of the Company, the investigation order issued by the Company from the Autorité des marchés financiers (the “AMF”) (the Company’s principal securities regulator in Canada), a number of pending ~~putative~~securities litigations (including certain pending opt-out actions in the U.S. (related to the recently settled securities class action, ~~litigations in~~(which is subject to final court approval, and remains subject to the risk and uncertainty that the U.S. ~~(including~~

~~related opt-out actions)~~District Court for the District of New Jersey may not approve the $1,210 million settlement agreement)) and the pending class action litigation in Canada ~~(including~~and related opt-out actions) and purported class actions under the federal RICO statute and other claims, investigations or proceedings that may be initiated or that may be asserted;

potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;

the past and ongoing scrutiny of our legacy business practices, including with respect to pricing (including the investigations by the U.S. Attorney's Offices for the District of Massachusetts and the Southern District of New York), and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof;

pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee’s commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits, or any future pricing actions we may take following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);

legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);

ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S. Food and Drug Administration (the "FDA") and the results thereof;

actions by the FDA or other regulatory authorities with respect to our products or facilities;

our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;

our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;

any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;

any delay in the filing of any future financial statements or other filings and any default under the terms of our senior notes indentures or Restated Credit Agreement as a result of such delays;

any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;

iii

and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;

changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;

•

the uncertainties associated with the acquisition and launch of new products (such as our recently launched Bryhali^®, Duobrii^® and Ocuvite^® Eye Performance products), including, but not limited to, our ability to provide the time, resources, expertise and costs required for the commercial launch of new products, the acceptance and demand for new pharmaceutical products, and the impact of competitive products and pricing, which could lead to material impairment charges;

our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;

our ability to retain, motivate and recruit executives and other key employees;

~~iii~~

our ability to implement effective succession planning for our executives and key employees;

•

factors impacting our ability to achieve anticipated growth in our Ortho Dermatologics business, including the success of recently launched products (such as Bryhali^® and Duobrii^®), the ability to successfully implement and operate ~~Dermatology.com,~~ our new cash-pay prescription program for certain of our Ortho Dermatologics branded products, and the ability of such program to achieve the anticipated goals respecting patient access and fulfillment, the approval of pending and pipeline products (and the timing of such approvals), expected geographic expansion, changes in estimates on market potential for dermatology products and continued investment in and success of our sales force;

factors impacting our ability to achieve anticipated revenues for our ~~Significant Seven~~ products, including changes in anticipated marketing spend on such products and launch of competing products;

the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;

our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;

our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, ~~and~~ limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other ~~indebtedness;~~indebtedness, and the impacts of the COVID-19 pandemic;

the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices (including as it relates to our current relationship with Walgreen Co. ("Walgreens")) may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;

the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;

the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;

our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;

the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company, including the impact to the Company of our former relationship with Philidor and any alleged legal or contractual non-compliance by Philidor;

created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);

adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do business;

the impact of the United States-Mexico-Canada Agreement (“USMCA”) and any potential changes to other trade agreements;

the final outcome and impact of Brexit negotiations;

the trade conflict between the United States and China;

•

our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the recent filing by ~~Sandoz~~Norwich Pharmaceuticals Inc. (“Norwich”) of its Abbreviated New Drug Application (“ANDA”) for Xifaxan^® (rifaximin) 550 mg tablets and the Company’s related lawsuit filed against Norwich in connection therewith);

the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;

our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;

any additional divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;

the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;

our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;

our ability to obtain components, raw materials or finished products supplied by third parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;

the disruption of delivery of our products and the routine flow of manufactured goods;

economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;

interest rate risks associated with our floating rate debt borrowings;

our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreens;


•	~~our ability to effectively promote our own products and those of our co-promotion partners, such as Doptelet~~^® ~~(Dova Pharmaceuticals, Inc.);~~ our ability to effectively promote our own products and those of our co-promotion partners;

the success of our fulfillment arrangements with Walgreens, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;

the acceptance and success of our new cash-pay prescription program for certain of our Ortho Dermatologics branded products;

our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;

the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the market;

the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;

the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;

the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of others;

the results of continuing safety and efficacy studies by industry and government agencies;

the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;

the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;

the seasonality of sales of certain of our products;


•	declines in the pricing and sales volume of certain of our products ~~or the products that we co-promote (such as Doptelet~~^®) that are distributed or marketed by third parties, over which we have no or limited control;

compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care “fraud and abuse” laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;

the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Health Care Reform Act”) and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;

the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its business and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;

the impact of changes in federal laws and policy under consideration by the Trump administration and Congress, including the effect that such changes will have on fiscal and tax policies, the potential revision of all or portions of the Health Care Reform Act, international trade agreements and policies and policy efforts designed to reduce patient out-of-pocket costs for medicines (which could result in new mandatory rebates and discounts or other pricing restrictions);

illegal distribution or sale of counterfeit versions of our products;

interruptions, breakdowns or breaches in our information technology systems; and

risks in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed on February ~~20, 2019,~~19, 2020, risks under 1A. “Risk Factors” of Part II of this Form 10-Q and risks detailed from time to time in our other filings with the SEC and the Canadian Securities Administrators (the “CSA”), as well as our ability to anticipate and manage the risks associated with the foregoing.

Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed on February ~~20, 2019,~~19, 2020, under Item 1A. “Risk Factors”, under 1A. “Risk Factors” of Part II of this Form 10-Q and in the Company’s other filings with the SEC and CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing

list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.

vivii

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

BAUSCH HEALTH COMPANIES INC.

CONSOLIDATED BALANCE SHEETS

(in millions, except share amounts)

(Unaudited)


	September 30, 2019			December 31, 2018			March 31, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	825		$	721		$	912		$	3,243
Restricted cash	2			2			1,011			1
Trade receivables, net	1,747			1,865			1,712			1,839
Inventories, net	1,100			934			1,124			1,107
Prepaid expenses and other current assets	631			689			745			779
Total current assets	4,305			4,211			5,504			6,969
Property, plant and equipment, net	1,390			1,353			1,450			1,466
Intangible assets, net	10,650			12,001			9,726			10,201
Goodwill	13,052			13,142			13,034			13,126
Deferred tax assets, net	1,868			1,676			1,740			1,690
Other non-current assets	402			109			411			411
Total assets	$	31,667		$	32,492		$	31,865		$	33,863
Liabilities
Current liabilities:
Accounts payable	$	437		$	411		$	444		$	503
Accrued and other current liabilities	3,198			3,197			4,438			4,511
Current portion of long-term debt and other	100			228			4			1,234
Total current liabilities	3,735			3,836			4,886			6,248
Acquisition-related contingent consideration	267			298			268			262
Non-current portion of long-term debt	23,466			24,077			24,424			24,661
Deferred tax liabilities, net	879			885			690			705
Other non-current liabilities	760			581			807			851
Total liabilities	29,107			29,677			31,075			32,727
Commitments and contingencies (Note 19)
Equity
Common shares, no par value, unlimited shares authorized, 352,387,430 and 349,871,102 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	10,168			10,121
Common shares, no par value, unlimited shares authorized, 354,579,990 and 352,562,636 issued and outstanding at March 31, 2020 and December 31, 2019, respectively							10,209			10,172
Additional paid-in capital	406			413			396			429
Accumulated deficit	(5,936		)	(5,664		)	(7,605		)	(7,452		)
Accumulated other comprehensive loss	(2,156		)	(2,137		)	(2,281		)	(2,086		)
Total Bausch Health Companies Inc. shareholders’ equity	2,482			2,733			719			1,063
Noncontrolling interest	78			82			71			73
Total equity	2,560			2,815			790			1,136
Total liabilities and equity	$	31,667		$	32,492		$	31,865		$	33,863

The accompanying notes are an integral part of these consolidated financial statements.

BAUSCH HEALTH COMPANIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2019			2018			2019			2018			2020			2019
Revenues
Product sales	$	2,180		$	2,108		$	6,291		$	6,173		$	1,986		$	1,989
Other revenues	29			28			86			86			26			27
	2,209			2,136			6,377			6,259			2,012			2,016
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	571			573			1,675			1,717			505			524
Cost of other revenues	13			9			40			32			14			13
Selling, general and administrative	648			614			1,886			1,847			633			587
Research and development	123			107			357			293			122			117
Amortization of intangible assets	475			658			1,452			2,142			436			489
Goodwill impairments	—			—			—			2,213
Asset impairments	33			89			49			434			14			3
Restructuring and integration costs	4			3			28			16			4			20
Acquisition-related contingent consideration	3			(19		)	2			(23		)	13			(21		)
Other expense (income), net	10			(15		)	15			(3		)	23			(3		)
	1,880			2,019			5,504			8,668			1,764			1,729
Operating income (loss)	329			117			873			(2,409		)
Operating income													248			287
Interest income	2			3			9			9			7			4
Interest expense	(406		)	(420		)	(1,221		)	(1,271		)	(396		)	(406		)
Loss on extinguishment of debt	—			—			(40		)	(75		)	(24		)	(7		)
Foreign exchange and other	9			—			12			18			(13		)	—
Loss before benefit from (provision for) income taxes	(66		)	(300		)	(367		)	(3,728		)
Benefit from (provision for) income taxes	18			(51		)	101			(74		)
Loss before benefit from income taxes													(178		)	(122		)
Benefit from income taxes													26			74
Net loss	(48		)	(351		)	(266		)	(3,802		)	(152		)	(48		)
Net (income) loss attributable to noncontrolling interest	(1		)	1			(6		)	(2		)
Net income attributable to noncontrolling interest													—			(4		)
Net loss attributable to Bausch Health Companies Inc.	$	(49	)	$	(350	)	$	(272	)	$	(3,804	)	$	(152	)	$	(52	)

Basic and diluted loss per share attributable to Bausch Health Companies Inc.	$	(0.14	)	$	(1.00	)	$	(0.77	)	$	(10.83	)	$	(0.43	)	$	(0.15	)

Basic and diluted weighted-average common shares	352.4			351.5			351.9			351.1			353.4			351.3

The accompanying notes are an integral part of these consolidated financial statements.

BAUSCH HEALTH COMPANIES INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in millions)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2019			2018			2019			2018			2020			2019
Net loss	$	(48	)	$	(351	)	$	(266	)	$	(3,802	)	$	(152	)	$	(48	)
Other comprehensive (loss) income
Foreign currency translation adjustment	(97		)	13			(20		)	(159		)	(192		)	21
Pension and postretirement benefit plan adjustments, net of income taxes	—			(1		)	(1		)	(2		)	(5		)	—
Other comprehensive (loss) income	(97		)	12			(21		)	(161		)	(197		)	21
Comprehensive loss	(145		)	(339		)	(287		)	(3,963		)	(349		)	(27		)
Comprehensive loss (income) attributable to noncontrolling interest	1			4			(4		)	2			2			(4		)
Comprehensive loss attributable to Bausch Health Companies Inc.	$	(144	)	$	(335	)	$	(291	)	$	(3,961	)	$	(347	)	$	(31	)

The accompanying notes are an integral part of these consolidated financial statements.

BAUSCH HEALTH COMPANIES INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in millions)

(Unaudited)


	Bausch Health Companies Inc. Shareholders' Equity																					Bausch Health Companies Inc. Shareholders' Equity
	Common Shares									Accumulated Other Comprehensive Loss			Bausch Health Companies Inc. Shareholders' Equity									Common Shares									Accumulated Other Comprehensive Loss			Bausch Health Companies Inc. Shareholders' Equity
	Shares	Amount		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Bausch Health Companies Inc. Shareholders' Equity			Noncontrolling Interest			Total Equity			Shares	Amount		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Bausch Health Companies Inc. Shareholders' Equity			Noncontrolling Interest			Total Equity

	Three Months Ended September 30, 2019																					Three Months Ended March 31, 2020
Balances, July 1, 2019	352.2	$	10,165	$	384		$	(5,887	)	$	(2,061	)	$	2,601		$	87		$	2,688
Balances, January 1, 2020																						352.6	$	10,172	$	429		$	(7,452	)	$	(2,086	)	$	1,063		$	73		$	1,136
Effect of application of new accounting standard: financial instruments - credit losses																						—	—		—			(1		)	—			(1		)	—			(1		)
Common shares issued under share-based compensation plans	0.2	3		(3		)	—			—			—			—			—			2.0	37		(36		)	—			—			1			—			1
Share-based compensation	—	—		26			—			—			26			—			26			—	—		27			—			—			27			—			27
Employee withholding taxes related to share-based awards	—	—		(1		)	—			—			(1		)	—			(1		)	—	—		(24		)	—			—			(24		)	—			(24		)
Noncontrolling interest distributions	—	—		—			—			—			—			(8		)	(8		)
Net (loss) income	—	—		—			(49		)	—			(49		)	1			(48		)
Net loss																						—	—		—			(152		)	—			(152		)	—			(152		)
Other comprehensive loss	—	—		—			—			(95		)	(95		)	(2		)	(97		)	—	—		—			—			(195		)	(195		)	(2		)	(197		)
Balances, September 30, 2019	352.4	$	10,168	$	406		$	(5,936	)	$	(2,156	)	$	2,482		$	78		$	2,560

	Three Months Ended September 30, 2018
Balances, July 1, 2018	349.6	$	10,114	$	391		$	(4,970	)	$	(2,068	)	$	3,467		$	91		$	3,558
Common shares issued under share-based compensation plans	0.2	3		(3		)	—			—			—			—			—
Share-based compensation	—	—		22			—			—			22			—			22
Employee withholding taxes related to share-based awards	—	—		(1		)	—			—			(1		)	—			(1		)
Noncontrolling interest distributions	—	—		—			—			—			—			(3		)	(3		)
Net loss	—	—		—			(350		)	—			(350		)	(1		)	(351		)
Other comprehensive income (loss)	—	—		—			—			15			15			(3		)	12
Balances, September 30, 2018	349.8	$	10,117	$	409		$	(5,320	)	$	(2,053	)	$	3,153		$	84		$	3,237
Balances, March 31, 2020																						354.6	$	10,209	$	396		$	(7,605	)	$	(2,281	)	$	719		$	71		$	790

	Nine Months Ended September 30, 2019																					Three Months Ended March 31, 2019
Balances, January 1, 2019	349.9	$	10,121	$	413		$	(5,664	)	$	(2,137	)	$	2,733		$	82		$	2,815		349.9	$	10,121	$	413		$	(5,664	)	$	(2,137	)	$	2,733		$	82		$	2,815
Common shares issued under share-based compensation plans	2.5	47		(44		)	—			—			3			—			3			2.0	30		(29		)	—			—			1			—			1
Share-based compensation	—	—		77			—			—			77			—			77			—	—		24			—			—			24			—			24
Employee withholding taxes related to share-based awards	—	—		(40		)	—			—			(40		)	—			(40		)	—	—		(34		)	—			—			(34		)	—			(34		)
Noncontrolling interest distributions	—	—		—			—			—			—			(8		)	(8		)
Net (loss) income	—	—		—			(272		)	—			(272		)	6			(266		)	—	—		—			(52		)	—			(52		)	4			(48		)
Other comprehensive loss	—	—		—			—			(19		)	(19		)	(2		)	(21		)
Balances, September 30, 2019	352.4	$	10,168	$	406		$	(5,936	)	$	(2,156	)	$	2,482		$	78		$	2,560

	Nine Months Ended September 30, 2018
Balances, January 1, 2018	348.7	$	10,090	$	380		$	(2,725	)	$	(1,896	)	$	5,849		$	95		$	5,944
Effect of application of new accounting standard: Income taxes	—	—		—			1,209			—			1,209			—			1,209
Common shares issued under share-based compensation plans	1.1	27		(26		)	—			—			1			—			1
Share-based compensation	—	—		65			—			—			65			—			65
Employee withholding taxes related to share-based awards	—	—		(10		)	—			—			(10		)	—			(10		)
Noncontrolling interest distributions	—	—		—			—			—			—			(9		)	(9		)
Net (loss) income	—	—		—			(3,804		)	—			(3,804		)	2			(3,802		)
Other comprehensive loss	—	—		—			—			(157		)	(157		)	(4		)	(161		)
Balances, September 30, 2018	349.8	$	10,117	$	409		$	(5,320	)	$	(2,053	)	$	3,153		$	84		$	3,237
Other comprehensive income																						—	—		—			—			21			21			—			21
Balances, March 31, 2019																						351.9	$	10,151	$	374		$	(5,716	)	$	(2,116	)	$	2,693		$	86		$	2,779

The accompanying notes are an integral part of these consolidated financial statements.

BAUSCH HEALTH COMPANIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(Unaudited)


	Nine Months Ended September 30,						Three Months Ended March 31,
	2019			2018			2020			2019
Cash Flows From Operating Activities
Net loss	$	(266	)	$	(3,802	)	$	(152	)	$	(48	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization of intangible assets	1,583			2,273			481			532
Amortization and write-off of debt premiums, discounts and issuance costs	49			62			15			17
Asset impairments	49			434			14			3
Acquisition-related contingent consideration	2			(23		)	13			(21		)
Allowances for losses on trade receivable and inventories	46			48			15			13
Deferred income taxes	(233		)	(2		)	(70		)	(116		)
(Gain) loss on sale of assets	(10		)	26
Additions (reductions) to accrued legal settlements	12			(30		)
Gain on sale of assets							(1		)	(10		)
Additions to accrued legal settlements							23			2
Payments of accrued legal settlements	(4		)	(222		)	(3		)	(1		)
Goodwill impairments	—			2,213
Share-based compensation	77			65			27			24
Foreign exchange loss (gain)	8			(16		)
Foreign exchange loss							16			—
Interest expense on cross-currency swaps							(6		)	—
Loss on extinguishment of debt	40			75			24			7
Payments of contingent consideration adjustments, including accretion	(1		)	(2		)
Other	27			(19		)	(7		)	9
Changes in operating assets and liabilities:
Trade receivables	110			56			69			89
Inventories	(205		)	(8		)	(94		)	(68		)
Prepaid expenses and other current assets	16			(53		)	(18		)	(15		)
Accounts payable, accrued and other liabilities	(33		)	107			(85		)	(4		)
Net cash provided by operating activities	1,267			1,182			261			413

Cash Flows From Investing Activities
Acquisition of businesses, net of cash acquired	(180		)	5			—			(180		)
Payments for intangible and other assets	(1		)	(76		)
Purchases of property, plant and equipment	(192		)	(95		)	(72		)	(47		)
Purchases of marketable securities	(8		)	(5		)	(2		)	(2		)
Proceeds from sale of marketable securities	3			5			2			1
Proceeds from sale of assets and businesses, net of costs to sell	44			32			21			25
Interest settlements from cross-currency swaps							11			—
Net cash used in investing activities	(334		)	(134		)	(40		)	(203		)

Cash Flows From Financing Activities
Net proceeds from the issuances of long-term debt	3,238			7,471
Issuance of long-term debt, net of discounts							(3		)	1,514
Repayments of long-term debt	(3,956		)	(8,200		)	(1,459		)	(1,621		)
Proceeds from the issuances of short-term debt	12			—
Repayments of short-term debt	(12		)	(1		)
Payments of employee withholding taxes related to share-based awards	(40		)	(10		)	(24		)	(34		)
Payments of acquisition-related contingent consideration	(27		)	(26		)	(17		)	(9		)
Payments of financing costs	(26		)	(62		)	(18		)	(1		)
Payments of deferred consideration	—			(18		)
Other	(1		)	(5		)	—			1
Net cash used in financing activities	(812		)	(851		)	(1,521		)	(150		)
Effect of exchange rate changes on cash and cash equivalents	(17		)	(21		)	(21		)	1
Net increase in cash and cash equivalents and restricted cash	104			176
Net (decrease) increase in cash and cash equivalents and restricted cash							(1,321		)	61
Cash and cash equivalents and restricted cash, beginning of period	723			797			3,244			723
Cash and cash equivalents and restricted cash, end of period	$	827		$	973		$	1,923		$	784

Cash and cash equivalents	$	825		$	973		$	912		$	782
Restricted cash, current	2			—			1,011			2
Cash and cash equivalents and restricted cash, end of period	$	827		$	973		$	1,923		$	784

The accompanying notes are an integral part of these consolidated financial statements.

BAUSCH HEALTH COMPANIES INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


1.	DESCRIPTION OF BUSINESS

Bausch Health Companies Inc. (the “Company”) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range ~~of: (i)~~of branded, ~~pharmaceuticals, (ii)~~ generic and branded generic pharmaceuticals, ~~(iii)~~ over-the-counter (“OTC”) products and ~~(iv)~~ medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.


2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators on February ~~20, 2019.~~19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited Consolidated Financial Statements for the year ended December 31, ~~2018,~~2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair ~~presentation~~statement of the Company’s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.

The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reaction of governments, private sector participants and the public in an effort to contain the spread of COVID-19 and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce generally, including disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as certain pandemic-related medical services and supplies, alongside decreased demand for others, such as elective surgery, retail, hospitality and travel.

The extent to which these events may impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the ultimate geographic spread and duration of the pandemic, new information which may emerge concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and/or address its impacts, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.

In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these ~~estimates.~~estimates and the differences could be material.

On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by

management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.

Principles of Consolidation

The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.

Reclassifications

Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Adoption of New Accounting Guidance

In ~~February~~June 2016, the Financial Accounting Standards Board ~~("FASB"~~(“FASB”) issued a new standard revising the accounting for leases to increase transparency and comparability among organizations that lease buildings, equipment and other assets by requiring the recognition of lease assets and lease liabilities on the balance sheet. Under the new standard, all leases are classified as either a finance lease or an operating lease. The classification is determined based on whether substantive control has been transferred to the lessee and its determination will govern the pattern of lease cost recognition. Finance leases are accounted for in substantially the same manner as capital leases under the former U.S. GAAP standard. Operating leases are accounted for in the statements of operations and statements of cash flows in a manner substantially consistent with operating leases under the former U.S. GAAP standard. However, as it relates to the balance sheet, operating lessees are, with limited exception, required to record a right-of-use asset and a corresponding lease liability, equal to the present value of the lease payments for each operating lease. Lessees are not required to recognize a right-of-use asset or lease liability for short-term leases, but instead recognizes lease payments as an expense on a straight-line basis over the lease term. The standard also

requires lessees and lessors to provide additional qualitative and quantitative disclosures to help financial statement users assess the amounts, timing and uncertainty of cash flows arising from leases.

The Company adopted the new standard effective January 1, 2019, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million. In addition, approximately $20 million of restructuring liabilities associated with facility closures and deferred rents, included in Other non-current liabilities as of December 31, 2018, were reclassified to reduce right-of-use assets. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard.

In August 2018, the FASB issued guidance aligning the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company has early-adopted this guidance prospectively for all implementation costs incurred after January 1, 2019.

~~Recently Issued Accounting Standards, Not Adopted as of September 30, 2019~~

~~In June 2016, the FASB~~ issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance iswas effective for ~~annual periods~~the Company beginning ~~after December 15, 2019,~~January 1, 2020 and ~~interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15,~~was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors. Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.

In August 2018, ~~and interim periods within those annual periods. In May 2019,~~ the FASB issued ~~an update allowing a targeted transition relief~~guidance modifying the disclosure requirements for fair value measurement. The guidance was effective for the ~~option~~Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.

In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to ~~irrevocably elect~~contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform. Optional expedients are provided for contract modification accounting within the ~~fair value option~~areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for ~~certain financial assets previously measured at amortized cost basis. The~~all entities as of March 12, 2020, through December 31, 2022. During the three months ended March 31, 2020, the Company ~~is evaluating~~has not entered into any contract modifications in which the optional expedients were applied. However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.

In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement. The guidance is effective for annual periods beginning after December 15, 2019. The Company is permitted to early-adopt any removed or modified disclosures upon issuanceRecently Issued Accounting Standards, Not Adopted as of ~~this update and delay adoption of the additional disclosures until the effective date. The Company is evaluating the impact of adoption of this guidance on its disclosures.~~March 31, 2020

In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on its disclosures.

In December 2019, the FASB issued guidance simplifying the accounting for income taxes. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.


3.	REVENUE RECOGNITION

The Company’s revenues are primarily generated from product sales, ~~primarily~~principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note ~~20,~~19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.

Product Sales Provisions

As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the

form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.

Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.

The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or ~~require~~ an adjustment related to past sales, or both. If the ~~trend in~~ actual amounts ~~of variable consideration varies~~paid vary from the Company’s ~~prior~~ estimates, the Company adjusts these estimates, ~~when such trends are believed to be sustainable. At that time, the Company would record the necessary adjustments~~ which would affect net product revenue and earnings ~~reported~~ in the ~~current period.~~

The following tables present the activity and ending balances of the Company’s variable consideration provisions for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019.


	Nine Months Ended September 30, 2019																		Three Months Ended March 31, 2020
(in millions)	Discounts and Allowances			Returns			Rebates			Chargebacks			Distribution Fees			Total			Discounts and Allowances			Returns			Rebates			Chargebacks			Distribution Fees			Total
Reserve balances, January 1, 2019	$	175		$	813		$	1,024		$	209		$	163		$	2,384
Acquisition of Synergy	—			3			12			—			1			16
Reserve balances, January 1, 2020																			$	182		$	691		$	927		$	168		$	82		$	2,050
Current period provisions	585			50			1,650			1,425			150			3,860			156			42			602			484			53			1,337
Payments and credits	(583		)	(187		)	(1,673		)	(1,480		)	(181		)	(4,104		)	(167		)	(75		)	(588		)	(501		)	(61		)	(1,392		)
Reserve balances, September 30, 2019	$	177		$	679		$	1,013		$	154		$	133		$	2,156
Reserve balances, March 31, 2020																			$	171		$	658		$	941		$	151		$	74		$	1,995

Included in Rebates in the table above are cooperative advertising credits due to customers of approximately ~~$26~~$32 million and $29 million as of March 31, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $4 million as of March 31, 2020.



	Three Months Ended March 31, 2019
(in millions)	Discounts and Allowances			Returns			Rebates			Chargebacks			Distribution Fees			Total
Reserve balances, January 1, 2019	$	175		$	813		$	1,024		$	209		$	163		$	2,384
Acquisition of Synergy	—			3			12			—			1			16
Current period provisions	204			33			533			443			48			1,261
Payments and credits	(210		)	(55		)	(568		)	(497		)	(85		)	(1,415		)
Reserve balances, March 31, 2019	$	169		$	794		$	1,001		$	155		$	127		$	2,246

Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $27 million and $26 million as of ~~September 30,~~March 31, 2019 and January 1, 2019, ~~respectively,~~ which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were 0 price appreciation credits for the ~~nine~~three months ended ~~September 30,~~March 31, 2019.

Nine Months Ended September 30, 2018
(in millions)
Discounts
and
Allowances
Returns Rebates Chargebacks
Distribution
Fees
Total
Reserve balances, January 1, 2018 $ 167
$ 863
$ 1,094
$ 274
$ 148
$ 2,546
Current period provisions 643
209
1,976
1,462
178
4,468
Payments and credits (632 ) (264 ) (1,939 ) (1,512 ) (167 ) (4,514 )
Reserve balances, September 30, 2018 $ 178
$ 808
$ 1,131
$ 224
$ 159
$ 2,500

Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $29 million as of September 30, 2018, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million for the nine months ended September 30, 2018.

Contract Assets and Contract Liabilities

There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented.

Allowance for Credit Losses

An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors. Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowances for credit losses were $48 million and $48 million as of March 31, 2020 and December 31, 2019, respectively. The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2020 is as follows. Write-offs charged against the allowance for credit losses and recoveries of amounts previously written off were not material.



(in millions)
Balance, January 1, 2020	$	48
Retrospective effect of application of new accounting standard	1
Provision	2
Foreign exchange and other	(3		)
Balance, March 31, 2020	$	48


4.	ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE

Acquisition of Certain Assets of Synergy Pharmaceuticals Inc.

On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired ~~are~~were the worldwide rights to the Trulance^® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.

Assets Acquired and Liabilities Assumed

The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting ~~since:~~as: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the ~~estimated~~ fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:



(in millions)
Accounts receivable	$	7
Inventories	24
Prepaid expenses and other current assets	5
Product brand intangible assets (estimated useful life - 7 years)	159
Accounts payable	(1		)
Accrued expenses	(17		)
Total identifiable net assets	177
Goodwill	3
Total fair value of consideration transferred	$	180

~~Due to the timing of the acquisition, the following are provisional and are subject to change:~~

~~amounts for intangible assets, property and equipment, inventories, receivables and other working capital adjustments pending finalization of the valuation;~~

~~amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and~~

~~amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.~~

The Company will finalize these amounts no later than one year from the acquisition date, once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the provisional amounts recognized at the acquisition date which will impact the reported results in the period those adjustments are identified. These adjustments, if any, could be material.

Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.

Revenue and Operating Results

Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through ~~September 30,~~December 31, 2019 were ~~$37~~$55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through ~~September 30,~~December 31, 2019 and pro-forma revenues and operating results for the ~~nine~~three months ended ~~September 30,~~March 31, 2019 and ~~2018~~the year 2019 were not material. Included in Other expense (income), net during the ~~nine~~three months ended ~~September 30,~~March 31, 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.

Licensing Agreements

In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, cannot be fairly predicted. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.

Assets Held for Sale

~~The~~In 2019, the Company ~~has~~ identified certain products in the Bausch + Lomb/International segment and 1 product in the Diversified Products segment for ~~disposal as of September 30, 2019.~~disposal. The products and the related assets and liabilities of this disposal group ~~qualify~~qualified as a business. Revenues associated with this business were ~~$11~~$14 million and $19 million for the ~~nine months ended September 30,~~years 2019 and ~~the year ended December 31,~~ 2018, respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of September 30, ~~2019. Included in Asset impairments in the Consolidated Statement of Operations during the three~~2019 and ~~nine months ended September 30, 2019, is~~ an impairment of $8 million associated with this ~~business.~~business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for the three months ended March 31, 2020.


5.	RESTRUCTURING AND INTEGRATION COSTS

The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or ~~under-utilized~~under utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of ~~September 30, 2019~~March 31, 2020 was ~~$28~~$27 million.

During the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, the Company incurred ~~$28~~$4 million of restructuring and integration costs. These costs included: (i) ~~$11~~$3 million of facility closure costs and (ii) $1 million of severance costs. The Company made payments of $4 million for the three months ended March 31, 2020.

During the three months ended March 31, 2019, the Company incurred $20 million of restructuring and integration costs. These costs included: (i) $10 million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) ~~$9 million of facility closure costs and (iii) $8~~$6 million of other severance ~~costs. The Company made payments of $27 million for the nine months ended September 30, 2019.~~

~~During the nine months ended September 30, 2018, the Company incurred $16 million of restructuring and integration costs. These costs included: (i) $8 million of severance~~ costs and ~~(ii) $8~~(iii) $4 million of facility closure costs. The Company made payments of ~~$29~~$16 million for the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019.


6.	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS

Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities;

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis:


	September 30, 2019								December 31, 2018								March 31, 2020								December 31, 2019
(in millions)	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	284	$	250	$	34	$	—	$	197	$	166	$	31	$	—	$	37	$	12	$	25	$	—	$	2,696	$	2,646	$	50	$	—
Restricted cash	$	2	$	2	$	—	$	—	$	2	$	2	$	—	$	—	$	1,011	$	1,011	$	—	$	—	$	1	$	1	$	—	$	—
Cross-currency swaps	$	8	$	—	$	8	$	—	$	—	$	—	$	—	$	—	$	55	$	—	$	55	$	—	$	—	$	—	$	—	$	—
Foreign currency exchange contracts																	$	1	$	—	$	1	$	—	$	—	$	—	$	—	$	—
Liabilities:
Acquisition-related contingent consideration	$	313	$	—	$	—	$	313	$	339	$	—	$	—	$	339	$	312	$	—	$	—	$	312	$	316	$	—	$	—	$	316
Cross-currency swaps																	$	—	$	—	$	—	$	—	$	13	$	—	$	13	$	—
Foreign currency exchange contracts																	$	6	$	—	$	6	$	—	$	—	$	—	$	—	$	—

Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.

As of March 31, 2020, Restricted cash includes $1,010 million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until final approval of the settlement as discussed in Note 18, "LEGAL PROCEEDINGS".

There were no transfers ~~between Level 1, Level 2~~into or out of Level 3 during the ~~nine~~three months ended ~~September 30, 2019.~~March 31, 2020.

Cross-currency Swaps

During the ~~third quarter of~~three months ended September 30, 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. ~~Prior to the third quarter of 2019, the~~The Company had no derivative instruments ~~for any period presented.~~

The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the ~~current period.~~three months ended March 31, 2019.

The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the ~~risk free~~risk-free interest rate and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps, is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the three ~~and nine-month periods~~months ended ~~September 30, 2019.~~March 31, 2020. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.

The fair value of the Company’s cross-currency swaps asset ~~at September 30, 2019~~as of March 31, 2020 was ~~$8 million and is included~~$55 million. Included in Other non-current assets are $52 million of cross-currency swaps and included in Prepaid expenses and other current assets is $3 million of earned interest within the Consolidated Balance Sheets. The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of ~~Operations:~~Operations for the three months ended March 31, 2020:


	Gain recognized in Other Comprehensive Loss				Gain excluded from assessment of hedge effectiveness				Location of gain in income of excluded component
(in millions)	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019		Location of gain in income of excluded component	Gain recognized in Other Comprehensive Loss		Gain excluded from assessment of hedge effectiveness		Location of gain in income of excluded component
Cross-currency swaps	$	5	$	5	$	3	$	3	Interest expense	$	73	$	6	Interest expense

~~During the nine months ended September 30, 2019, there were 0 payments or receipts in settlement~~Settlement of the ~~Company’s~~Company's cross-currency swaps ~~as the settlement dates~~ occur in February and August of each ~~year, with~~year. During the ~~first settlement~~three months ended March 31, 2020, the Company received $11 million in ~~February 2020. Future~~ settlements ~~of the Company’s cross-currency swaps will be~~which are reported as investing activities in the Consolidated ~~Statement~~Statements of Cash Flows.

Foreign Currency Exchange Contracts

During the three months ended March 31, 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $163 million. The Company had no foreign currency exchange contracts during 2019.

The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company's foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company’s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.

The fair value of the Company's foreign currency exchange contracts as of March 31, 2020 was $5 million. Included in Accrued and other current liabilities are $6 million and included in Prepaid expenses and other current assets are $1 million of foreign currency exchange contracts within the Consolidated Balance Sheets. During the three months ended March 31, 2020, the net change in fair value was a loss of $5 million. Settlements of the Company's foreign currency exchange contracts are reported as operating activities in the Consolidated Statements of Cash Flows.

Acquisition-related Contingent Consideration Obligations

The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At ~~September 30, 2019,~~March 31, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 5% to 25%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at March 31, 2020.

The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:


(in millions)	2019						2018						2020					2019
Balance, beginning of period				$	339					$	387				$	316					$	339
Adjustments to Acquisition-related contingent consideration:
Accretion for the time value of money	$	16					$	18					$	6				$	6
Fair value adjustments due to changes in estimates of other future payments	(14		)				(41		)				7					(27		)
Acquisition-related contingent consideration				2						(23		)			13						(21		)
Payments				(28		)				(28		)			(17		)				(9		)
Balance, end of period				313						336					312						309
Current portion included in Accrued and other current liabilities				46						54					44						45
Non-current portion				$	267					$	282				$	268					$	264

Included in Fair value adjustments due to changes in estimates of other future payments in the table above for the nine months ended September 30, 2019, is an $8 million fair value adjustment related to an acquisition which occurred in 2011.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:


	September 30, 2019								December 31, 2018								March 31, 2020								December 31, 2019
(in millions)	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Other non-current assets:
Non-current assets held for sale	$	39	$	—	$	—	$	39	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	39	$	—	$	—	$	39

Non-current assets held for sale of $39 million included in the Consolidated Balance Sheets as of ~~September 30,~~December 31, 2019 were remeasured to their estimated fair values less costs to sell. Included in Asset impairments for the three and nine months ended September 30, 2019, is a charge of $8 million associated with these assets held for sale. The estimated fair values of these assets less costs to sell ~~were~~ determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. ~~See~~As discussed in Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" ~~for additional details regarding~~, due to changing business dynamics, the Company decided not to sell these assets ~~held for sale.~~during the three months ended March 31, 2020.

Fair Value of Long-term Debt

The fair value of long-term debt as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 was ~~$25,005~~$24,462 million and ~~$23,357~~$27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).


7.	INVENTORIES

Inventories, net of allowances for obsolescence consist of:


(in millions)	September 30, 2019		December 31, 2018		March 31, 2020		December 31, 2019
Raw materials	$	317	$	275	$	310	$	319
Work in process	171		95		155		149
Finished goods	612		564		659		639
	$	1,100	$	934	$	1,124	$	1,107


8.	INTANGIBLE ASSETS AND GOODWILL

Intangible Assets

The major components of intangible assets consist of:


	September 30, 2019							December 31, 2018							March 31, 2020							December 31, 2019
(in millions)	Gross Carrying Amount		Accumulated Amortization and Impairments			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization and Impairments			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization and Impairments			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization and Impairments			Net Carrying Amount
Finite-lived intangible assets:
Product brands	$	20,963	$	(13,125	)	$	7,838	$	20,891	$	(11,958	)	$	8,933	$	20,989	$	(13,924	)	$	7,065	$	21,011	$	(13,544	)	$	7,467
Corporate brands	925		(317		)	608		926		(263		)	663		914		(348		)	566		930		(338		)	592
Product rights/patents	3,292		(2,828		)	464		3,292		(2,658		)	634		3,284		(2,918		)	366		3,297		(2,887		)	410
Partner relationships	159		(157		)	2		168		(166		)	2		155		(154		)	1		166		(165		)	1
Technology and other	206		(183		)	23		208		(173		)	35		203		(186		)	17		209		(189		)	20
Total finite-lived intangible assets	25,545		(16,610		)	8,935		25,485		(15,218		)	10,267		25,545		(17,530		)	8,015		25,613		(17,123		)	8,490
Acquired IPR&D not in service	17		—			17		36		—			36		13		—			13		13		—			13
Bausch + Lomb Trademark	1,698		—			1,698		1,698		—			1,698		1,698		—			1,698		1,698		—			1,698
	$	27,260	$	(16,610	)	$	10,650	$	27,219	$	(15,218	)	$	12,001	$	27,256	$	(17,530	)	$	9,726	$	27,324	$	(17,123	)	$	10,201

Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.

Asset impairments for the ~~nine~~three months ended ~~September 30, 2019 include impairments of: (i) $38~~March 31, 2020 were $14 million ~~reflecting~~due to decreases in forecasted sales of a certain product ~~lines~~line.

Asset impairments for the three months ended March 31, 2019 were $3 million due to ~~generic competition and other factors, (ii) $8 million related to assets being classified as held for sale and (iii) $3 million, in aggregate, related to certain product/patent assets associated with~~ the discontinuance of a specific product ~~lines~~line not aligned with the focus of the Company's core businesses.

~~Asset impairments for the nine months ended September 30, 2018 include impairments of: (i) $341 million reflecting decreases in forecasted sales for the Uceris~~^® Tablet product and other product lines due to generic competition, (ii) $60 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and revisions to forecasted sales, (iii) $28 million to Acquired IPR&D not in service related to a certain product and (iv) $5 million related to assets being classified as held for sale.

Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such products would decrease shortly following a loss of exclusivity, due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.

~~As a result of the launch of a generic competitor in July 2018, the Company revised its near and long-term financial projections of the Uceris~~^® ~~Tablet related intangible assets. As of June 30, 2018, the carrying value of the Uceris~~^® ~~Tablet related intangible assets exceeded the undiscounted expected cash flows from the Uceris~~^® ~~Tablet. As a result, the Company recognized an impairment of $263 million to reduce the carrying value of the Uceris~~^® ~~Tablet related intangible assets to their estimated fair value. As of September 30, 2019, the remaining carrying value of the Uceris~~^® Tablet related intangible assets was $70 million. Prior to its launch, the Company initiated infringement proceedings against this generic competitor. The Company continues to believe that its Uceris^® ~~Tablet-related patents are enforceable and is proceeding in the ongoing litigation between the Company and the generic competitor, however the ultimate outcome of the matter is not predictable.~~

Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. In review of the Company’s finite-lived intangible assets, management revised the estimated useful lives of certain intangible assets in 2018.

~~Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan~~^®-related intangible assets due to the positive impact of the agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan^® tablets, 550 mg. As discussed in further detail in Note 20, "LEGAL PROCEEDINGS" to the Company's Annual Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018, the parties agreed to dismiss all litigation related to Xifaxan^® ~~tablets, 550 mg and all intellectual property protecting Xifaxan~~^® ~~will remain intact and enforceable. As a result, the useful life of the Xifaxan~~^®-related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan^®-related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $353 million, and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.00 for the nine months ended September 30, 2019. As of September 30, 2019, the net carrying value of the Xifaxan^®~~-related intangible assets was $4,444 million.~~

Estimated amortization expense of finite-lived intangible assets for the remainder of ~~2019~~2020 and each of the five succeeding years ending December 31 and thereafter is as follows:


(in millions)	Remainder of 2019		2020		2021		2022		2023		2024		Thereafter		Total		Remainder of 2020		2021		2022		2023		2024		2025		Thereafter		Total
Amortization	$	444	$	1,623	$	1,374	$	1,224	$	1,080	$	952	$	2,238	$	8,935	$	1,188	$	1,374	$	1,217	$	1,071	$	942	$	832	$	1,391	$	8,015

Goodwill

The changes in the carrying amounts of goodwill during the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and the year ended December 31, ~~2018~~2019 were as follows:

(in millions) Bausch + Lomb/ International Branded Rx U.S. Diversified Products Salix Ortho Dermatologics Diversified Products Total
Balance, January 1, 2018 $ 6,016
$ 6,631
$ 2,946
$ —
$ —
$ —
$ 15,593
Impairment of the Salix and Ortho Dermatologics reporting units —
(2,213 ) —
—
—
—
(2,213 )
Realignment of Global Solta reporting unit goodwill (82 ) 115
(33 ) —
—
—
—
Goodwill reclassified to assets held for sale and subsequently disposed (2 ) —
—
—
—
—
(2 )
Realignment of segment goodwill —
(4,533 ) (2,913 ) 3,156
1,267
3,023
—
Impairment of the Dentistry reporting unit —
—
—
—
—
(109 ) (109 )
Foreign exchange and other (127 ) —
—
—
—
—
(127 )
Balance, December 31, 2018 5,805
—
—
3,156
1,267
2,914
13,142
Acquisition of certain assets of Synergy —
—
—
3
—
—
3
Goodwill reclassified to assets held for sale (Note 4) (18 ) —
—
—
—
—
(18 )
Foreign exchange and other (75 ) —
—
—
—
—
(75 )
Balance, September 30, 2019 $ 5,712
$ —
$ —
$ 3,159
$ 1,267
$ 2,914
$ 13,052



(in millions)	Bausch + Lomb/ International			Salix		Ortho Dermatologics		Diversified Products		Total
Balance, January 1, 2019	$	5,805		$	3,156	$	1,267	$	2,914	$	13,142
Acquisition of certain assets of Synergy	—			3		—		—		3
Goodwill reclassified to assets held for sale (Note 4)	(18		)	—		—		—		(18		)
Foreign exchange and other	(1		)	—		—		—		(1		)
Balance, December 31, 2019	5,786			3,159		1,267		2,914		13,126
Assets held for sale reclassified to goodwill (Note 4)	18			—		—		—		18
Foreign exchange and other	(110		)	—		—		—		(110		)
Balance, March 31, 2020	$	5,694		$	3,159	$	1,267	$	2,914	$	13,034

Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs.

The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, ~~2018,~~2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount (Step 0). Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit (Step 1). The quantitative fair value test was performed utilizing long-term growth rates ~~for its reporting units ranging from 1.0% to 3.0%~~ and discount rates applied to the estimated cash flows ~~ranging from~~

~~7.5% to 14.0%~~ in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an ~~in perpetuity~~in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value.

The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.

~~2018~~

~~Adoption of New Accounting Guidance for~~2019 Goodwill Impairment Testing

~~In January 2017,~~During the ~~FASB issued guidance which simplifies the subsequent measurement~~interim periods of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. The Company elected to adopt this guidance effective January 1, 2018.

Upon adopting the new guidance, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value. As a result of the adoption of new accounting guidance, the Company recognized a goodwill impairment of $1,970 million associated with the Salix reporting unit.

As of October 1, 2017, the date of the 2017 annual goodwill impairment test, the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017, when the Company performed its 2017 annual goodwill impairment test. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million.

~~2018 Realignment of Solta Business~~

Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/International segment in prior periods, are reported in the new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment.

~~2018 Realignment of Segment Structure~~

In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was2019, no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units.

~~2018 Annual Goodwill Impairment Test~~

The Company conducted its annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million for the Dentistry reporting unit, representing the full amount of goodwill for the reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results. The Company is taking steps to address these changing market and business conditions.

The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was 0 impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%.

~~2019 Interim Goodwill Impairment Assessment~~

No events occurred, or circumstances changed ~~during the period October 1, 2018 (the date goodwill was last tested for impairment) through September 30, 2019~~ that would indicate that the fair value of any reporting unit might be below its carrying ~~value. Based on the results of the October 1, 2018~~value and therefore, no impairments were recorded. The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was 0 impairment to the goodwill of any reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit and

the Neurology and Other reporting unit as compared to their respective projections and will perform qualitative interim assessments of the carrying value and fair value ~~of the Ortho Dermatologics reporting unit~~ on a quarterly basis to determine if impairment testing of goodwill will be warranted. The Company performed quantitative fair value tests for the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019, utilizing long-term growth rates of 2.0% and 1.5%, and discount rates of 9.8% and 9.0%, respectively, in estimation of the fair value of these reporting units.

2020 Interim Goodwill Impairment Assessment

The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events and reactions to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict at this time.

In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and in the periods that follow, including the costs of idling and reopening certain facilities in affected areas. Further, precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's reported revenues for the three months ended March 31, 2020 are less than forecasted and additional pandemic-related declines in revenues are expected in the second quarter and possibly the remainder of 2020, there is currently no indication that these trends are materially other than COVID-19 related.

The negative impacts of the COVID-19 pandemic on the global economy were not existing conditions as of October 1, 2019 (the date goodwill was last tested for impairment) and have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows. In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value.

During the pandemic, the public has been advised to: (i) remain at home, (ii) limit social interaction, (iii) close non-essential businesses and (iv) postpone certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, this has negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses particularly in Asia where the COVID-19 pandemic originated. The Company anticipates further revenue declines in these businesses during 2020 as it experienced steeper declines in these business revenues in the month of March. Beginning in the second quarter, the Company started experiencing and is anticipating COVID-19 pandemic-related revenue declines in intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Ophthalmology business, in medical aesthetics and therapeutic products of its Global Solta business, and in certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses. These revenues declines are expected, as the offices of many health care providers are closed and certain surgeries and elective medical procedures are being deferred. To date, the COVID-19 pandemic appears to have had only a limited impact on the revenues of the Company's Xifaxan^® products.

Based on its assessment the Company believes its revenues will be most impacted by the pandemic during the second quarter, as the infection rate of the COVID-19 virus accelerated in March into April, and the virus had spread beyond Asia into different geographies, including the U.S. and Europe, and the number of shelter-in-place directives issued by local authorities increased. Although the affected businesses and geographies are expected to recover at different rates, overall the Company anticipates that the negative trend in revenues will begin to stabilize during its second quarter and continue into its third quarter with the revenues of all businesses possibly returning to pre-pandemic levels as early as late 2020, but, if not, then in 2021. This assessment assumes, among other matters, that the precautionary measures taken by the public are successful in decelerating the spread of the virus, there will be no resurgence of the virus in the second half of 2020 that will lead to significant social restrictions, there will be no significant social restrictions in place at the end of 2020, responses from governments and private sector participants will be successful in bringing about a quick orderly recovery of the global economy, there will be no major

interruptions in the Company's supply, manufacturing and distribution channels and the Company continues to execute on its strategies in response to the pandemic.

The Company's latest forecasts of cash flows gives consideration to the nature and timing of the expected revenue losses disclosed above. The changes in the amounts and timing of these revenues as presented in the latest forecasts include a range of potential outcomes and are not substantial enough to materially adversely affect the recoverability of any of the associated reporting units’ assets and are not material enough to indicate that the fair values of those reporting units might be below their respective carrying values.

Based on the results of the October 1, 2019 annual goodwill impairment test, the Company performed qualitative interim assessments of the respective carrying values and fair values of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of March 31, 2020 to determine if quantitative fair value testing was warranted. As part of these qualitative assessments, management considered the ~~qualitative assessment as~~totality of ~~September 30, 2019, management compared~~all relevant events or circumstances that effect the carrying amount or fair value of each reporting unit, including comparing the reporting ~~unit’s~~units’ operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, ~~2018. Based~~2019. Management believed that based on ~~the~~its qualitative assessment, ~~management believed~~it was more likely than not that the carrying ~~value~~amount of ~~Ortho Dermatologics~~the Neuro and Other reporting unit ~~did not exceed~~was less than its fair value and, therefore, concluded a quantitative assessment was not required at ~~September 30, 2019.~~March 31, 2020. However, the operating results for the Ortho Dermatologics reporting unit for three months ended March 31, 2020 were less than those forecasted as of October 1, 2019 for the same period. Further, the Company adjusted its forecasted cash flows for the Ortho Dermatologics reporting unit for the wide range of potential impacts of the COVID-19 pandemic and longer launch cycles for certain new products. These factors are indicators that there is less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment. Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections, including a range of potential outcomes, along with a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 10.0%. Based on the quantitative test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result, there was no impairment to the goodwill of the reporting unit, however, the headroom was reduced from the prior year’s assessment. The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit and Neuro and Other reporting unit including: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for new products and (iv) ongoing pricing pressures, which could negatively impact the reporting units' results over the long term.

If market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management’s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.

No other events occurred or circumstances changed during the period October 1, 2019 (the date goodwill was last tested for impairment) through March 31, 2020 that indicate it is more likely than not the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit may be below its carrying value.

Accumulated goodwill impairment charges through ~~September 30, 2019~~March 31, 2020 were $3,711 million.


9.	ACCRUED AND OTHER CURRENT LIABILITIES

Accrued and other current liabilities consist of:


(in millions)	September 30, 2019		December 31, 2018		March 31, 2020		December 31, 2019
Legal matters and related fees					$	1,416	$	1,397
Product rebates	$	987	$	998	909		$	898
Product returns	679		813		658		691
Interest	388		273		382		305
Employee compensation and benefit costs	291		301		249		304
Income taxes payable	150		167		184		196
Other	703		645		640		720
	$	3,198	$	3,197	$	4,438	$	4,511


10.	FINANCING ARRANGEMENTS

Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following:


			September 30, 2019				December 31, 2018						March 31, 2020				December 31, 2019
(in millions)		Maturity	Principal Amount		Net of Premiums, Discounts and Issuance Costs		Principal Amount		Net of Premiums, Discounts and Issuance Costs			Maturity	Principal Amount		Net of Premiums, Discounts and Issuance Costs		Principal Amount		Net of Premiums, Discounts and Issuance Costs
Senior Secured Credit Facilities:
2023 Revolving Credit Facility		June 2023	$	—	$	—	$	75	$	75		June 2023	$	—	$	—	$	—	$	—
June 2025 Term Loan B Facility		June 2025	3,932		3,826		4,394		4,269			June 2025	3,766		3,671		3,869		3,768
November 2025 Term Loan B Facility		November 2025	1,312		1,293		1,481		1,456			November 2025	1,275		1,257		1,275		1,257
Senior Secured Notes:
6.50% Secured Notes		March 2022	1,250		1,241		1,250		1,239			March 2022	1,250		1,243		1,250		1,242
7.00% Secured Notes		March 2024	2,000		1,982		2,000		1,979			March 2024	2,000		1,984		2,000		1,983
5.50% Secured Notes		November 2025	1,750		1,732		1,750		1,730			November 2025	1,750		1,734		1,750		1,733
5.75% Secured Notes		August 2027	500		493		—		—			August 2027	500		493		500		493
Senior Unsecured Notes:
5.625%		December 2021	—		—		700		697
5.50%		March 2023	402		400		1,000		995			March 2023	292		291		402		400
5.875%		May 2023	1,548		1,540		3,250		3,229			May 2023	201		200		1,448		1,441
4.50% euro-denominated debt		May 2023	1,635		1,626		1,720		1,709			May 2023	1,655		1,647		1,682		1,674
6.125%		April 2025	3,250		3,229		3,250		3,226			April 2025	3,250		3,231		3,250		3,230
9.00%		December 2025	1,500		1,472		1,500		1,469			December 2025	1,500		1,474		1,500		1,473
9.25%		April 2026	1,500		1,484		1,500		1,482			April 2026	1,500		1,485		1,500		1,484
8.50%		January 2027	1,750		1,756		750		738			January 2027	1,750		1,756		1,750		1,756
7.00%		January 2028	750		740		—		—			January 2028	750		741		750		741
5.00%												January 2028	1,250		1,234		1,250		1,234
7.25%		May 2029	750		740		—		—			May 2029	750		741		750		740
5.25%												January 2030	1,250		1,234		1,250		1,234
Other		Various	12		12		12		12			Various	12		12		12		12
Total long-term debt and other			$	23,841	23,566		$	24,632	24,305				$	24,701	24,428		$	26,188	25,895
Less: Current portion of long-term debt and other	Less: Current portion of long-term debt and other				100				228		Less: Current portion of long-term debt and other				4				1,234
Non-current portion of long-term debt					$	23,466			$	24,077					$	24,424			$	24,661

Covenant Compliance

The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.

In March 2020, the World Health Organization declared COVID-19 a global pandemic, resulting in an adverse impact on the global economy. While there are a number of standard borrowing conditions that must be met to make borrowings under the 2023 Revolving Credit Facility, the Company has considered the economy's impact on its non-financial and financial maintenance covenants and believes the current state of the economy does not limit its access to capital under the 2023 Revolving Credit Facility at this time.

As of ~~September 30, 2019,~~March 31, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast as adjusted for the ~~next twelve months from~~potential impacts of the ~~date of issuance of these financial statements,~~COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations ~~over that same period.~~

for at least the twelve months following the date of issuance of these financial statements.

The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.

Senior Secured Credit Facilities

On ~~February 13, 2012,~~June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s ~~Third~~Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the ~~“Third Amended~~“Restated Credit Agreement”) with a syndicate of financial institutions and investors as lenders. As of January 1, 2018, the Third Amended Credit Agreement, as amended, provided for: (i) $1,500 million of revolving credit facilities, which included a sublimit for the issuance of standby and commercial letters of credit and a sublimit for swing line loans and (ii) a series of tranche B term loans maturing on April 1, 2022 (the "Series F Tranche B Term Loan Facility").

~~On June 1, 2018, the Company entered into the Restated Credit Agreement.~~ The Restated Credit Agreement ~~amended and restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with~~provides for a revolving credit facility of $1,225 million, (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a seven year Tranche B Term Loan Facility of $4,565 million (the “June 2025 Term Loan B Facility”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA") (formerly Valeant Pharmaceuticals International).

~~The 2023 Revolving Credit Facility~~which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company ~~or BHA~~and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 ~~million.~~million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the “June 2025 Term Loan B Facility”) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers ~~with respect to the 2023 Revolving Credit Facility. Borrowings~~ under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.

On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), (ii) $578 million of 6.75% Senior Unsecured Notes due 2021(the "August 2021 Unsecured Notes"), (iii) $550 million of 7.25% Senior Unsecured Notes due 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due 2020 (the “6.375% October 2020 Unsecured Notes” and together with the March 2020 Unsecured Notes, August 2021 Unsecured Notes and July 2022 Unsecured Notes the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility, the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “June 2018 Refinancing Transactions”).

In connection with the Restated Credit Agreement, the Company incurred a loss on extinguishment of debt of $48 million. Certain payments made to the lenders and third parties of $74 million associated with the Restated Credit Agreement were capitalized and are being amortized as interest expense over the remaining terms of the debt. Third-party expenses of $4 million were expensed as Interest expense.

On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500 million (the "November 2025 Term Loan B Facility") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “July 2021 Unsecured Notes”) in a tender offer (the "November 2018 Refinancing Transactions"). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes.

In connection with the repayment of the July 2021 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $43 million. Certain payments made to the lenders and third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility.

As of September 30, 2019, the Company had 0 outstanding borrowings, $170 million of issued and outstanding letters of credit and remaining availability of $1,055 million under its 2023 Revolving Credit Facility. During October 2019, the Company had drawn net borrowings of $200 million under its 2023 Revolving Credit Facility.

Current Description of Senior Secured Credit Facilities

Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% ~~and~~or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.

Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin.

annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.

Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.

The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of ~~September 30, 2019,~~March 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were ~~5.04%~~3.61% and ~~4.79%~~3.36% per annum, respectively.

The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of ~~September 30, 2019,~~March 31, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were ~~$1,226~~$1,023 million through November 1, 2025.

The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings. As of ~~September 30, 2019,~~March 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was ~~5.04%~~3.36% per annum. As of March 31, 2020, the Company had 0 outstanding borrowings, $168 million of issued and outstanding letters of credit and remaining availability of $1,057 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.

The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.

Senior Secured Notes

The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes.

The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated

to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral.

Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.

5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions

On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027 (the "January 2027 Unsecured ~~Notes~~Notes") and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private ~~placement, a~~placement. A portion of the ~~net~~ proceeds, ~~of which,~~ and cash on hand, were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.

The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.

Senior Unsecured Notes

If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.

~~9.25% Senior Unsecured Notes due 2026 - March 2018 Refinancing Transactions~~

On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.25% Senior Unsecured Notes due 2026 (the “April 2026 Unsecured Notes”) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes, which consisted of: (i) $1,017 million in principal amount of the March 2020 Unsecured Notes, (ii) $411 million in principal amount of the 6.375% October 2020 Unsecured Notes and (iii) $72 million in principal amount of the August 2021 Unsecured Notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the “March 2018 Refinancing Transactions”). The March 2018 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $26 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. The April 2026 Unsecured Notes accrue interest at the rate of 9.25% per year, payable semi-annually in arrears on each of April 1 and October 1.

8.50% Senior Unsecured Notes due 2027 - ~~June 2018 Refinancing Transactions and~~ March 2019 Refinancing Transactions

As part of the June 2018 Refinancing Transactions, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement, the proceeds of which, when combined with the remaining net proceeds from the June 2025 Term Loan B Facility and cash on hand, were deposited with The Bank of New York Mellon Trust Company, N.A., as trustee under the indentures governing the June 2018 Unsecured Refinanced Debt, to redeem the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged. The January 2027 Unsecured Notes accrue interest at the rate of 8.50% per year, payable semi-annually in arrears on each of January 31 and July 31.

As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of ~~8.50% Senior~~January 2027 Unsecured ~~Notes due January 2027.~~Notes. These are additional notes and form part of the same series as BHA’s existing January 2027 Unsecured Notes.

7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions

On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the ~~"January~~"7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private ~~placement, the net~~placement. The proceeds ~~of which,~~ and cash on hand, were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the “May 2019 Refinancing Transactions”). ~~The May~~

5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions ~~were accounted for as an extinguishment of debt and~~

On December 30, 2019, the Company ~~incurred a loss on extinguishment of debt of $32~~issued: (i) $1,250 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30.

The January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of ~~the~~5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured ~~Notes or the May 2029~~Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes ~~respectively, using~~due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the ~~proceeds~~$1,210 million settlement of certain ~~equity offerings at~~U.S. securities litigation, subject to final court approval, as discussed in Note 18, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the ~~redemption price set forth in the respective indenture.~~"December 2019 Financing and Refinancing Transactions").

Weighted Average Stated Rate of Interest

The weighted average stated rate of interest for the Company's outstanding debt obligations as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 was ~~6.39%~~6.01% and ~~6.23%~~6.21%, respectively.

Maturities and Mandatory Payments

In order to reduce future cash interest payments, as well as future maturities and mandatory payments, the Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. During the three months ended March 31, 2020, the Company repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $17 million in the open market, for an aggregate cost of $16 million. In connection with these repurchases, the Company recognized a gain of $1 million included in Loss on extinguishment of debt.

Maturities and mandatory payments of debt obligations for the remainder of ~~2019,~~2020, the five succeeding years ending December 31 and thereafter are as follows:


(in millions)
Remainder of 2019	$	100
2020	—
Remainder of 2020				$	4
2021	203			—
2022	1,553			1,553
2023	3,788			2,447
2024	2,303			2,303
2025				10,632
Thereafter	15,894			7,762
Total debt obligations	23,841			24,701
Unamortized premiums, discounts and issuance costs	(275		)	(273		)
Total long-term debt and other	$	23,566		$	24,428

During October 2019, the Company (i) repaid $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023 and (ii) had drawn net borrowings of $200 million under its 2023 Revolving Credit Facility. These transactions are not reflected in the table above.


11.	PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS

The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ consists of:


	Pension Benefit Plans												Postretirement Benefit Plan						Pension Benefit Plans												Postretirement Benefit Plan
	U.S. Plan						Non-U.S. Plans						Postretirement Benefit Plan						U.S. Plan						Non-U.S. Plans						Postretirement Benefit Plan
(in millions)	2019			2018			2019			2018			2019			2018			2020			2019			2020			2019			2020			2019
Service cost	$	1		$	1		$	2		$	2		$	—		$	—		$	—		$	—		$	1		$	1		$	—		$	—
Interest cost	6			5			4			4			1			1			2			2			1			1			—			—
Expected return on plan assets	(10		)	(11		)	(4		)	(4		)	—			—			(3		)	(3		)	(1		)	(1		)	—			—
Amortization of prior service credit	—			—			(1		)	(1		)	(2		)	(2		)
Amortization of net loss	—			—			1			1			—			—
Amortization of prior service credit and other																			—			—			(4		)	—			(1		)	—
Net periodic (benefit) cost	$	(3	)	$	(5	)	$	2		$	2		$	(1	)	$	(1	)	$	(1	)	$	(1	)	$	(3	)	$	1		$	(1	)	$	—


12.	~~LEASES~~

The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of one to twenty years, some of which include termination options and options to extend the lease term from one to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.

As discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" under the new standard for accounting for leases, which the Company adopted effective January 1, 2019, the Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent,

taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.

All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable. As of September 30, 2019, the Company's finance leases were not material.

~~Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of September 30, 2019 as follows:~~

(in millions)
Right-of-use assets included in:
Other non-current assets $ 263
Lease liabilities included in:
Accrued and other current liabilities $ 49
Other non-current liabilities 235
Total lease liabilities $ 284

~~Sub-lease income is not material. Lease expense includes:~~

(in millions) Three Months Ended
September 30, 2019 Nine Months Ended
September 30, 2019
Operating lease costs $ 15
$ 47
Variable operating lease costs $ 3
$ 12
Short-term lease expense $ 1
$ 2

~~Other information related to operating leases for the nine months ended September 30, 2019 is as follows:~~

(dollars in millions)
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 56
Right-of-use assets obtained in exchange for new operating lease liabilities $ 28
Weighted-average remaining lease term 8.5 years
Weighted-average discount rate 6.2 %

Right-of-use assets obtained in exchange for new operating lease liabilities during the nine months ended September 30, 2019 of $28 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption.

~~As of September 30, 2019, future payments under noncancelable operating leases for the remainder of 2019, each of the five succeeding years ending December 31 and thereafter are as follows:~~

(in millions)
Remainder of 2019 $ 16
2020 63
2021 49
2022 39
2023 34
2024 28
Thereafter 146
Total 375
Less: Imputed interest 91
Present value of remaining lease payments 284
Less: Current portion 49
Non-current portion $ 235

Upon adopting the new lease guidance, the Company elected the modified retrospective approach without revising prior periods. Accordingly, the Company is providing the following table of future payments under noncancelable operating leases as of December 31, 2018, for each of the five succeeding years ending December 31 and thereafter as previously disclosed under prior accounting guidance:

(in millions) 2019 2020 2021 2022 2023 Thereafter Total
Future payments $ 78
$ 60
$ 44
$ 39
$ 32
$ 166
$ 419


~~13.~~	SHARE-BASED COMPENSATION

In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan iswas equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.

Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan ~~included~~includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan ~~was~~has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards ~~were made~~are expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.

Approximately ~~9,916,000~~3,892,000 common shares were available for future grants as of ~~September 30, 2019.~~March 31, 2020. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.

~~During the three months ended March 31, 2017,~~Effective April 28, 2020, the Company ~~introduced~~further amended and restated the Amended and Restated 2014 Plan (the “Further Amended and Restated 2014 Plan”). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (“SARs”) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii) additional provisions clarifying that: (a) stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b) the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted “underwater” stock option or SAR and (iv) other housekeeping and/or clerical changes.

The Company has a long-term incentive program with the objective ~~to re-align~~of realigning the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (“RSUs”) and performance-based RSUs. Performance-based RSUs are comprised ofof: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”).

The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
(in millions)	2019		2018		2019		2018		2020		2019
Stock options	$	5	$	6	$	17	$	17	$	4	$	6
RSUs	21		16		60		48		23		18
	$	26	$	22	$	77	$	65	$	27	$	24

Research and development expenses	$	2	$	3	$	7	$	7	$	3	$	2
Selling, general and administrative expenses	24		19		70		58		24		22
	$	26	$	22	$	77	$	65	$	27	$	24

Share-based awards granted consist of:


	Nine Months Ended September 30,				Three Months Ended March 31,
	2019		2018		2020		2019
Stock options
Granted	1,725,000		2,106,000		2,260,000		1,684,000
Weighted-average exercise price	$	23.16	$	15.46	$	24.77	$	23.16
Weighted-average grant date fair value	$	8.46	$	7.82	$	6.60	$	8.47

Time-based RSUs
Granted	2,895,000		2,844,000		2,453,000		2,401,000
Weighted-average grant date fair value	$	23.93	$	17.36	$	23.37	$	24.05

TSR performance-based RSUs
Granted	454,000		469,000		425,000		454,000
Weighted-average grant date fair value	$	34.53	$	29.35	$	26.13	$	34.53

ROTC performance-based RSUs
Granted	505,000		409,000		472,000		505,000
Weighted-average grant date fair value	$	25.03	$	18.80	$	27.05	$	25.03

~~The granted stock options, time-based RSUs and performance-based RSUs includes long-term incentive awards granted to the Company’s Chief Executive Officer ("CEO") during the three months ended~~As of March 31, 2018, which had an aggregate value of $10 million. In connection with his 2018 award, approximately 933,000 performance-based RSUs received by the CEO upon his hire in 2016 were cancelled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the Amended and Restated 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation

~~associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award.~~

~~As of September 30, 2019,~~2020, the remaining unrecognized compensation expense related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to ~~$119~~$161 million, which will be amortized over a weighted-average period of ~~1.71~~1.95 years.


~~14.~~13.	ACCUMULATED OTHER COMPREHENSIVE LOSS

Accumulated other comprehensive loss consists of:

(in millions) September 30,
2019 December 31,
2018
Foreign currency translation adjustments $ (2,129 ) $ (2,111 )
Pension and postretirement benefit plan adjustments, net of tax (27 ) (26 )
$ (2,156 ) $ (2,137 )



(in millions)	March 31, 2020			December 31, 2019
Foreign currency translation adjustment	$	(2,236	)	$	(2,046	)
Pension and postretirement benefit plan adjustments, net of income taxes	(45		)	(40		)
	$	(2,281	)	$	(2,086	)

Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.

During the three ~~and nine~~ months ended ~~September 30, 2019,~~March 31, 2020, amounts reclassified from Accumulated other comprehensive loss into the Company's operating results were 0t material.


~~15.~~14.	RESEARCH AND DEVELOPMENT

Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
(in millions)	2019		2018		2019		2018		2020		2019
Product related research and development	$	114	$	98	$	329	$	265	$	114	$	107
Quality assurance	9		9		28		28		8		10
	$	123	$	107	$	357	$	293	$	122	$	117


~~16.~~15.	OTHER EXPENSE (INCOME), NET

Other expense (income), net consists of:


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
(in millions)	2019			2018			2019			2018			2020			2019
Net (gain) loss on sale of assets	$	(1	)	$	26		$	(10	)	$	26
Net gain on sale of assets													$	(1	)	$	(10	)
Acquired in-process research and development costs													1			1
Acquisition-related costs	—			—			8			1			—			8
Litigation and other matters	9			(40		)	12			(30		)	23			2
Other, net	2			(1		)	5			—			—			(4		)
	$	10		$	(15	)	$	15		$	(3	)	$	23		$	(3	)

Included in Other, net in the table above for the nine months ended September 30, 2019, is $9 million of in-process research and development costs associated with the upfront payments to enter into certain exclusive licensing agreements.


~~17.~~16.	INCOME TAXES

For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company's ordinary income, subject to certain limitations on the benefit of losses. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company's income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company's estimated annual effective income tax rate may be revised, if necessary, in each interim period.

Benefit from income taxes for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 was ~~$101~~$26 million and included: (i) ~~$46~~$21 million of net income tax benefit for discrete items, which includes: (a) $10 million in tax benefits recognized for changes in uncertain tax positions, (b) a $5 million tax benefit related to a deduction for stock compensation and (c) $4 million of net tax benefits associated with filing certain tax returns and (ii) $5 million of income tax benefit for the Company's ordinary loss during the three months ended March 31, 2020.

Benefit from income taxes for the three months ended March 31, 2019 was $74 million and included: (i) $51 million of net income tax expense for discrete items, which includes: (a) $32 million of tax benefit recognized upon a ruling from the Polish tax authorities confirming the deductibility of royalty payments by an affiliate, (b) ~~$13~~$15 million inof net tax benefits associated with ~~the~~ filing of certain tax returns and (c) $1$4 million ~~of net~~in tax ~~charges related to other~~benefits recognized for changes in uncertain tax positions and (ii) ~~$55~~$23 million of income tax benefit for the Company's ordinary loss during the ~~nine~~three months ended ~~September 30,~~March 31, 2019.

Provision for income taxes for the nine months ended September 30, 2018 was $74 million and included: (i) $203 million of net income tax expense for discrete items, which includes: (a) $255 million of tax charges related to internal restructurings and (b) a $57 million tax benefit related to the impairment of intangible assets and (ii) $129 million of income tax benefit for the Company's ordinary loss during the nine months ended September 30, 2018.

The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was ~~$3,126~~$2,824 million and ~~$2,913~~$2,831 million as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, respectively. The ~~increase~~decrease was primarily due to ~~continued losses~~income in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.

As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, the Company had ~~$622~~$967 million and ~~$654~~$1,002 million of unrecognized tax benefits, which included ~~$48~~$46 million and ~~$42~~$45 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of ~~September 30, 2019, $316~~March 31, 2020, $321 million would reduce the Company’s effective tax rate, if recognized. The Company ~~anticipates~~believes that it is reasonably possible that the total amount of unrecognized tax benefits ~~resolved within~~at March 31, 2020 could decrease by approximately $110 million in the next 12 months ~~will not be material.~~as a result of the resolution of certain tax audits and other events.

The Company continues to be under examination by the Canada Revenue Agency. The Company’s position as of ~~September 30, 2019~~March 31, 2020 with regard to proposed audit adjustments has not changed and the proposed adjustments continue to result primarily in a loss of tax attributes that are subject to a full valuation allowance.

The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The Company has filed tax returns which used a capital loss generated in 2017 to offset capital gains generated in 2014. As these tax returns were filed subsequent to the commencement of the examination by the Internal Revenue Service, the Company’s 2014 tax year ~~cannot be closed commensurate with~~remains open to the ~~examination’s conclusion.~~extent of a 2017 capital loss carried back to that year. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's ~~consolidated financial statements.~~Consolidated Financial Statements.

The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2012 through 2017.

The Company’s subsidiaries in Germany are under audit for tax years ~~2013~~2014 through ~~2017.~~2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's ~~consolidated financial statements.~~Consolidated Financial Statements.

The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's ~~consolidated financial statements.~~Consolidated Financial Statements.

Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time,

the Company does not expect that proposed adjustments, if any, would be material to the Company's ~~consolidated financial statements.~~Consolidated Financial Statements.


~~18.~~17.	LOSS PER SHARE

Loss per share attributable to Bausch Health Companies Inc. were calculated as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
(in millions, except per share amounts)	2019			2018			2019			2018			2020			2019
Net loss attributable to Bausch Health Companies Inc.	$	(49	)	$	(350	)	$	(272	)	$	(3,804	)	$	(152	)	$	(52	)

Basic and diluted weighted-average common shares outstanding	352.4			351.5			351.9			351.1			353.4			351.3

Basic and diluted loss per share attributable to Bausch Health Companies Inc.	$	(0.14	)	$	(1.00	)	$	(0.77	)	$	(10.83	)	$	(0.43	)	$	(0.15	)

During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately ~~4,453,000~~5,207,000 and ~~4,238,000~~4,920,000 common shares for the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018, respectively, and approximately 4,589,000 and 3,323,000 common shares for the nine months ended September 30, 2019 and 2018,~~ respectively.

During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, time-based RSUs, performance-based RSUs and stock options to purchase approximately ~~5,363,000 common shares were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three~~9,561,000 and ~~nine months ended September 30, 2018, time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,750,000 and 3,979,000~~5,370,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.


~~19.~~18.	LEGAL PROCEEDINGS

From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described ~~below.~~in Note 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the three months ended March 31, 2020.

On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of ~~September 30, 2019,~~March 31, 2020, the Company's Consolidated Balance ~~Sheet~~Sheets includes accrued current loss contingencies of ~~$20~~$1,416 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.

Governmental and Regulatory Inquiries

SEC Investigation

Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the staff of the SEC’s Los Angeles Regional Office issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters. The Company ~~is cooperating~~continues to cooperate with the SEC in this ~~matter.~~matter, has responded to the Wells Notice and continues to engage in settlement discussions with the staff. The

Company has agreed to a tolling agreement with the SEC

regarding ~~certain~~these potential claims. ~~The~~Although the Company cannot predict the outcome or the duration of the SEC investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of the SEC ~~investigation.~~investigation, the Company expects that it will likely result in damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against the Company and/or certain of its former legacy directors and officers, any of which could be material. As a result, although no agreement has been reached, the Company has recorded an estimated liability based on these discussions which is included in the Company's accrued current loss contingencies. The final resolution may differ from the Company's current estimate and it could be material to the Company’s results of operations.

As referenced above, during the three months ended March 31, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under “Governmental and Regulatory Inquiries” inNote 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Such matters include:

AMF Investigation

On April 12, 2016, the Company received a ~~request~~ letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors, ~~(established to review certain allegations regarding the Company’s former relationship with Philidor and related matters),~~ the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. ~~The Company is cooperating with the AMF in this matter.~~ In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. ~~The Company cannot predict whether any enforcement action against the Company will result from such investigation.~~

~~Investigation by the State of Texas~~

On May 27, 2014, the State of Texas served Bausch & Lomb Incorporated ("B&L Inc.") with a Civil Investigative Demand concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&L products for the period from 1995 to the date of the Civil Investigative Demand. The Company and B&L Inc. have cooperated fully with the State's investigation and have produced all of the documents requested by the State to date. In April 2016, the State sent B&L Inc. a demand letter claiming damages in the amount of $20 million. The Company and B&L Inc. have evaluated the letter and disagree with the allegations and methodologies set forth in the letter. In June 2016, the Company and B&L Inc. responded to the State. In August 2019, the State provided an initial response to the Company’s June 2016 letter. The matter remains pending. The Company cannot predict the duration or outcome of the matter or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of the investigation.

Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin^®

In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of ~~Massachusetts. The~~Massachusetts, requesting materials ~~requested pursuant to the subpoena include~~including documents concerning the sales, marketing, coverage and reimbursement of Arestin^®, including related support services, and other matters.

The Company is cooperating with ~~this investigation.~~all these investigations. The Company cannot predict the outcome or the duration of ~~this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.~~

~~Investigation by the U.S. Attorney's Office for the District of Massachusetts - re patient assistance and pricing~~

In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, and, in June 2016, the Company received a follow-up subpoena. The materials requested, pursuant to the subpoenas and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company’s pricing of its products. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigationthese investigations or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.

~~Investigation by the U.S. Attorney's Office for the Southern District of New York~~

In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York. The materials requested, pursuant to the subpoena and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company’s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company’s pricing (including discounts and rebates), marketing and distribution of its products; the Company’s compliance program; and employee compensation. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.

Securities and RICO Class Actions and Related Matters

U.S. Securities Litigation - Opt-Out Litigation

On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658).

In October 2015, 4 putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor.

On May 31, 2016, the ~~Court~~court entered an order consolidating the 4 actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 3:15-cv-07658. On June 24, 2016, the lead plaintiff filed a consolidated complaint asserting claims under Sections 10(b) and 20(a) of the Exchange Act against the Company, and certain current or former officers and directors, as well as claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) against the Company, certain current or former officers and directors, and certain other parties. The lead plaintiff seeks to bring these claims on behalf of a putative class of persons who purchased the Company’s equity securities and senior notes in the United States between January 4, 2013 and March 15, 2016, including all those who purchased the Company’s securities in the United States in the Company’s debt and stock offerings between July 2013 to March 2015. On September 13, 2016, the Company and the other defendants moved to dismiss the consolidated complaint. On April 28, 2017, the ~~Court~~court dismissed certain claims arising out of the Company's private placement offerings and otherwise denied the motions to dismiss. On September 20, 2018, lead plaintiff filed an amended complaint, adding claims against ValueAct Capital Management L.P. and affiliated entities ("ValueAct"). On October 31, 2018, a ~~third party~~third-party defendant, ValueAct, filed a motion to dismiss. On June 30, 2019, the Court denied the motion to ~~dismiss~~dismiss.

On December 16, 2019, the Company, the current or former officers and directors, ValueAct, ~~has filed~~and the underwriters announced that they agreed to resolve the securities action for ~~interlocutory appeal~~$1,210 million, subject to final court approval. Once approved by the

court, the settlement will resolve and discharge all claims against the Company in the class action. As part of ~~this decision.~~the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. On January 27, 2020 the court preliminarily approved the settlement and scheduled the final settlement approval hearing for May 27, 2020. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment is being paid in accordance with the payment schedule outlined in the settlement agreement. The opt-out litigations discussed below remain ongoing.

On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 2:18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 3:15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.

In addition to the consolidated putative class action, ~~as previously reported in the Company’s Form 10-K,~~ NaN groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions ~~pending~~ in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. In addition to the matters captioned Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (“Maverick”) and Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (“Templeton”), these actions were captioned previously in the Company’s Annual Report on Form 10K for the year ended December 31, 2019, filed on February 19, 2020. NaN of the NaN opt out actions have been dismissed; and while the total number of remaining opt out actions pending in the District of New Jersey is NaN actions, the Company has reached agreement in principle to resolve several of these actions and expects those actions to be dismissed shortly.

These individual shareholder actions assert claims under Sections 10(b), ~~18,~~ and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, ~~and~~ negligent misrepresentation, claims under ~~state law,~~the New Jersey Racketeer Influenced and Corrupt Organizations Act and one plaintiff asserts claims under the Connecticut Uniform Securities Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. ~~Some plaintiffs additionally assert claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act and 1 plaintiff asserts claims under the Connecticut Uniform Securities Act.~~ The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed ~~-and~~and in most cases ~~decided-~~decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 3:18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 3:18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On December 13, 2019, the Court granted the Company’s motion to dismiss the Catalyst complaint in its entirety.

The Company ~~believes~~disputes the claims against it in the remaining individual opt-out complaints ~~and the consolidated putative class action are without merit~~ and intends to defend itself vigorously.

Canadian Securities Litigation

In 2015, 6 putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and ~~Quebec, as previously reported~~Quebec. The Company is also aware of 2 additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in ~~the Company's Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 20, 2019.~~

these actions are substantially similar to those outlined above.

The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.

~~The Rosseau-Godbout~~

Each of these putative class actions, other than the Catucci action ~~was stayed by~~in the Quebec Superior Court, ~~by consent order. The Kowalyshyn action~~ has been ~~consolidated with the O’Brien action and that consolidated action is stayed in favor of the Catucci action.~~discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings. A timetable for certain pre-trial procedural matters in the action has been set and the notice of certification has been disseminated to class members. Among other things, the timetable established a deadline of June 19, 2018 for class members to exercise their right to opt-out of the class.

The Company is aware of 2 additional putative class actions that have been filed with the applicable court but which have not yet been served on the Company, as previously reported in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 20, 2019, and the factual allegations made in these actions are substantially similar to those outlined above. The Company has been advised that the plaintiffs in these actions do not intend to pursue the actions.

In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.

The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, 1 of the entities which exercised its opt-out rights (“CalSTRS”) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, ~~California State Teachers’ Retirement System~~CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.

~~A settlement approval hearing has been scheduled for November 11, 2019 in~~On February 3, 2020, the Quebec Superior Court granted the applications of ~~Justice~~CalSTRS and BlackRock for leave to ~~hear~~pursue their respective actions asserting claims under the Quebec Securities Act. On March 11, 2020, the Company and the other defendants filed applications for leave to appeal from the decision of the Quebec Superior Court. The applications for leave to appeal are scheduled to be heard on June 9, 2020.

After a ~~motion brought by~~hearing on November 11, 2019, the ~~plaintiffs~~court approved a settlement in the Catucci action ~~for approval of a settlement~~ between the class members and the Company’s auditors.

The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.

Insurance Coverage Lawsuit

On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during 2 distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493). In the lawsuit, the Company seeks coverage ~~for (1)~~for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and ~~(2)~~(ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period).

Derivative Lawsuits

On September 10, 2019 and September 13, 2019, 2 alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833).

Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities

Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint. Briefing on this motion will conclude on July 6, 2020. The Company disputes these claims and intends to defend itself vigorously.

Other Securities and RICO Class Actions and Related Matters

As referenced above during the three months ended March 31, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under “Securities and RICO Class Actions and Related Matters” inNote 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Such matters include:

RICO Class Actions

Between May 27, 2016 and September 16, 2016, ~~3 virtually identical~~three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced

Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain ~~Company branded~~Company-branded drugs between January 2, 2013 and November 9, 2015. ~~On November 30, 2016, the Court entered an order consolidating the 3 actions under the caption~~ ~~In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation, No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016.~~ The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts ~~regarding~~regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription. The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute. ~~The Company moved to dismiss~~A decision on the consolidated complaint on February 13, 2017. On March 14, 2017, other defendants filed a motion to stay the RICO class action pending the resolution of criminal proceedings against Andrew Davenport and Gary Tanner. On August 9, 2017, the Court granted the motion to stay and entered an order staying all proceedings in the case and accordingly terminating other pending motions. On April 12, 2019, the court lifted the stay. On July 30, 2019, the plaintiffs filed an amended complaint. On August 28, 2019, the Company filed aCompany’s motion to dismiss ~~the amended complaint. Briefing on~~ this ~~motion concluded on October 25, 2019.~~

complaint is pending. The Company believes these claims are without merit and intends to defend itself vigorously.

Hound Partners Lawsuit

OnIn October ~~19,~~ 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer ~~County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit~~County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The factual allegations made in this complaint are similar to those made in the District of New Jersey Hound Partners action. On March 29, 2019, the Company, certain individual defendants, and Plaintiffs submitted a consent order to stay further proceedingsThis matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out ~~case Hound Partners Offshore Funds, LP et al. v. Valeant Pharmaceuticals International, Inc. (Case No. 3:18-cv-08705). On October 9, 2019, the Court entered the consent order.~~cases. The Company disputes the claims and intends to vigorously defend this matter.

~~Derivative Lawsuits~~

~~On September 10, 2019 and September 13, 2019, 2 alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are~~ ~~Wessels v. Pearson~~ ~~(Case No. 3:19-cv-17833) and~~ ~~Shabbouei v. Pearson~~ (Case No. 3:19-cv-17987). Plaintiffs in both cases assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The claims alleged in these cases are based on the same purported conduct that is at issue in ~~In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. The~~ ~~Shabbouei~~ complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The Company disputes these claims and intends to defend itself vigorously.

Antitrust

~~Generic Pricing Antitrust Class Action~~

As of June 2018, the Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this subsection, collectively, the “Company”), were added as defendants in putative class action multidistrict antitrust litigation entitled ~~In re: Generic Pharmaceuticals Pricing Antitrust Litigation~~, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuit to which the Company was added was filed by direct purchaser plaintiffs and seeks damages under federal antitrust laws, alleging that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. Specific claims against the Company’s subsidiaries relate to generic pricing of the Company’s metronidazole vaginal product as part of an

alleged overarching conspiracy among generic drug manufacturers. As of December 2018, 3 direct purchaser plaintiffs that had opted out of the putative class filed an amended complaint in the MDL that added Oceanside, Bausch Health US and Bausch Health Americas, alleging similar claims as the direct purchaser plaintiffs’ putative class action complaint. On October 18, 2019, Humana Inc. filed a related complaint against Oceanside, Bausch Health US and Bausch Health Americas, as well as other defendants, alleging similar claims. Separate complaints by other plaintiffs which had been consolidated in the same multidistrict litigation do not name the Company or any of its subsidiaries as a defendant. The Company has filed motions to dismiss the earlier-filed actions. On August 15, 2019, the Court denied defendants’ joint motion to dismiss claims asserting the existence of an overarching multi-drug conspiracy. The Company’s individual motion to dismiss the earlier-filed actions remains pending. Discovery against the Company’s subsidiaries has commenced. The Company continues to vigorously defend these matters. On July 18, 2019, 87 health plans filed a Praecipe to commence an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation. As of the date hereof, Plaintiffs have not filed a Complaint.

Glumetza Antitrust ~~Class Actions~~Litigation

InBetween August ~~September~~2019 and ~~October 2019, 6 (6)~~February 2020, 7 (7) putative antitrust class actions and 3 (3) non-class complaints were filed in the Northern District of California against the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (among other defendants) (the “California Actions”). ~~Four~~In February 2020, an eighth putative class action was filed in the Southern District of Florida; this action was transferred to the Northern District of California. NaN (3) of the ~~cases~~class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated amended complaint on November 25, 2019. The 5 (5) class actions filed by end payer purchasers have all been voluntarily dismissed. The 3 (3) non-class complaints were filed by direct ~~purchasers~~purchasers. These actions have been consolidated and ~~two of the cases were filed by end payer purchasers. The~~coordinated in In re Glumetza Antitrust Litigation, Case No. 3:19-cv-05822-WHA.

Both class and non-class direct purchaser ~~defendants~~plaintiffs seek damages ~~under federal antitrust laws and the end payer purchasers seek damages under state antitrust, consumer protection, and unjust enrichment laws as well as injunctive relief~~ under federal antitrust laws. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza^® delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza^® or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza^® and ~~metformin hydrochloride~~its generic equivalent both prior to and after generic entry. On April 29, 2020, the purported classes of direct purchasers filed their motion for class certification. Briefing on the motion is expected to conclude in June 2020. The Company and its affiliates named in these cases dispute the claims against them and intend to vigorously defend these matters.

Other Antitrust Matters

As referenced above during the three months ended March 31, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under “Antitrust” inNote 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019), filed with the SEC on February 19, 2020. This includes the following matter:

Generic Pricing Antitrust Litigation

Certain of the Company’s subsidiaries are defendants in a multidistrict antitrust litigation (“MDL”) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania. The lawsuits (which include claims by direct purchasers, end payers, indirect resellers and opt-outs) seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The Company disputes the claims against it and continues to defend itself vigorously.

Intellectual Property

Patent Litigation/Paragraph IV Matters

From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor^®, Uceris^®, Xifaxan^® 200mg, Xifaxan^® 550mg, Plenvu^®, ~~Bryhali~~Bepreve^®, ~~Prolensa~~Bryhali^®and Jublia^®in the United States and Jublia^®in Canada, or other similar suits. ~~These matters are proceeding in the ordinary course.~~

~~In July 2019,~~On February 17, 2020, the Company ~~announced that the U.S. District Court of New Jersey had upheld the validity of~~ and ~~determined Actavis' infringement of a patent protecting the Company's Relistor~~^® ~~tablets, expiring in March 2031. In July 2019, the Company also announced that it had agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc.~~Alfasigma S.p.A. ("~~Teva"~~Alfasigma") ~~regarding Apriso~~^® ~~extended-release capsules 0.375g. As part of the settlement, the parties agreed to dismiss all litigation related to Apriso~~^®~~, and intellectual property protecting Apriso~~^®~~will remain intact and enforceable. In addition, the Company will grant Teva a non-exclusive license effective October 1, 2021to the intellectual property relating to Apriso~~^®in the United States (provided that Teva will be able to begin marketing prior to such date if another generic version of the product is granted approval and starts selling or distributing such generic prior to October 1, 2021).

~~In September 2019, the Company~~ received a Notice of Paragraph IV Certification from ~~Sandoz,~~Norwich Pharmaceuticals Inc. (“~~Sandoz”~~Norwich”), in which ~~Sandoz~~Norwich asserted that the ~~following~~ U.S. patents ~~each of which is~~ listed in the ~~FDA’s~~U.S. Food and Drug Administration's (the "FDA") Orange Book for ~~Salix Pharmaceuticals, Inc.’s (“Salix Inc.”)~~the Company’s Xifaxan^® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of ~~Sandoz’s~~Norwich’s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Sandoz: U.S. Patent No. 8,309,569 (the “‘569 patent”), U.S. Patent No. 7,045,620 (the “‘620 patent”), U.S. Patent No. 7,612,199 (the “‘199 patent”), U.S. Patent No. 7,902,206 (the “‘206 patent”), U.S. Patent No. 7,906,542 (the “‘542 patent”), U.S. Patent No. 7,915,275 (the “‘275 patent”), U.S. Patent No. 8,158,644 (the “‘644 patent”), U.S. Patent No. 8,158,781 (the “‘781 patent”), U.S. Patent No. 8,193,196 (the “‘196 patent”), U.S. Patent No. 8,518,949 (the “‘949 patent”), U.S. Patent No. 8,741,904 (the “‘904 patent”), U.S. Patent No. 8,835,452 (the “‘452 patent”), U.S. Patent No. 8,853,231 (the “‘231 patent”),Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and ~~U.S. Patent No. 9,271,968 (the “’968 Patent”) (collectively, the “Xifaxan~~^® ~~Patents”). Salix Inc.~~Bausch Health Ireland Limited, holds the ~~NDA~~New Drug Application for Xifaxan^® and ~~its affiliate, Salix Pharmaceuticals, Ltd. (“Salix Ltd.”), is the owner~~owns or exclusively licenses (from Alfasigma) these patents. On March 26, 2020, certain of the ~~‘569 patent~~Company’s subsidiaries and ~~Alfa Sigma S.p.A. (“Alfa Sigma”) is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the~~

‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, and the ‘968 patent, each of which has been exclusively licensed to Salix Inc. and its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan^® ~~tablets, 550 mg. On September 30, 2019, Salix Inc. and its affiliates, Salix Ltd. and BIRL, and Alfa Sigma (the “Plaintiffs”)~~Alfasigma filed suit against ~~Sandoz~~Norwich in the U.S. District Court for the District of ~~New Jersey~~Delaware (Case No. ~~19-18566)~~20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by ~~Sandoz~~Norwich of one or more claims ~~of each~~ of the Xifaxan^® Patents, thereby triggering a 30-month stay of the approval of ~~Sandoz’s~~Norwich’s ANDA for rifaximin tablets, 550 mg. Xifaxan^® is protected by 23 patents covering the composition of matter and the use of Xifaxan^® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The ~~claim is substantially similar to the claim brought by Actavis in February 2016 that was settled in September 2018. The~~ Company remains confident in the strength of the Xifaxan^® patents and will continue to vigorously pursue this matter and defend its intellectual property.

A similar suit was also filed against Sandoz, Inc. (“Sandoz”) in September 2019, alleging infringement by Sandoz of one or more claims of certain of these Xifaxan^® Patents by the commercial manufacture, use or sale of Sandoz’s generic rifaximin tablets, 550 mg, for which an ANDA had been filed. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan^® (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan^® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan^® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan^® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan^® (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028.The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.

In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent & Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR

challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS’s IPR petition, the U.S. Patent and Trial Appeal Board, in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia^®and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. Jublia^®continues to be covered by ~~eight~~eleven other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through ~~2034.~~2035.

Product Liability

As referenced above, during the three months ended March 31, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under “Product Liability” inNote 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:

Shower to Shower^® Products Liability Litigation

Since 2016, the Company has been named in ~~one hundred and sixty-five (165)~~a number of product liability lawsuits involving the Shower to Shower^® body powder product acquired in September 2012 from Johnson & Johnson; due to dismissals, only twelve (12) of such product liability suits currently remain ~~pending, and these twelve (12) matters are subject to the Johnson & Johnson indemnification referenced below.~~

pending. Potential liability (including its attorneys’ fees and costs) arising out of ~~the covered Shower to Shower~~^® ~~lawsuits filed against the Company~~these remaining suits is subject to ~~certain~~full indemnification obligations of Johnson & Johnson owed to the Company, and legal fees and costs will be paid by Johnson & Johnson. ~~The Company and Johnson & Johnson reached an agreement on April 17, 2019, regarding the scope~~Ten of ~~the indemnification relating to the majority of the Shower to Shower~~^® matters (the “Covered Matters”) and the Company has dismissed the demand for arbitration that the Company filed against Johnson & Johnson to assert its rights to indemnification. Johnson & Johnson will fully indemnify the Company in the Covered Matters, which include (i) personal injury and products liability actions arising from alleged exposure to Shower to Shower^® ~~prior to March 2020 and (ii) consumer fraud, consumer protection, false advertising or other regulatory actions arising out of the manufacture, use, or sale of Shower to Shower~~^® ~~up to and including September 9, 2012. The Company does not believe that the Covered Matters will have a material impact on the Company’s financial results going forward.~~

~~The various lawsuits include 3 cases originally filed in the~~ ~~In re Johnson & Johnson Talcum Powder Litigation~~, Multidistrict Litigation 2738, pending in the United States District Court for the District of New Jersey, and one case that was filed in the District of Puerto Rico and subsequently transferred to the MDL. The Company and Bausch Health US were first named in a lawsuit filed directly into the MDL alleging that the use of the Shower to Shower^® product caused the plaintiff to develop ovarian cancer. The plaintiff agreed to a dismissal of all claims against the Company and Bausch Health US without prejudice. The Company has subsequently been named in 1 additional lawsuit, originally filed in the District of Puerto Rico and subsequently transferred into the MDL, but has not been served in that case. The Company was also named in 2 additionalthese lawsuits filed ~~directly into the MDL that have also not yet been served.~~

~~These lawsuits also include a number of matters filed in the Superior Court of Delaware and 6 cases filed in the Superior Court of New Jersey alleging~~by individual plaintiffs allege that the use of Shower to Shower^® caused the plaintiffs to develop ovarian cancer. The Company has been voluntarily dismissed from nearly all of these cases, with claims against Bausch Health US only remaining in 2 cases pending in New Jersey and 1 case pending in Delaware. NaN of the 6 cases in the Superior Court of New Jersey were voluntarily dismissed as to Bausch Health US as well.cancer or mesothelioma. The allegations in ~~the remaining 3~~these cases ~~specifically directed to Bausch Health US~~ include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, ~~and~~loss of consortium and/or punitive damages. One hundred twenty-two (122) of the Delaware actions were voluntarily dismissed without prejudice pursuant to stipulation in January 2019, and although the stipulation permitted the cases to be filed again within 60 days, 0ne of the cases have been refiled.

In addition, these lawsuits also include a number of cases filed in certain state courts in the United States (including the Superior Courts of California, Delaware and New Jersey); the District Court of Louisiana; the Supreme Court of New York (Niagara County); the District Court of Oklahoma City, Oklahoma; the South Carolina Court of Common Pleas (Richland County); and the District Court of Nueces County, Texas (transferred to the asbestos MDL docket in the District Court of Harris County, Texas for pre-trial purposes) alleging use of Shower to Shower^® and other products resulted in the plaintiffs developing mesothelioma. The Company has been successful in obtaining voluntarily dismissals in most of these cases or the plaintiffs have not opposed summary judgment. Presently, 4 cases remain pending in the Superior Court of New Jersey. The allegations in these cases generally include design defect, manufacturing defect, failure to warn, negligence, and punitive damages, and in some cases breach of express and implied warranties, misrepresentation, and loss of consortium. The damages sought ~~by the various Plaintiffs~~ include compensatory damages, including medical expenses, lost wages or earning capacity, ~~and~~ loss of ~~consortium. In addition, Plaintiffs seek~~consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys’ fees.

Additionally, 2two proposed class actions have been filed in Canada against the Company and various Johnson & Johnson entities (1(one in the Supreme Court of British Columbia and 1one in the Superior Court of Quebec)~~. The Company also acquired the rights to the Shower to Shower~~^® ~~product in Canada from Johnson & Johnson in September 2012. In the British Columbia matter, the plaintiff seeks to certify a proposed class action~~, on behalf of persons ~~in British Columbia and Canada~~ who have purchased or used Johnson & Johnson’s Baby Powder or Shower to Shower^®~~, including their estates, executors and personal representatives, and is alleging that~~. The class actions allege the use of ~~this~~the product increases certain health ~~risks. In the Quebec matter, the plaintiff sought to certify a proposed class action on behalf of persons in Quebec who have used Johnson & Johnson’s Baby Powder~~risks (British Columbia) or ~~Shower to Shower~~^®~~, as well as their family members, assigns and heirs, and is alleging~~ negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner. A certification (also known as authorization) hearing was held in the Quebec matter and the Court certified (or as stated under Quebec law, authorized) the bringing of a class action by a representative plaintiff on behalf of people in Quebec who have used Johnson & Johnson's Baby Powder and/or Shower to Shower^® ~~in their perineal area and have been diagnosed with ovarian cancer and/or family members, assigns and heirs.~~manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages.

~~The~~ In accordance with the indemnification agreement, Johnson & Johnson will continue to vigorously defend the Company ~~intends to defend itself vigorously~~ in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.

General Civil Actions

California Proposition 65 Related Matters

On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (Graham v. Bausch Health Companies, Inc., et al., Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.

On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson & Johnson (Gutierrez, et al. v. Johnson & Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US on June 28, 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs’ claims, which was granted on April 27, 2020 without prejudice.

The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.

New Mexico Attorney General Consumer Protection Action

The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson & Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower^® and its alleged causal link to mesothelioma and other cancers. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act, the New Mexico Medicaid Fraud Act, the New Mexico Fraud Against Taxpayers Act, and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. The Company disputes the claims asserted in this lawsuit and intends to vigorously defend the matter. On April 17, 2020, Bausch Health US filed a motion to dismiss.

Other General Civil Actions

As referenced above, during the three months ended March 31, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under “General Civil Actions” inNote 21, “LEGAL PROCEEDINGS,” to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019), filed with the SEC on February 19, 2020. These matters include:

Doctors Allergy Formula Lawsuit

In April 2018, Doctors Allergy Formula, LLC (“Doctors Allergy”), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas. Doctors Allergy claims its damages are not less than $23 million. The Company has asserted counterclaims against Doctors Allergy.

Litigation with Former Salix CEO

On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.

The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.

Completed or Dormant Matters

The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2020 or the Company anticipates that no further material activity will take place with respect thereto, or the matters have been dormant for several quarters. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.

California Proposition 65 Related Matters

On February 11, 2019, plaintiffs filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of their intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of the California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65) by manufacturing and distributing Shower to Shower^® that they allege contained talc contaminated with asbestos, a listed carcinogen. That notice letter was served on the Company on February 22, 2019. By statute, a private lawsuit may not be filed until at least 60 days have passed following service of this pre-suit notice letter. In April 2019, rather than filing a lawsuit against Bausch Health US, the plaintiffs moved for leave to amend their complaint in a pending Proposition 65 lawsuit (Luna, et al. v. Johnson & Johnson, et al., case 2:18-cv-04830-GW-KS) against Johnson & Johnson in federal court in California to

add Bausch Health US as a defendant. Plaintiffs subsequently filed a motion to dismiss the lawsuit without prejudice. The court ~~has ordered that~~dismissed the case ~~be dismissed~~ without ~~prejudice.~~

On April 15, 2019, a plaintiff filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of their intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of Proposition 65 by manufacturing and distributing Shower to Shower^® ~~that they allege contained silica, arsenic, lead and chromium (hexavalent compounds), which they allege are known to cause cancer and/or reproductive toxicity. That notice letter was served~~prejudice on ~~the Company on April~~December 18, 2019. ~~While the statutory 60 days have passed before a private lawsuit may be filed, no lawsuit has been filed to date.~~

~~On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson & Johnson (Gutierrez, et al. v. Johnson & Johnson, et al.~~, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California

Safe Cosmetics Act. This lawsuit was served on Bausch Health US on June 28, 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.

~~Doctors Allergy Formula Lawsuit~~

In April 2018, Doctors Allergy Formula, LLC (“Doctors Allergy”), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, Index No. 651597/2018. Doctors Allergy asserts breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas. Doctors Allergy claims its damages are not less than $23 million. On June 14, 2018, Bausch Health Americas filed a motion to dismiss the complaint in part and a motion to strike. On July 16, 2019 the court granted the Company's motion in part and dismissed Doctor's Allergy's fraud and punitive damages claims. On August 28, 2019, the Company filed an Amended Answer and asserted Counterclaims against Doctors Allergy alleging breach of the covenant of good faith and fair dealing and tortious interference with contract. Discovery is proceeding. Bausch Health Americas disputes the claims against it and intends to vigorously defend against those claims and enforce its rights as asserted in its Counterclaims.

~~Litigation with Former Salix CEO~~

On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. The Company disputes the claims and intends to vigorously defend the matter.

~~Completed or Inactive Matters~~

The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2019, have been inactive from the Company’s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.

Contact Lens Antitrust Class Actions

Beginning in March 2015, a number of civil antitrust class action suits were filed by purchasers of contact lenses against B&L Inc., 3 other contact lens manufacturers, and a contact lens distributor, alleging that the defendants engaged in an anticompetitive scheme to eliminate price competition on certain contact lens lines through the use of unilateral pricing policies, and alleging violations of Section 1 of the Sherman Act, 15 U.S.C. § 1, and of various state antitrust and consumer protection laws. These cases have been consolidated in the Middle District of Florida by the Judicial Panel for Multidistrict Litigation, under the caption In re Disposable Contact Lens Antitrust Litigation, Case No. 3:15-md-02626-HES-JRK. On August 19, 2019, B&L Inc. entered into a settlement, subject to ~~Court~~court approval, by which it agreed to pay $10 million to fully and finally resolve plaintiffs’ class claims against B&L Inc. in the case. On October 8, 2019, the settlement agreement was preliminarily approved by the ~~Court. Trial against~~court. A final fairness hearing regarding the ~~remaining defendants is scheduled for~~settlement was held on February 3,25, 2020. On March 4, 2020, the Court granted final approval of the settlement agreement in all respects and dismissed the case with prejudice as to B&L Inc., except as to any claim by persons who validly and timely requested exclusion from the settlement classes.

Mississippi Attorney General Consumer Protection Action

The Company and Bausch Health US were named in an action brought by James Hood, Attorney General of Mississippi, in the Chancery Court of the First Judicial District of Hinds County, Mississippi (Hood ex rel. State of Mississippi, Civil Action No. G2014-1207013, filed on August 22, 2014), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to the Shower to Shower^® body powder product and its alleged causal link to ovarian cancer. As indicated above, the Company acquired the Shower to Shower^® body powder product in September 2012 from Johnson & Johnson. The State sought compensatory damages, punitive damages, injunctive relief requiring warnings for talc-containing products, removal from the market of products that fail to warn, and

to prevent the continued violation of the Mississippi Consumer Protection Act (“MCPA”). The State also sought disgorgement of profits from the sale of the product and civil penalties. The State did not make specific allegations as to the Company or Bausch Health US. The Company and Bausch Health US ~~have~~ agreed to resolve this litigation pursuant to a settlement agreement with the State of Mississippi for a non-material amount. ~~At this time,~~On January 8, 2020, an order of dismissal ~~has not yet been~~with prejudice was entered by the Court.

Investigation by the State of Texas

On May 27, 2014, the State of Texas served Bausch & Lomb Incorporated (“B&L Inc.”) with a Civil Investigative Demand (“CID”) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&L products for the period from 1995 to the date of the CID. B&L Inc. has cooperated fully with the State's investigation and produced all the documents requested by the State to date. After an exchange of positions, B&L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. As part of the settlement, the underlying Texas Medicaid Fraud case will be dismissed.

Investigation by the U.S. Attorney's Office for the District of Massachusetts regarding patient assistance and pricing

In October 2015 and June 2016, the Company received two subpoenas from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents and witness interviews with respect to the Company’s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company’s pricing of its products. The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter nor has the Company had recent contact from the U.S. Attorney's Office for the District of Massachusetts with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.

Investigation by the U.S. Attorney's Office for the Southern District of New York

In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York, requesting materials including documents and witness interviews with respect to the Company’s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company’s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company’s pricing (including discounts and rebates), marketing and distribution of its products; the Company’s compliance program; and employee

compensation. The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.


~~20.~~19.	SEGMENT INFORMATION

Reportable Segments

~~Consistent~~The Company’s Chief Executive Officer ("CEO"), who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s ~~CEO currently:~~CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct ~~reports; the~~reports. The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment.

The following is a brief description of the Company’s segments:

•

The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.


•	The Salix segment consists of sales in the U.S. of GI products.


•	The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.


•	The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.

Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures.

Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, In-process research and development costs, Restructuring and integration costs, Acquisition-related contingent consideration costs and Other ~~income,~~expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.

Segment Revenues and Profits

Segment revenues and profits were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
(in millions)	2019			2018			2019			2018			2020			2019
Revenues:
Bausch + Lomb/International	$	1,175		$	1,147		$	3,501		$	3,459		$	1,114		$	1,118
Salix	551			460			1,505			1,323			477			445
Ortho Dermatologics	147			176			407			457			133			138
Diversified Products	336			353			964			1,020			288			315
	$	2,209		$	2,136		$	6,377		$	6,259		$	2,012		$	2,016

Segment profits:
Bausch + Lomb/International	$	333		$	341		$	989		$	988		$	325		$	319
Salix	375			304			995			868			319			288
Ortho Dermatologics	58			88			156			190			48			57
Diversified Products	246			267			714			766			202			236
	1,012			1,000			2,854			2,812			894			900
Corporate	(158		)	(167		)	(435		)	(442		)	(156		)	(125		)
Amortization of intangible assets	(475		)	(658		)	(1,452		)	(2,142		)	(436		)	(489		)
Goodwill impairments	—			—			—			(2,213		)	—			—
Asset impairments	(33		)	(89		)	(49		)	(434		)	(14		)	(3		)
Restructuring and integration costs	(4		)	(3		)	(28		)	(16		)	(4		)	(20		)
Acquisition-related contingent consideration	(3		)	19			(2		)	23			(13		)	21
Other income (expense), net	(10		)	15			(15		)	3
Operating income (loss)	329			117			873			(2,409		)
Other (expense) income, net													(23		)	3
Operating income													248			287
Interest income	2			3			9			9			7			4
Interest expense	(406		)	(420		)	(1,221		)	(1,271		)	(396		)	(406		)
Loss on extinguishment of debt	—			—			(40		)	(75		)	(24		)	(7		)
Foreign exchange and other	9			—			12			18			(13		)	—
Loss before benefit from (provision for) income taxes	$	(66	)	$	(300	)	$	(367	)	$	(3,728	)
Loss before benefit from income taxes													$	(178	)	$	(122	)

Revenues by Segment and Product Category

Revenues by segment and product category were as follows:

Three Months Ended September 30, 2019 Three Months Ended September 30, 2018
(in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total
Pharmaceuticals $ 217
$ 551
$ 97
$ 207
$ 1,072
$ 222
$ 460
$ 140
$ 233
$ 1,055
Devices 375
—
46
—
421
365
—
29
—
394
OTC 371
—
—
—
371
352
—
—
—
352
Branded and Other Generics 197
—
—
119
316
192
—
—
115
307
Other revenues 15
—
4
10
29
16
—
7
5
28
$ 1,175
$ 551
$ 147
$ 336
$ 2,209
$ 1,147
$ 460
$ 176
$ 353
$ 2,136

Nine Months Ended September 30, 2019 Nine Months Ended September 30, 2018
(in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products
Total
Pharmaceuticals $ 670
$ 1,505
$ 265
$ 617
$ 3,057
$ 667
$ 1,323
$ 346
$ 714
$ 3,050
Devices 1,127
—
130
—
1,257
1,117
—
90
—
1,207
OTC 1,063
—
—
—
1,063
1,046
—
—
—
1,046
Branded and Other Generics 582
—
—
332
914
576
—
—
294
870
Other revenues 59
—
12
15
86
53
—
21
12
86
$ 3,501
$ 1,505
$ 407
$ 964
$ 6,377
$ 3,459
$ 1,323
$ 457
$ 1,020
$ 6,259



	Three Months Ended March 31, 2020										Three Months Ended March 31, 2019
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	201	$	477	$	77	$	182	$	937	$	217	$	445	$	95	$	211	$	968
Devices	341		—		51		—		392		366		—		38		—		404
OTC	351		—		—		—		351		324		—		—		—		324
Branded and Other Generics	203		—		—		103		306		191		—		—		102		293
Other revenues	18		—		5		3		26		20		—		5		2		27
	$	1,114	$	477	$	133	$	288	$	2,012	$	1,118	$	445	$	138	$	315	$	2,016

The top 10 products for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ represented ~~38%~~40% and 36% of total revenues for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively.

Geographic Information

Revenues are attributed to a geographic region based on the location of the customer and were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
(in millions)	2019		2018		2019		2018		2020		2019
U.S. and Puerto Rico	$	1,369	$	1,329	$	3,851	$	3,766	$	1,211	$	1,200
Canada									90		79
Poland									73		62
Egypt									58		53
China	86		91		276		273		58		89
Canada	85		78		252		231
Japan	67		59		181		165		54		55
France									47		53
Germany									44		45
Mexico	56		56		158		153		41		46
Egypt	55		45		157		134
France	45		46		156		159
Poland	49		49		156		164
Russia	47		38		124		106		34		36
Germany	33		38		119		130
United Kingdom	27		29		85		87		23		29
Spain									20		21
Italy	18		19		62		64		20		22
Spain	18		17		62		61
Other	254		242		738		766		239		226
	$	2,209	$	2,136	$	6,377	$	6,259	$	2,012	$	2,016

Major Customers

Customers that accounted for 10% or more of total revenues were as follows:


	Nine Months Ended September 30,		Three Months Ended March 31,
	2019	2018	2020	2019
AmerisourceBergen Corporation			19%	16%
McKesson Corporation (including McKesson Specialty)	17%	18%	16%	17%
AmerisourceBergen Corporation	17%	18%
Cardinal Health, Inc.	14%	13%	13%	14%

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

INTRODUCTION

Unless the context otherwise indicates, as used in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” the terms “we,” “us,” “our,” “the Company,” and similar terms refer to Bausch Health Companies Inc. and its subsidiaries. This “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been updated through ~~November 4, 2019~~May 7, 2020 and should be read in conjunction with the unaudited interim Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended ~~September 30, 2019~~March 31, 2020 (this “Form 10-Q”). The matters discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1993, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, “Forward-Looking Statements”). See “Forward-Looking Statements” at the end of this discussion.

Our accompanying unaudited interim Consolidated Financial Statements as of ~~September 30, 2019~~March 31, 2020 and for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December 31, ~~2018,~~2019, which were included in our Annual Report on Form 10-K filed on February ~~20, 2019.~~19, 2020. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at www.sedar.com and on the SEC website at www.sec.gov. All currency amounts are expressed in U.S. dollars, unless otherwise noted.

OVERVIEW

We are a global ~~pharmaceutical and medical device~~ company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.

~~Business Strategy~~

Core Businesses

Our strategy is to focus our business on core therapeutic classes that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We believe this strategy has reduced complexity in our operations and ~~maximized~~maximizes the value of our: (i) eye-health, (ii) GI and (iii) dermatology businesses which collectively now represent a substantial portion of our revenues. We have found and continue to believe there is significant opportunity in these businesses and we believe ~~that~~ our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders. We identify these businesses as “core”, meaning that we believe we are best positioned to grow and develop them.

Reportable Segments and Strategies

Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.

The Bausch + Lomb/International segment - consists of our Global Bausch + Lomb eye-health business and our International Rx business. Our Global Bausch + Lomb eye-health business includes our Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx products, which in aggregate accounted for approximately ~~42%~~41%, ~~43%~~42% and ~~41%~~43% of our Company's revenues for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and the years ~~2018~~2019 and ~~2017,~~2018, respectively. Our International Rx business, with the exception of our Solta products, includes sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products ~~OTC products~~ and ~~medical device~~OTC products, which in aggregate accounted for approximately ~~13%~~14%, 13% and ~~14%~~13% of our Company's revenues for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and the years 2019 and 2018, ~~and 2017,~~ respectively.

Our Bausch + Lomb business is a fully-integrated eye-health business, which we believe is critical to maintaining and developing our position in the global eye-health market. As a ~~fully-integrated~~fully integrated eye-health business with a 165-year legacy, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices,

vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye-health market.

As part of our Global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment and growth. For instance, one of these trends ~~myopia,~~ is the increasing ~~substantially,~~rate of myopia, and importantly, myopia isas a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors, such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population for example, as more and more baby-boomers in the U.S. are reaching the age of 65. To supplement our well-established Bausch + Lomb product lines, we continue to identify new products tailored to address these key trends, which we develop internally with our own research and development (“R&D”) team to generate organic growth. We also license selective molecules or technology in leveraging our own R&D expertise through ~~development.~~development, as well as seek out external product development opportunities. Recent product launches include Biotrue^® ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA^® contact lenses, SiHy Daily contact lenses, Lumify^® (an eye redness treatment), Vyzulta^® (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite^® Eye Performance (vitamins to protect the eye from stressors such as ~~sun light~~sunlight and blue light emitted from digital devices).

The Salix segment - consists of sales in the U.S. of GI products and includes our Xifaxan^® product. Our Xifaxan^®product ~~which~~ accounted for ~~approximately 17%, 14%~~revenues of $375 million, $1,452 million and ~~11% of our total revenues~~$1,195 million for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and the years ~~2018~~2019 and ~~2017,~~2018, respectively.

As part of our acquisition of Salix ~~Pharmaceutical,~~Pharmaceuticals, Ltd. in April 2015 (the "Salix Acquisition"), we acquired the intellectual property to a number of products that have provided us with year-over-year revenue growth, particularly the intellectual ~~properties~~property behind Xifaxan^® for, amongst other indications, irritable bowel syndrome with diarrhea (“IBS-D”), and Relistor^® for opioid induced ~~constipation (“OIC”).~~constipation. Revenues from our Xifaxan^® ~~and Relistor~~^® ~~products~~product increased approximately 23%, 22% and ~~37%, respectively, in 2018 when compared to 2017 and increased 19% and 9%, respectively, for~~22% during the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and in the years 2019 ~~when compared~~and 2018, respectively.

We attribute the growth in our Salix revenues to the ~~nine months ended September 30, 2018. We attribute these increases, in part, to our January~~investments we have been making since 2017, including: (i) hiring 200 trained and experienced sales force ~~expansion program described later in~~representatives to expand the ~~discussion of our Salix infrastructure.~~

~~Our Salix business strategy includes building upon our~~commercial field force for Xifaxan^® ~~and Relistor~~^® ~~business models. Specifically, we have identified and continue to look for opportunities to capitalize~~, (ii) increasing the focus on the ~~sales force and infrastructure we have built around our Xifaxan~~^® ~~and Relistor~~^® ~~products. Part~~development of that strategy is to gain access to new products through innovation, co-promotion and acquisition. We have been executing on these strategies in the second half of 2018 and during 2019, as we: (i) are in the process of developing next generation formulations of our Salix intellectual ~~properties~~property to address new indications, ~~(ii) have completed~~(iii) completing the strategic acquisition of certain assets of Synergy Pharmaceuticals Inc. (“Synergy”), which included the Trulance^® product, (iv) increasing the number of sales force representatives for Trulance^® and ~~(iii) have entered~~(v) entering into licensing agreements for investigational products, which, once developed and if approved by the U.S. Food and Drug Administration ~~(the "FDA"~~("FDA"), will be new treatments for certain GI and liver diseases. Each of these opportunities potentially provides us with the ability to expand our GI portfolio and allows us to leverage our existing GI sales force, supply channel and distribution channel.

The Ortho Dermatologics segment - consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological products) and (ii) global sales of Solta dermatological devices.

The Ortho Dermatologics business is our medical dermatology business dedicated to the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis, onychomycosis and other dermatoses and includes our Duobrii^®, Bryhali^®, Jublia^®and Siliq^® product lines. As part of our business strategy for the Ortho Dermatologics segment, we have made significant investments to build out our psoriasis, atopic dermatitis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities, with a focus on topical gel and lotion products over injectable biologics. We continue to support and develop injectable biologics; however, we believe some patients prefer topical products as an alternative to injectable biologics. Further, as topical products can, in many cases, defer the use of injectable biologics that often come with associated risk/benefit profiles, a topical product is usually ~~more~~ readily adopted by payors, is less expensive and can be more cost-effective than injectable biologics. Therefore, we believe topical products represent alternative treatments for physicians, payors and patients, and as the preferred choice of treatment, have the potential to drive greater volumes, generate better margins and will ultimately be a key contributing factor of our Ortho Dermatologics business.

~~In addition~~During 2017 through the date of this filing, we have made significant investments to build out our ~~established~~aesthetics, psoriasis and ~~in-development~~acne product ~~lines,~~portfolios, which we ~~also look to gain access to other dermatology products through strategic licensing agreements. We~~ believe, ~~this allows us to leverage~~coupled with our experienced dermatology sales leadership team and our recently expanded Ortho Dermatologics sales force, ~~to drive growth in~~will position our Ortho Dermatologics ~~business.~~

business for growth.

Our Solta business is dedicated to the development of innovative treatment technologies that provide proven and effective medical aesthetic and therapeutic benefits to consumers. Global Solta revenues were $51 million and $38 million for the three months ended March 31, 2020 and 2019 and $194 million and $135 million the years 2019 and 2018, respectively. The ~~Solta portfolio which includes our~~increase in revenue is primarily attributable to Next Generation Thermage FLX^®, a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX^® ~~systems, Fraxel~~was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia,

Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX^® ~~system, Clear + Brilliant~~^® ~~systems~~revenues for three months ended March 31, 2020 and ~~VASERlipo~~^® ~~system, collectively make up a comprehensive platform to address a range of aesthetic skin~~2019 were $26 million and ~~body issues.~~$12 million, respectively and in full-year 2019 were $77 million.

The Diversified Products segment - consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, such as Wellbutrin^®, Aplenzin^®, Cuprimine^®, Ativan^® and Migranal^®, (ii) generic products, such as Uceris^® ~~AG,~~authorized generic (“AG”), Elidel^® AG and Diastat^® AG and (iii) dentistry products, such as Arestin^® and NeutraSal^®.

~~Significant Seven~~

~~We have focused our R&D~~ The Company utilizes the Diversified Products segment to ~~advance development programs~~extend the long-term cash flows from a number of assets that ~~we believe will drive growth in our core businesses, while creating efficiencies in our R&D efforts~~are expected to decline over time due to the loss of exclusivity, by launching and ~~expenses. These programs include the following products which we have dubbed our "Significant Seven", all~~selling authorized generic versions of ~~which have been launched as of June 2019.~~


•	~~Duobrii~~certain branded assets.^® (Ortho Dermatologics) - Launched in June 2019 and is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults.


•	~~Bryhali~~^® ~~(Ortho Dermatologics) - Launched in November 2018 and is a novel product that contains a unique, lower concentration of halobetasol propionate for the treatment of moderate-to-severe psoriasis.~~


•	~~Lumify~~^® ~~(Bausch + Lomb) - Launched in May 2018 and is an OTC eye drop developed as an ocular redness reliever.~~


•	~~SiHy Daily AQUALOX~~^TM~~(Bausch + Lomb) - Launched in Japan in September 2018 and is a silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day.~~


•	~~Siliq~~^® ~~(Ortho Dermatologics) - Launched in the U.S. in 2017 and is an IL-17 receptor blocker monoclonal antibody for patients with moderate-to-severe plaque psoriasis.~~


•	~~Vyzulta~~^® ~~(Bausch + Lomb) - Launched in December 2017 and is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle glaucoma or ocular hypertension.~~


•	~~Relistor~~^® (Salix) - Launched in 2016 and is given to adults who use narcotic medicine to treat severe chronic pain that is not caused by cancer to prevent constipation without reducing the pain-relieving effects of the narcotic.

~~As outlined later in this discussion, we believe the prospects for this group of products to be substantial and anticipate devoting significant marketing efforts toward their promotion.~~

For a comprehensive discussion of our business, business strategy, products and other business matters, see Item 1. “Business” included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC and the Canadian Securities Administrators ("CSA") on SEDAR on February ~~20, 2019.~~19, 2020.

~~Focus~~Impact of COVID-19 Pandemic

The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel.

As ~~part~~the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events and reactions relating to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict at this time. The extent and duration of the pandemic, the rapidly evolving reactions of governments, private sector participants and the public to the COVID-19 pandemic and the associated disruption to business and commerce generally, and the extent to which these may impact the Company's business, financial condition, cash flows, development programs and results of operations in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the ultimate geographic spread and duration of the pandemic, new information which may emerge concerning the severity of the COVID-19 pandemic, the effectiveness and intensity of measures to contain COVID-19 and/or address its impacts, and the ultimate economic impact of the pandemic. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on our business, financial condition, cash flows and results of operations.

To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although, it is difficult to predict the broad macroeconomic effects that the COVID-19 virus will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand. Primarily due to this assessment, we have taken actions to manage the level of our ~~commitment~~investment in support of certain existing products, anticipated launches and the expansion of our sales footprint in Europe. Postponing these investments may impact the extent and timing in achieving our longer-term forecasts for certain business units, however we believe these actions will not have a material impact on the underlying value of the related businesses or their associated assets.

We are and will continue to closely monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic.

We believe we have responded quickly to the human and commercial challenges brought on by COVID-19 and that our early actions have, so far, enabled us to keep our employees safe and our supply lines largely intact and we believe these actions have laid the foundation for us to work our way through the uncertainties to come. Importantly, we believe that the steps we took over the last several years to manage our capital structure place us in a strong position to maintain sufficient liquidity to continue operations through an extended pandemic and we believe that our businesses will not see their long-term value diminished by this unprecedented situation.

Our Employees

The health and safety of our employees is paramount. Our senior management team meets regularly to assess this ongoing situation and has implemented multiple actions to protect our employees. In most locations, employees not directly involved in production, including our sales forces, are working remotely. For essential personnel in our manufacturing and distribution centers, we are taking every precaution to ensure that these employees are working in an environment that is as safe as possible, including following procedures as prescribed by global public health organizations, such as the WHO and U.S. Centers for Disease Control and Prevention.

Our Supply Chain and Manufacturing Facilities

Our objective is to maintain the uninterrupted availability of our products to meet the needs of patients, consumers and our customers, and in fact, we have stepped up production to meet increased demand for certain of our consumer products. Business continuity plans and site-level biosecurity procedures are in place to ensure the well-being of our employees while we work to maintain the integrity of our supply chain. As of the date of this filing, we have not experienced any disruption in our supply chain that would have a material impact on our results of operations.

Our global supply chain team worked diligently to stay ahead of this challenge once it appeared in Asia and has used that experience to put in place procedures to mitigate the risks of closures and disruptions at our manufacturing facilities in other regions. We have multiple sources of active pharmaceutical ingredients ("API") and intermediates for many of our products, the availability of which has not had, and at this time we do not expect will have, a material impact on our supply chain. We have been largely successful in keeping our manufacturing facilities operational, although our facilities in Milan, Laval and China were closed for short periods of time but have since resumed operations. With respect to our ~~core businesses,~~largest product, Xifaxan^®, as of April 30, 2020, we ~~began analyzing the strategic alternatives~~have over five months’ supply of Xifaxan^® on hand and enough API to manufacture another five months’ supply of Xifaxan^® finished goods. We also have open orders for ~~business units and assets~~API that ~~fall outside~~we currently expect will arrive on schedule. However, if we were to experience a lack of availability of API for Xifaxan^®, such disruption to our ~~definition of “core”. In order to focus~~supply chain could have a significant adverse effect on our ~~objectives, in 2016~~business, financial condition and ~~2017,~~results of operations.

Our Product Pipeline

Our leadership team actively manages the Company's product pipeline to identify what we ~~divested businesses~~believe are innovative and ~~assets, which were not~~realizable projects aligned with our core ~~business objectives. This~~businesses that are expected to provide incremental and sustainable revenues and growth. During the COVID-19 pandemic, our R&D team remains focused on meeting these objectives in a timely manner; however, there are significant events and circumstances regarding the COVID-19 pandemic that may materially affect our R&D team’s ability to do so, many of which are beyond the Company's control. As a result of these events and circumstances, we have had to pause certain early stage clinical trial and research efforts, which in turn is expected to lead to delays in the development and the anticipated launch of certain projects.

Due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, we have been forced to pause certain R&D activities. Clinical trials that started prior to governmental shutdowns remain enrolled and existing patients are progressing, while new patient enrollments in clinical trials have been temporarily paused as most trial sites are not ~~only allowed us~~able to ~~better focus~~accept new patients. While we anticipate resuming these projects as soon as possible, the ultimate impact on the timing and completion of the affected clinical trial programs, and the expected approval and launch of the product candidates to which these development programs relate, is dependent upon when many COVID-19 pandemic uncertainties are resolved and we may resume new patient enrollments and other impacted development activities. As of the date of this filing, the delays in our ~~internal resources~~clinical trials have not had a material impact on our ~~eye-health, GI~~operating results. However, continued delays in our ability to resume new patient enrollments along with other possible COVID-19 pandemic related challenges impacting our R&D projects, which are beyond the Company's control, could lead to additional disruptions. Other possible COVID-19 pandemic related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and ~~dermatology businesses, but also provided us with~~surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays caused by COVID-19 pandemic challenges such as these and others, will likely adversely affect the timely approval, launch, commercialization and the commercial success of our products, which could have a significant adverse effect on our future operating results.

Our Liquidity

Our primary sources of ~~capital, which we used to reduce~~liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our 2023 Revolving Credit Facility, issuances of long-term debt and ~~improve~~issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least twelve months from the date of issuance of this Form 10-Q. Further, in 2019 and 2018, we generated positive cash from operations of $1,501 million and $1,501 million, respectively. Should our operating results during the COVID-19 pandemic materially suffer in comparison to our 2019 and 2018

operating results, we believe we would continue to generate sufficient cash flows from operations to meet our obligations in the ordinary course of business.

As of the date of this filing, we have no debt maturing or mandatory amortization of debt payments until the first quarter of 2022. Additionally, we have no outstanding borrowings, $168 million of issued and outstanding letters of credit and remaining availability of $1,057 million under our 2023 Revolving Credit Facility as defined below. In the event of a future, unexpected, need for near-term liquidity, our 2023 Revolving Credit Facility would be a source of funding for us. After reviewing the terms of our Restated Credit Agreement as defined below and considering a broad range of possible outcomes of the COVID-19 pandemic, we expect that we will have access to capital ~~structure.~~under our 2023 Revolving Credit Facility across a broad range of scenarios in the event it is required.

Our Operating Results

While we are taking actions to mitigate the impact of the COVID-19 pandemic on our daily operations, the pandemic has and is expected to impact our operating results until the pandemic subsides. The changing dynamics of the pandemic, related responses from governments and private sector participants and the precautionary measures taken by our customers and the health care patients and consumers we serve, are expected to impact the timing and amount of our revenues in the near-term. Certain of our businesses have experienced COVID-19 pandemic related declines in revenues during the three months ended March 31, 2020 and we expect continued pandemic-related revenue declines in these and other businesses in the second quarter and possibly the remainder of 2020.

During the pandemic, the public has been advised to: (i) remain at home, (ii) limit social interaction, (iii) close non-essential businesses and (iv) postpone certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors have negatively impacted, most notably, the revenues of our Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. We anticipate further revenue declines in these businesses during 2020, as we saw steeper declines in these revenues in the month of March as social restrictions, particularly in the U.S. and Europe, were put in place. Beginning in March and into our second quarter, we also experienced and are anticipating COVID-19 pandemic-related revenue declines in intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of our Ophthalmology business, in medical aesthetics and therapeutic products of our Global Solta business, and in certain branded pharmaceutical products of our Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers are closed and certain surgeries and elective medical procedures are being deferred.

Based on our assessment, we believe our revenues will be most impacted by the pandemic during our second quarter, as the infection rate of the COVID-19 virus accelerated in March into April, the virus had spread beyond Asia into different geographies including the U.S. and Europe, and the number of shelter-in-place directives issued by local authorities increased. Although we expect each of the affected businesses and geographies to recover at different rates, overall we anticipate that the negative trend in our revenues will begin to stabilize during our second quarter and continue into our third quarter with the revenues of all our businesses possibly returning to pre-pandemic levels as early as late 2020, but, if not, then in 2021. This assessment assumes, among other matters, that the precautionary measures taken by the public are successful in decelerating the spread of the virus, there will be no resurgence of the virus in the second half of 2020 that will lead to significant social restrictions,there will be no significant social restrictions in place at the end of 2020, responses from governments and private sector participants will be successful in bringing about a quick orderly recovery of the global economy, there will be no major interruptions in our supply, manufacturing and distribution channels and we are able to continue to execute on our strategies in response to the pandemic.

The changes in our segment revenues and segment profits, including the impact of the COVID-19 virus on our revenues for the three months ended March 31, 2020, are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

Through the date of this filing, the impacts of the COVID-19 pandemic appears to have only a limited impact on our Xifaxan^® product revenues and the COVID-19 pandemic is not expected to have a material impact on the Company's revenues once the pandemic subsides. As such, the impacts of the COVID-19 pandemic on the amounts and timing of the Company's revenues are not expected to be substantial enough to materially adversely affect the recoverability of any of the Company's assets and are not material enough to indicate that the fair values of any reporting unit may be below their respective carrying values.

However, if market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management’s expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.

Business Strategy

Our Focus on Core Businesses

In order to continue to focus on our core businesses where we believe there is potential for strong operating margins and evidence of growth opportunities, we have: (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in ~~improving~~effectively managing our capital structure, (iii) increased our efforts to improve patient access and ~~(iii) aggressively addressed and resolved certain legacy legal matters~~(iv) continued to ~~eliminate disruptions~~invest in sustainable growth drivers to ~~our operations.~~position us for long-term growth.

Direct Capital Allocation ~~of Capital~~ to Drive Growth Within Our Core Businesses

~~In support of~~Our capital allocation is driven by our ~~core activities, we~~long-term growth strategies. We have been aggressively allocating resources ~~to: (i)~~to promote our core businesses globally through: (i) strategic acquisitions, (ii) ~~make~~R&D investment and (iii) strategic investments in our ~~infrastructure and (iii) direct R&D to our Bausch + Lomb, GI and dermatology businesses to drive growth organically.~~infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.

Strategic ~~Acquisition~~Acquisitions - We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as "bolt on" acquisitions. In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities. Recently, we have entered into transactions that, although not immediately impactful to our operating results, are expected to be accretive to our bottom line in future years and contribute to our long-term growth strategies.

In March 2019, we completed the acquisition of certain assets of Synergy whereby we acquired the worldwide rights to the Trulance^® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC

and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance^® product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.

~~Continued Investment in Emerging Markets~~ ~~- In October 2018,~~On February 18, 2019, we acquired the ~~40% minority interests of Medpharma Pharmaceutical and Chemical Industries LLC ("Medpharma") for $18 million, thereby completing~~U.S. rights to EM-100 from Eton Pharmaceuticals, Inc. EM-100, is an investigational eye drop that, if approved by the ~~planned acquisition of this joint venture. Medpharma formulates, manufactures and distributes certain branded generic pharmaceuticals and non-patented generic pharmaceuticals~~FDA, will be the first OTC preservative-free formulation eye drop for the ~~Company~~treatment of ocular itching associated with allergic conjunctivitis. A Phase 3 trial has been completed and ~~third parties. In 2014,~~submitted to the FDA for review and we entered into the Medpharma joint venture to provide the Company with a presence in the United Arab Emirates ("UAE"). The completion of this acquisition provides us with full control over the business activities of Medpharma and allows us to wholly benefit from the allocation of additional Company resources and the growth, if any, in the UAE and the surrounding region.

~~Strategic Investments in our Infrastructure~~ - In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland and our Rochester facility in New York.

~~To meet the forecasted demand for our Biotrue~~^® ONEday lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility. The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.

~~To address the expected global demand for our Bausch + Lomb ULTRA~~^® ~~contact lens, in December 2017, we completed a multi-year, $200 million strategic upgrade to our Rochester facility. The upgrade increased production capacity in support of our Bausch + Lomb Ultra~~^® ~~and SiHy Daily AQUALOX~~^TM ~~product lines and better supports the production of other well-established contact lenses, such as our PureVision~~^®~~, PureVision~~^®~~2 (SVS, Toric, and Multifocal), SofLens~~^® ~~38 and SilSoft~~^®.

To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. SiHy Daily disposable contact lenses, one of our Significant Seven products, are expected to be launched in the U.S.anticipate their response in the second half of 2020.

~~We believe the investments in~~ If approved, EM-100 is expected to complement our ~~Waterford and Rochester facilities and related expansion~~broad range of ~~labor forces further demonstrates the growth potential we see in our~~ Bausch + Lomb ~~products and~~integrated eye-health products.

We are considering further acquisition opportunities within our ~~eye-health business.~~core therapeutic areas, some of which could be material in size.

~~Direct~~ R&D Investment ~~to our Bausch + Lomb, GI and Dermatology Businesses to Drive Growth Organically~~ - We continuously search for new product opportunities through internal development and strategic licensing agreements, that if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market.

Internal R&D Projects - Our R&D organization focuses on the development of products through clinical trials. As of December 31, ~~2018,~~2019, approximately ~~1,200~~1,400 dedicated R&D and quality assurance employees in 23 R&D facilities were involved in our R&D ~~efforts.~~efforts internally.

~~As part~~Our R&D expenses for the three months ended March 31, 2020 and the years 2019 and 2018, were $122 million, $471 million and $413 million, respectively, and was approximately 6% as a percentage of ~~our turnaround, we removed projects related to divested businesses~~revenue for the three months ended March 31, 2020 and ~~rebalanced our portfolio to better align with our long-term plans~~5% as a percentage of revenue in each of the years 2019 and ~~focus on core businesses.~~2018. Our investment in R&D reflects our commitment to drive organic growth through internal development of new products, a pillar of our ~~new~~ strategy.

We have over 225 projects in our global ~~pipeline and anticipate submitting approximately 115 of those~~pipeline. Certain core R&D projects ~~for regulatory approval in 2019 and 2020.~~

~~Core assets~~ that have received a significant portion of our R&D investment in current and prior periods are listed below. However, due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, we have been forced to pause certain R&D activities. Clinical trials that started prior to governmental shutdowns remain enrolled and existing patients are progressing, while new patient enrollments in clinical trials have been temporarily paused as most trial sites are not able to accept new patients. While we anticipate resuming these projects as soon as possible, the ultimate impact on the timing and completion of the affected clinical trial programs, and the expected approval and launch of the product candidates to which these development programs relate, is dependent upon when many COVID-19 pandemic uncertainties are resolved and we may resume new patient enrollments and other impacted development activities. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results. However, continued delays in our ability to resume new patient enrollments along with other possible COVID-19 pandemic related challenges impacting our R&D projects, which are beyond the Company's control, could lead to additional disruptions. Other possible COVID-19 pandemic related challenges include, but are not limited to, facility closures, delays by third-party

service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays caused by COVID-19 pandemic challenges such as these and others, will likely adversely affect the timely approval, launch, commercialization and the commercial success of our products. As a result, our estimates regarding the timing and success of our R&D efforts (some of which are set out below), including as it relates to study initiation, enrollment and completion, availability of study results, regulatory submissions, regulatory approvals and commercial launches, may change.

•

Dermatology - In June 2019, we launched Duobrii^®, the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults. Halobetasol propionate and tazarotene are each approved to treat plaque psoriasis when used separately, but the duration of halobetasol propionate is limited by FDA labeling constraints and the use of tazarotene can be limited due to tolerability concerns. However, the combination of these ingredients in Duobrii^®, with a dual mechanism of action, allows for expanded duration of use, with reduced adverse events.


•	~~Dermatology - In November 2018, we launched Bryhali~~^®, a novel product that contains a unique, lower concentration of halobetasol propionate for the treatment of moderate-to-severe psoriasis which is FDA approved for 8 weeks of use. The FDA has previously approved halobetasol propionate to treat plaque psoriasis, but limited duration of use to two weeks.

Dermatology - Internal Development Project ("IDP") 131 is a new chemical entity, KP-470, for the topical treatment of psoriasis. On February 27, 2018, we announced that we entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. to develop and commercialize the compound. An early proof of concept study was initiated in the first half of 2019. If approved by the FDA, KP-470 could represent a novel drug with an alternative mechanism of action in the topical treatment of psoriasis.

•

~~Bausch + Lomb - Bausch + Lomb ULTRA~~^® ~~for Astigmatism is a monthly planned replacement contact lens for astigmatic patients. The Bausch + Lomb ULTRA~~^® ~~for Astigmatism lens was developed using the proprietary MoistureSeal~~^® ~~technology. In addition, the Bausch + Lomb ULTRA~~^® ~~for Astigmatism lens integrates an OpticAlign~~^® design engineered for lens stability and to promote a successful wearing experience for the astigmatic patient. In 2017, we launched this product and the extended power range for this product. In 2018, we launched the Bausch + Lomb ULTRA^® ~~for Astigmatism -2.75 cylinder expanded SKU range.~~

•

Bausch + Lomb - SiHy Daily ~~AQUALOX~~^TMis a silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. ~~Product validation was completed~~In September 2018, we launched this product in ~~June 2018 and~~Japan under the branded name SiHy Daily AQUALOX^TM™ ~~was launched in Japan in September 2018.~~. We ~~expect to launch~~anticipate launching our SiHy Daily ~~disposable~~ contact lens in the U.S. induring the second half of ~~2020.~~2020 under its U.S. branded name which is yet to be announced.

Dermatology - ~~IDP-126~~Internal Development Project ("IDP") 126 is an acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 studies ~~are planned to start~~initiated in December ~~2019.~~2019 have been paused as a result of COVID-19 related factors and are expected to resume in the second half of 2020 assuming clinical sites throughout the various geographies re-open to allow for enrollment of new patients.


•	Bausch + Lomb - Lumify^® (brimonidine tartrate ophthalmic solution, 0.025%) is an OTC eye drop developed as an ocular redness reliever. We have several line extensions ~~currently~~ under ~~development and further~~development. Further clinical studies are planned ~~to start in 2020.~~for late 2020 and early 2021.

Gastrointestinal - ~~We have initiated a~~Topline data from our Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation of rifaximin ~~which~~showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The topline results of this study will help inform further research on potential new indications for rifaximin using this formulation, including in sickle cell anemia where we ~~acquired as part of the Salix Acquisition. We~~ expect our clinical trials to ~~complete an interim analysis by the first quarter of 2020.~~commence late 2020 or early 2021.

•

Gastrointestinal - Following the read out of the overt hepatic encephalopathy study, we are planning to initiate a study potentially evaluating the new formulation of rifaximin in potential hepatic encephalopathy and gastrointestinal conditions. The study is expected to start in the second half of 2020. This study replaces the planned Xifaxan^® ~~550mg tablets Phase 2 study evaluating the prevention of complications of decompensation cirrhosis referenced in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019.~~

Gastrointestinal - We are ~~initiating~~preparing to initiate a Phase 2 study to evaluate rifaximin for the treatment of small intestinal bacterial overgrowth or SIBO. Patient enrollment ~~is expected~~remains subject to ~~begin~~getting clinical sites activated post COVID-19 and we expect our clinical trials to commence in the ~~first~~second half of 2020.

Gastrointestinal - We have entered into a collaboration with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS. Studies to support this research program have been paused as a result of COVID-19 related factors and are expected to resume upon the re-opening of the relevant clinical sites.

Dermatology - IDP-120 is an acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 enrollment has been completed with results expected in the second half of 2020.


•	Dermatology - Arazlo^™ (tazarotene) Lotion, 0.045% (formerly IDP-123) is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. The FDA approved the New Drug Application ("NDA") for Arazlo^™on December 18, 2019, which we expect to launch in the first half of 2020.

Gastrointestinal - Our partner Alfasigma S.p.A. ("Alfasigma") is initiating a Phase 2/3 study for the treatment of postoperative Crohns disease using a novel rifaximin extended release ~~formulation. The study is expected to start~~formulation in the ~~first~~second quarter of 2021; the start has been delayed due to COVID-19 related factors.

Gastrointestinal - We are developing a probiotic supplement to address gastrointestinal disturbances. Clinical trial is completed and a full data set is available. We expect to launch this product in the second half of 2020.

~~Dermatology - IDP-120 is an acne product with a fixed combination of mutually incompatible ingredients; benzoyl peroxide and tretinoin. Phase 3 clinical studies are ongoing.~~

Dermatology - IDP-123 is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. The FDA has accepted for review our New Drug Application (“NDA”) for IDP-123 and set a Prescription Drug User Fee Act (“PDUFA”) action date of December 22, 2019.

Dermatology - IDP-124 is a topical lotion product designed to treat moderate to severe atopic dermatitis, with ~~pimecrolimus, currently in~~pimecrolimus. Phase 3 ~~testing.~~

~~Dermatology - IDP-135 is a topical retinoid product~~enrollment has been completed with results expected in ~~development. An FDA guidance meeting was held in September 2019 and~~ the ~~development strategy is in progress.~~second half of 2020.

•

Bausch + Lomb - Biotrue^® ONEday for Astigmatism is a daily disposable contact lens for astigmatic patients. The Biotrue^® ONEday ~~lenses incorporate~~contact lens incorporates Surface Active Technology^TM™to provide a dehydration barrier. The Biotrue^® ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient. We launched this product in December 2016 and launched an extended power range and further extended power range in 2017 and 2018, respectively. We expect to launch a further power expansion for this product in 2019.

launched this product in December 2016 and launched an extended power range and further extended power ranges in 2017, 2018 and November 2019.

Bausch + Lomb - We are developing a new Ophthalmic Viscosurgical Device ("OVD") product, with a formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during interocular lens delivery. ~~In September 2019, we received an investigative device exemption (“IDE”) to start a cohesive~~The FDA clinical study for ~~the dispersive product~~cohesive OVD started in January 2020 and ~~expect~~has been paused as a result of COVID-19 related factors and is expected to ~~complete process validation in the fourth quarter of 2019. If successful,~~resume as soon as possible. In April 2021, we ~~anticipate filing~~filed a Premarket Approval application for the dispersive OVD with the ~~FDA in the first quarter of 2020.~~FDA.


•	Bausch + Lomb - In April 2019, we launched Lotemax^®SM (loteprednol etabonate ophthalmic gel) 0.38%, a new formulation for the treatment of post-operative inflammation and pain following ocular surgery. Lotemax^®SM is the lowest concentrated loteprednol ophthalmic corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery in the U.S.

~~lowest concentrated loteprednol ophthalmic corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery in the U.S.~~


•	Bausch + Lomb - enVista^® Trifocal intraocular lens is an innovative lens design. We initiated an ~~IDE~~investigative device exemption study for this product in May 2018 and ~~expect to initiate~~initiated a Phase 2 study in ~~the fourth quarter of~~October 2019.


•	~~Bausch + Lomb - Enhanced enVista~~^® ~~Toric intraocular lens was launched in July 2018.~~

Bausch + Lomb - We are developing a preloaded intraocular lens injector platform for enVista interocular lens. We have received approvals from the EUEuropean Union and Canada and received FDA clearance offor the injector. We anticipate launching this platform in the second half of 2020.

Bausch + Lomb - We are developing an extended depth of focus intraocular lens which we anticipate approval in Europe in the second half of 2021 due to COVID-19 delays.

•

Bausch + Lomb - Bausch + Lomb ULTRA^® Multifocal for Astigmatism contact lens is the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive^™ multifocal design with the stability of its OpticAlign^® toric with MoistureSeal^® technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam. Bausch + Lomb ULTRA^® Multifocal for Astigmatism was launched in June 2019.

•

Bausch + Lomb - Renu^® Advanced Multi-Purpose Solution (“MPS”) contains a triple disinfectant system that kills 99.9% of germs, and has a dual surfactant system that provides up to 20 hours of moisture. Renu^® Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfectant, rinse and store soft contact lenses including those composed of silicone hydrogels. Renu^® Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia and Singapore.

Bausch + Lomb - Custom soft contact lens (Ultra buttons) is a latheable silicone hydrogel button for custom soft specialty lenses ~~including;~~including: Sphere, Toric, Multifocal, Toric Multifocal and irregular corneas. If approved by the FDA, we expect to launch in the ~~first~~fourth quarter of ~~2021.~~

~~Bausch + Lomb - In January 2019, we launched Zen™ Multifocal Scleral Lens for presbyopia exclusively available with Zenlens™ and Zen™ RC scleral lenses and will allow eye care professionals~~2021; the change in date is due to ~~fit presbyopic patients with irregular and regular corneas and those with ocular surface disease, such as dry eye. The Zen™ Multifocal Scleral Lens incorporates decentered optics, enabling~~specification change activities delaying the ~~near power to be positioned over the visual axis.~~original launch date.

•

Bausch + Lomb - In January 2019, we launched Zen^™ Multifocal Scleral Lens for presbyopia exclusively available with Zenlens^™ and Zen^™ RC scleral lenses and will allow eye care professionals to fit presbyopic patients with irregular and regular corneas and those with ocular surface disease, such as dry eye. The Zen^™ Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.

•

Bausch + Lomb - In March 2019, we launched Tangible^® Hydra-PEG^® is, a high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. Tangible^® Hydra-PEG^® coating technology in combination with our Boston^® materials and ~~Zenlens™~~Zenlens^™ family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.

~~In addition~~Strategic Licensing Agreements -To supplement our internal R&D initiatives and to ~~the internal development of products in~~build-out and refresh our ~~pipeline as discussed above,~~product portfolio, we also ~~seek ways~~search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.

In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational ~~treatments.~~ treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA, (iii) covered by third-party payors or (iv) profitable for distribution cannot be fairly predicted.

In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease ("DED") associated with Meibomian gland dysfunction ("MGD"). We expect to initiate a Phase 3 study for this product in the second half of 2020. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye-health products.

In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. ("Clearside") for the commercialization and development of ~~Xipere™~~Xipere^™ (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. ~~Xipere™~~Xipere^™ is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside's proprietary SCS ~~Microinjector™~~Microinjector^™ that is being investigated as a targeted treatment of macular edema associated with uveitis. Clearside expects to resubmit its ~~NDA~~New Drug Application for ~~Xipere™~~Xipere^™ to the FDA in the ~~first~~fourth quarter of 2020.

In April 2019, we entered into two licensing agreements which present us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements is with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (“NAFLD”), nonalcoholic steatohepatitis (“NASH”) and other GI and liver diseases. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We ~~believe Xipere™ will complement~~have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive and we expect to initiate a Phase 2 study in the second half of 2020.

On February 27, 2018, we announced that we entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") to develop and commercialize a new chemical entity, IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study has been completed and the results did not meet expectations. As a result, the Company no longer believes that IDP-131 can be viably developed for the treatment of psoriasis. The Company and Kaken are currently considering whether this new chemical entity can be developed to treat other indications.

Strategic Investments in our Infrastructure - In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland and our Rochester facility in New York.

To meet the forecasted demand for our Biotrue^® ONEday lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility. The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.

To address the expected global demand for our Bausch + Lomb ~~portfolio~~ULTRA^® contact lens, in December 2017, we completed a multi-year, $200 million strategic upgrade to our Rochester facility. The upgrade increased production capacity in support of ~~integrated eye-health~~our Bausch + Lomb Ultra^® and SiHy Daily AQUALOX^™ product lines and better supports the production of other well-established contact lenses, such as our PureVision^®, PureVision^®2 (SVS, Toric, and Multifocal), SofLens^® 38 and SilSoft^®.

To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. SiHy Daily disposable contact lenses are expected to be launched in the U.S. in the second half of 2020.

We believe the investments in our Waterford and Rochester facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and ~~if approved by the FDA, Xipere™ will be the first therapy available for patients suffering from macular edema associated with uveitis.~~our eye-health business.

~~Improve~~Effectively Managing Our Capital Structure

We ~~have made measurable progress in improving~~continue to effectively manage our capital structure by: (i) reducing our debt through repayments, ~~and~~ (ii) extending the maturities of debt through ~~refinancing. Using~~refinancing and (iii) improving our credit ratings.

Debt Repayments - Excluding the ~~net cash proceeds from divestitures~~impact of ~~non-core assets, cash generated from operations and cash generated from tighter working capital management,~~the $1,210 million financing of the U.S. Securities Litigation settlement discussed below, we have been able to repay (net of additional borrowings) over $7,900 million of long-term debt during the period January 1, 2016 through the date of this filing we repaid (net of additional borrowings) over $7,450 million of long-term debt since the beginning of 2016, in the aggregate. Further, as a result of the refinancing and debt repayments outlined below, as of the date of this filing, we have eliminated all mandatory scheduled principal repayments of our debt obligations through 2020 and our mandatory scheduled principal repayments through 2021 are approximately $203 million.

~~Divestitures -~~ During 2017, we divested businesses and assets not aligned with our core business objectives, which simplified our operating model and generated over $3,200 million of net cash proceeds that we used to improve our capital structure, the most significant of which were the divestitures of the Company's interests in the CeraVe^®~~, AcneFree~~^™ ~~and AMBI~~^® skincare brands (March 3, 2017), the iNova Pharmaceuticals business (September 29, 2017), the Company's equity interest in Dendreon Pharmaceuticals LLC (June 28, 2017) and the Obagi Medical Products, Inc. business (November 9, 2017).

~~Debt Repayments~~ ~~- During the years 2016 through 2018, we repaid (net of additional borrowings) over $6,800 million of long-term debt~~ using the net cash proceeds from divestitures of non-core assets, cash generated from operations and cash generated from tighter working capital management. During the nine months ended September 30, 2019, we repaid approximately $700 million of long-term debt, net of borrowings under our 2023 Revolving Credit Facility (as defined below). Repayments of long-term debt during the nine months ended September 30, 2019 included: (i) $462 million of our seven year Tranche B Term Loan Facility maturing in June 2025 (the “June 2025 Term Loan B Facility”), (ii) $169 million of our seven year Tranche B Term Loan Facility maturing in November 2025 (the "November 2025 Term Loan B Facility") and (iii) $75 million, net of borrowings, of our 2023 Revolving Credit Facility. In addition to these repayments, during October 2019, we redeemed $100 million aggregate principal amount of our outstanding 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes") and had drawn net borrowings of $200 million under our 2023 Revolving Credit Facility primarily used for the payment of interest due in October 2019 and other short-term capital needs.

2017 Refinancing Transactions - In March, October, November and December of 2017, we accessed the credit markets and completed a series of transactions, whereby we extended approximately $9,500 million in aggregate maturities of certain debt

obligations due to mature in April 2018 through April 2022, out to March 2022 through December 2025. As part of these transactions, we also extended commitments under our revolving credit facility, originally set to expire in April 2018, out to April 2020.

2018 Refinancing Transactions - In March, June and November 2018, we accessed the credit markets and completed a series of transactions, whereby we extended approximately $8,300 million in aggregate maturities of certain debt obligations due to mature in March 2020 through July 2022, out to June 2025 through January 2027. As part of these transactions, we obtained less stringent loan financial maintenance covenants under our Senior Secured Credit Facilities and extended commitments under our revolving credit facility by more than three years by replacing our then-existing revolving credit facility, set to expire in April 2020 with a revolving credit facility of $1,225 million due in June 2023 (the “2023 Revolving Credit Facility”).

2019 Refinancing Transactions - In March, May and ~~May~~December 2019, we accessed the credit markets and completed a series of transactions, whereby, we extended ~~$3,000~~$4,240 million in aggregate maturities of certain debt obligations due to mature in December 2021 through May 2023, out to January 2027 through ~~May 2029.~~January 2030.

~~On March 8,~~Financing of Litigation Settlement - In December 2019, we announced that we had agreed to resolve the putative securities class action litigation in the U.S. (the "U.S. Securities Litigation") for $1,210 million, subject to final court approval. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. This settlement, once approved by the court, will resolve and discharge all claims against the Company in the class action, and as a result will resolve the most significant of the Company's remaining legacy legal matters and eliminate a material uncertainty regarding our Company.

To finance the settlement of the U.S. Securities Litigation, on December 30, 2019, we accessed the credit markets and issued: (i) ~~$1,000~~$1,250 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027 and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes") in a private placement. The unsecured notes form part of the same series as our existing 8.50% Senior Unsecured Notes due January 2027 (the "January 2027 Unsecured Notes"). A portion of the net proceeds of the January 2027 Unsecured Notes and the August 2027 Secured Notes and cash on hand were used to: (i) repurchase the remaining $700 million outstanding principal amount of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (ii) repurchase $584 million of May 2023 Unsecured Notes, (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes") and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”).

~~On May 23, 2019, we issued: (i) $750 million aggregate principal amount of 7.00%~~5.00% Senior Unsecured Notes due January 2028 (the ~~"January~~"5.00% January 2028 Unsecured Notes") and (ii) ~~$750~~$1,250 million aggregate principal amount of ~~7.25%~~5.25% Senior Unsecured Notes due ~~May 2029~~January 2030 (the ~~"May 2029~~"January 2030 Unsecured Notes") in a private placement. The ~~net~~ proceeds and cash on hand were used to: (i) ~~repurchase $1,118~~redeem $1,240 million of ~~May~~5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured ~~Notes,~~Notes") on January 16, 2020, (ii) ~~repurchase $382~~finance amounts owed under the Company's recently announced $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to final court approval), of which we paid $200 million during January 2020 and $810 million during March ~~2023 Unsecured Notes~~2020 and (iii) pay all fees and expenses associated with these transactions (collectively, the ~~“May~~"December 2019 Financing and Refinancing ~~Transactions”~~Transactions"). Through this financing, we have in effect extended the payment terms of the pending settlement of $1,210 million out to 2028 and 2030, without negatively impacting our working capital available for operations.

See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for the details of our debt portfolio as of March 31, 2020 and December 31, 2019.

The debt repayments and refinancings outlined above have allowed us to: (i) improve our credit ratings, (ii) finance amounts owed under the Company's recently announced $1,210 million settlement agreement relating to the U.S. Securities Litigation without negatively impacting our working capital available for operations and (iii) as of the date of this filing, have no debt maturing, or mandatory amortization of debt payments, until the first quarter of 2022.

AsOur prepayment and refinancings of debt over the last four years translate into lower repayments of principal over the next four years, which, in turn, we believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt amounts. The mandatory scheduled principal repayments of our debt obligations as of May 7, 2020, the date of this filing, were as follows and reflects repurchases of our senior unsecured notes in the open market of $8 million, in aggregate, in April 2020:



(in millions)
2020		2021		2022		2023		2024		2025		2026		2027		2028		2029		2030		Total
$	—	$	—	$	1,553	$	2,443	$	2,303	$	10,632	$	1,500	$	2,250	$	2,012	$	750	$	1,250	$	24,693

In addition, as a result of ~~prepayments and a series of refinancing transactions through September 30, 2019, we have extended~~ the ~~maturities of a substantial portion~~changes in our debt portfolio, approximately 80% of our ~~long-term~~ debt ~~providing us with additional liquidity and greater flexibility to execute our business plans. The tables below summarize our outstanding~~is fixed rate debt ~~portfolio and maturities~~ as of ~~September 30, 2019~~March 31, 2020, as compared to ~~December 31, 2018.~~

September 30, 2019 December 31, 2018
(in millions) Maturity Principal Amount Net of Premiums, Discounts and Issuance Costs Principal Amount Net of Premiums, Discounts and Issuance Costs
Senior Secured Credit Facilities:
2023 Revolving Credit Facility June 2023 $ —
$ —
$ 75
$ 75
June 2025 Term Loan B Facility June 2025 3,932
3,826
4,394
4,269
November 2025 Term Loan B Facility November 2025 1,312
1,293
1,481
1,456
Senior Secured Notes:
5.75% Secured Notes August 2027 500
493
—
—
All other Senior Secured Notes March 2022 through November 2025 5,000
4,955
5,000
4,948
Senior Unsecured Notes:
5.625% December 2021 —
—
700
697
5.50% March 2023 402
400
1,000
995
5.875% May 2023 1,548
1,540
3,250
3,229
8.50% January 2027 1,750
1,756
750
738
7.00% January 2028 750
740
—
—
7.25% May 2029 750
740
—
—
All other Senior Unsecured Notes May 2023 through April 2026 7,885
7,811
7,970
7,886
Other Various 12
12
12
12
Total long-term debt and other $ 23,841
$ 23,566
$ 24,632
$ 24,305

approximately 60% as of January 1, 2016. The weighted average stated interest rate of the Company's outstanding debt as of ~~September 30, 2019~~March 31, 2020 andDecember 31,
2018 ~~was 6.39% and 6.23%, respectively.~~

~~The scheduled principal repayments of our debt obligations as of September 30, 2019 compared with~~ December 31, ~~2018 were as follows:~~2019 was 6.01% and 6.21%, respectively.

(in millions) September 30, 2019 December 31, 2018
2019 $ 100
$ 228
2020 —
303
2021 203
1,003
2022 1,553
1,553
2023 3,788
6,348
2024 2,303
2,303
Thereafter 15,894
12,894
Gross maturities $ 23,841
$ 24,632

~~During October 2019,~~We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. While we ~~redeemed $100 million aggregate principal amount of~~anticipate focusing any future divestiture activities on non-core assets, consistent with our ~~outstanding May 2023 Unsecured Notes~~duties to our shareholders and ~~had drawn net borrowings of $200 million under our 2023 Revolving Credit Facility primarily used~~other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the ~~payment of interest due in October 2019~~Company. Also, the Company regularly evaluates market conditions, its liquidity profile and ~~other short-term~~various financing alternatives for opportunities to enhance its capital ~~needs. These transactions~~structure. If the Company determines that conditions are ~~not reflected in~~favorable, the ~~table above.~~Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.

See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements and “Management's Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt” for ~~further details.~~additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in “Management's Discussion and Analysis - Off-Balance Sheet Arrangements and Contractual Obligations.”

~~Address Legacy Legal Matters~~

The Company was burdened with addressing certain ongoing legal matters, some of which were inherited as part of the acquisitions we completed in 2015 and prior. In order to better focus on our core activities and simplify our operations, we have been vigorously addressing many of these matters, and, through the date of this filing, we achieved dismissals and other positive outcomes in a number of litigations, disputes and investigations, as we continue to actively address others. For example, in July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined Actavis Laboratories FL, Inc.’s ("Actavis") infringement of a patent protecting our Relistor^® tablets, expiring in March 2031. In July 2019, we also announced that we had agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. ("Teva") regarding Apriso^® ~~extended-release capsules 0.375g. As part of the settlement, the parties agreed to dismiss all litigation related to Apriso~~^®~~, and intellectual property protecting Apriso~~^®~~will remain intact and enforceable. In addition, we will grant Teva a non-exclusive license effective October 1, 2021to the intellectual property relating to Apriso~~^®in the United States (provided that Teva will be able to begin marketing prior to such date if another generic version of the product is granted approval and starts selling or distributing such generic prior to October 1, 2021). The Company has now resolved litigation related to Apriso^® with two out of the four Paragraph IV filers. In addition, in August 2019, we entered into a settlement to fully and finally resolve the plaintiffs’ class claims against one of our affiliates in a civil antitrust class action suit relating to certain contact lens lines. Also, in October 2019, we entered into a settlement agreement with the State of Mississippi to resolve an action that had alleged consumer protection claims against the Company, among others, related to the Shower to Shower^® ~~body powder product and its alleged causal link to ovarian cancer (an order of dismissal has not yet been entered by the Court in this matter).~~

These matters and other significant matters are discussed in further detail in Note 19, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements presented elsewhere in this Form 10-Q and Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for the year ended December 31, 2018, which were included in our Annual Report on Form 10-K filed on February 20, 2019.

~~Address Regulatory Matters~~

In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review, by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations, including the FDA. Currently, all of our global operations and facilities have the relevant operational certificates. Through the date of this filing, the Company's operating sites are in good compliance standing, and all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (“VAI”) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited in the Form 483, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have observed any condition that in their judgment may constitute violations of current good manufacturing practice.

Improve Patient Access ~~and Pricing Committee and New Pricing Actions~~

Improving patient access to our products, as well as making them more affordable, is ~~an important~~a key element of our ~~turnaround.~~business strategy.

Patient Access and Pricing Committee - In ~~May~~ 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to ~~ensure launch prices and~~market product pricing, price changes ~~are assessed~~ and ~~implemented~~their impact across channels ~~with a focus~~ on patient accessibility and ~~affordability while maintaining profitability. Since that time, the~~affordability. The Patient Access and Pricing Committee has been committed to limiting the average annual price increase for our branded prescription pharmaceutical products to no greater than single digits and has reaffirmed this commitment for 2019. We expect that the Patient Access and Pricing Committee will continue to implement or recommend additional price changes and/or new programs in-line with this commitment to enhance patient access to our drugs.2020. These pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our company revenue ~~trends.~~and profit.

~~Dermatology.com~~ Cash-pay Prescription Program

- In February 2019, we launched Dermatology.com, a cash-pay ~~prescription~~product acquisition program ~~to make~~offering certain ~~Ortho Dermatologics~~ branded products available directly to patients with a valid prescription, regardless of their insurance status and without prior authorizations needed. The program is specifically designed to provide patients with direct access to a range of proven treatment options for certain disease states that typically encounter insurance coverage hassles and high prescription costs including acne, actinic keratosis, superficial basal cell carcinoma, barrier repair (e.g. eczema treatments), wounds and corticosteroid-responsive diseases such as rashes, psoriasis and atopic dermatitis.

Through Dermatology.com, all patients, regardless of their insurance status, will be able to purchase medicines at prices ranging from $50 to $115 per prescription. By doing so, the program will provide branded options that offer proven medicines with straightforward access. It will include certain Ortho Dermatologics brands, such as Retin-A^® ~~(tretinoin) cream, as well as novel products, such as Altreno~~^®~~(tretinoin) Lotion, 0.05%. All products included in the Dermatology.com program will be eligible~~

for Flexible Spending Accounts or Health Saving Accounts and will continue to be supported by the Company's Patient Assistance Program, which offers free medication for patients who meet income and other eligibility criteria. We plan to include approximately 15 Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name in order to secure the name Dermatology.com for only online usage including future digital teledermatology and e-commerce offerings. The cash pay program ~~by January 2020 including some investigational therapies that will be added~~is designed to address the ~~program as soon as,~~affordability and ~~if, they~~availability of certain branded dermatology products, when insurers and pharmacy benefit managers are ~~approved by the FDA.~~no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.

Walgreens Fulfillment Arrangements

- In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. ("Walgreens") ~~and extended these programs to additional participating independent retail pharmacies.~~. Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made ~~available~~ certain ~~of our~~dermatology and ophthalmology products available to eligible patients through a patient access and co-pay ~~program available~~assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. ~~The program~~Our products available under this ~~20-year~~fulfillment agreement ~~initially covers~~include certain ~~of our dermatology~~Ortho Dermatologics products, including our Jublia^®, Luzu^®, Retin-A Micro^® Gel ~~0.08%~~ and ~~0.06%,~~ Onexton^®, and select branded prescription pharmaceutical products included in our cash-pay prescription program and certain ~~of our~~ ophthalmology products, including our Vyzulta^®, Besivance^®, Lotemax^®, Alrex^®, Prolensa^®, Bepreve^® and Zylet^®. In July 2019, the Company announced that it had entered into an amendment to its existing fulfillment agreement with Walgreens, which the Company believes will further improve the distribution and sales of its products and bring patients lower prices, increased transparency and convenience for the products in the program. As part of this amendment, the arrangement was expanded to cover select dermatology products included in our Dermatology.com cash-pay prescription program. products.

~~Increase~~Business Trends

In addition to the ~~Focus of~~actions previously outlined, the events described below have affected and may affect our ~~Pipeline~~business trends. The matters discussed in this section contain Forward-Looking Statements. Please see “Forward-Looking Statements” for additional information.

Invest in Sustainable Growth Drivers to Position us for Long-Term Growth

We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader.

We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum. We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.

~~During 2018, we launched and/or relaunched innovative products across multiple countries that contributed to organic growth~~Invest in ~~most~~our Eye-Health Business - As part of our ~~core businesses~~Global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing.

For instance, there is an increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65). To extend our market share in eye-health, we ~~currently have over 225~~continually seek to identify new products tailored to address these key trends for development internally with our own R&D ~~projects in our global pipeline. In addition~~team to ~~these projects, we have completed the launch of the products we have dubbed our "Significant Seven". These Significant Seven products are: (i) Bryhali~~generate organic growth. Recent product launches include Biotrue^® ~~(Ortho Dermatologics), (ii) Duobrii~~ONEday

daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA^® ~~(Ortho Dermatologics), (iii)~~contact lenses, SiHy Daily contact lenses, Lumify^® ~~(Bausch + Lomb)~~(an eye redness treatment), ~~(iv) Relistor~~^® ~~(Salix), (v) SiHy Daily (Bausch + Lomb), (vi) Siliq~~^® ~~(Ortho Dermatologics) and (vii)~~ Vyzulta^® ~~(Bausch + Lomb)~~(a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite^® Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices). ~~Revenues~~

We also license selective molecules or technology in leveraging our own R&D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired exclusive licenses for the commercialization and development in the U.S. and Canada for Xipere^™ which, if approved by the FDA, will be the first treatment for patients suffering from macular edema associated with uveitis, and for NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD. We also acquired the U.S. rights to EM-100 an investigational eye drop that, if approved by the FDA, will be the first OTC preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye-health products.

As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland to meet the forecasted demand for our ~~Significant Seven were greater than $150 million~~Biotrue^® ONEday lenses and our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA^® contact lens. During late 2018, ~~and were approximately $75 million~~we began investing in ~~2017.~~ additional expansion projects at these facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses expected to be launched in the U.S. in the second half of 2020.

We believe our recent product launches, licensing arrangements and the ~~prospects for this group of products to be substantial~~investments in our Waterford and ~~anticipate devoting significant marketing efforts toward their promotion. We also believe that the strength and impact of these products on their respective markets will~~Rochester facilities demonstrate the ~~effectiveness of our pipeline and R&D strategies and promote further innovation~~growth potential we see in our ~~businesses.~~Bausch + Lomb products and our eye-health business and that these investments will position us to further extend our market share in the eye-health market.

Leveraging our Salix Infrastructure

~~As we~~ - We strongly believe in our ~~Xifaxan~~^®GI product portfolio and ~~Relistor~~^® ~~business models, as part of our transformation,~~ we have ~~taken~~implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these ~~products.~~products to extend our market share.

In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (“PCP”). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment.

This initiative provided us with positive results, as we experienced consistent growth in demand for ~~these~~our GI products throughout 2017 and ~~2018. Revenues from~~2018, which was evident by our ~~Xifaxan~~^® ~~and Relistor~~^® ~~products increased approximately 22% and 37%, respectively,~~growth in Salix revenues of 12% in 2018 when compared to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and, in the later portion of 2018 and in 2019, we ~~have~~ identified and executed on certain opportunities which we describe below.

Strategic Acquisition - As previously discussed, in March 2019, we completed the acquisition of certain assets of Synergy, whereby we acquired the worldwide rights to the Trulance^® product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance^® product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.

~~For instance,~~Licensing Arrangements - As previously discussed, in April 2019, we entered into two licensing agreements. The first is for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in NAFLD, NASH and other GI and liver diseases. The second is to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. These licenses present unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases and if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.

Investment in Next Generation Formulations - We continue to see growth in our Xifaxan^® product. Revenues from our Xifaxan^® product increased approximately 22%, 22% and 11% in 2019, 2018 and 2017, respectively. In order to ~~continue to generate~~extend growth in ~~these products,~~Xifaxan^®, we continue to directly invest in next generation formulations of Xifaxan^® and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan^® product. In addition to one R&D program in progress, we have three other R&D programs planned to start in 2020 for next generation formulations of Xifaxan^® ~~and rifaximin~~(rifaximin) which address new indications.

In addition to driving growth through internal R&D development, we seek to align ourselves with new external product development opportunities. In April 2019, we entered into two licensing agreements which present us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements is with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (“NAFLD”), nonalcoholic steatohepatitis (“NASH”) and other GI and liver diseases. We believe this compound, once fully developed, could address certain unmet medical needs in the treatment of NAFLD and NASH. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We plan to initiate a Phase 2 study for the development of MT-1303 in ulcerative colitis in the first half of 2020. Additionally, the cardiovascular Holter study is expected to readout around year end.

In addition to product development opportunities, we strive to access innovative and established GI products outside our existing Salix business that allow us to leverage our GI sales force, supply channel and distribution channel to bring about growth through incremental acquisitions. For instance, in March 2019, we completed the acquisition of certain assets of Synergy whereby we acquired the worldwide rights to the Trulance^® ~~(plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C.~~ We believe that the ~~Trulance~~^® ~~product complements our existing Salix products~~acquisition and ~~allows us to effectively leverage our existing GI sales force. As we focus on reestablishing momentum in the Trulance~~^® ~~product, we have reviewed certain strategies for the Salix business and as a result, we mutually agreed with US WorldMeds, LLC to terminate our arrangement to co-promote Lucemyra~~^® ~~effective September 30, 2019.~~

~~We continue to see growth in our Xifaxan~~^® ~~and Relistor~~^® ~~products. Revenues from our Xifaxan~~^® ~~and Relistor~~^® ~~franchises increased approximately 19% and 9%, respectively, for the nine months ended September 30, 2019 when compared to the nine months ended September 30, 2018. We therefore believe that the~~ licensing ~~and acquisition~~ opportunities ~~as previously~~ discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to ~~either~~ our Xifaxan^® ~~or Relistor~~^® ~~businesses,~~business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.

~~Refocus~~

Position the Ortho Dermatologics Business

for Growth - In support of our Ortho Dermatologics business and the opportunities we see for growth in this business, we continue to allocate resources and make additional investments in this business to recruit and retain talent and focus on our core dermatology portfolio of products.

To ~~turnaround our dermatology~~position the Ortho Dermatologics business for growth, we have taken and are taking a number of actions ~~which~~that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) rebranding our dermatology business, (ii) recruiting a new experienced leadership team, (iii) making significant investment in our core dermatology portfolio, (iv) increasing and reorganizing our dermatology sales force around roughly ~~150~~195 territories, as we work to rebuild relationships with prescribers of our products and (v) improving patient access to our Ortho Dermatologics products through ~~Dermatology.com,~~ our cash-pay prescription program previously discussed. With these actions substantially complete, we believed that our Ortho Dermatologics business was positioned for growth in 2020. While we continue to believe that our strategies will return our Ortho Dermatologics business to growth sometime in the future, the impacts of the COVID-19 pandemic has had us reassess this timing. The closure of many health care facilities and medical offices during the pandemic has limited patient access to new prescriptions and we now believe that we will not see the Ortho Dermatologics business return to growth until the COVID-19 pandemic subsides and the U.S. economy stabilizes.

Recruit and Retain Talent - In 2017, we identified and retained a proven leadership team of experienced dermatology sales professionals and marketers. In January 2018, the leadership team, encouraged by the success of our GI sales force expansion program, increased our Ortho Dermatologics sales force by more than 25% in support of our growth initiatives for our Ortho Dermatologics business. We believe the additional sales force is vital to meet the demand we expect from our recently launched products and those we expect to launch in the ~~near term,~~near-term, pending FDA approval. We continue to monitor our pipeline for other ~~near term~~near-term launches that we believe will create opportunity needs in our other core businesses requiring us to make additional investment to retain people for additional leadership and sales force roles.

Investment in Our Core Dermatology Portfolio - We have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which are the markets within dermatology where we see the greatest ~~opportunities.~~opportunities to extend our market share.

Aesthetics - ~~On September 22,~~In 2017, we ~~received 510(k) clearance from the FDA and~~ launched our Next Generation Thermage FLX^® product in the ~~United States. Next Generation Thermage FLX~~^® isU.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX^® was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX^® revenues for ~~the nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 were $26 million and $12 million, respectively, and in ~~excess of $47~~full-year 2019 were $77 million. ~~We expect additional launches of Next Generation Thermage FLX~~^® ~~in Asia and Europe in the near term, paced by country-specific regulatory registrations.~~

Psoriasis - As the number of reported cases of psoriasis in the U.S. has increased, we believe there is a need to make further investments in this market in order to maximize our opportunity and supplement our current psoriasis product portfolio. We

have filed NDAs for several new topical psoriasis products, launched Duobrii^® in June 2019 and launched Bryhali^® in November ~~2018 and launched~~2018. We expect that Duobrii^® ~~in June 2019. We expect that~~and Bryhali^® ~~and Duobrii~~^®will ~~line up~~align well with our existing topical portfolio of psoriasis treatments and, supplemented by our injectable biologic products, such as Siliq^®, will provide a diverse choice of psoriasis treatments to doctors and patients. In July 2017, we launched Siliq^®, an IL-17 receptor blocker monoclonal antibody biologic for treatment of moderate-to-severe plaque psoriasis, which we estimate to be an over $5,000 million market in the U.S. (Siliq^® has a Black Box Warning for the risks in patients with a history of suicidal thoughts or behavior and was approved with a Risk Evaluation and Mitigation Strategy involving a one-time enrollment for physicians and one-time informed consent for ~~patients.) In addition, on February 27, 2018, we announced that~~patients). As previously discussed, we entered into an exclusive license agreement with Kaken ~~Pharmaceutical Co., Ltd.~~ to develop and commercialize products containing a new chemical entity, ~~KP-470,~~IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study ~~was initiated in~~has now been completed and the ~~first half of 2019. If approved by~~results did not meet expectations. As a result, the ~~FDA, KP-470 could represent a novel drug with an alternative mechanism of action in~~Company no longer believes that IDP-131 can be viably developed for the ~~topical~~ treatment of psoriasis. The Company and Kaken are currently considering whether this new chemical entity can be developed to treat other indications.

Acne - In support of our established acne product portfolio, we have developed several products, which include Retin-A Micro^® 0.06% (launched in January 2018) and Altreno^®(launched in the U.S. October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne. ~~Revenues for the nine months ended September 30, 2019 were approximately $15 million and $4 million for Retin-A Micro~~We also anticipate launching Arazlo^®TM ~~0.06%~~(tazarotene) Lotion in the first half of 2020 and ~~Altreno~~^®~~, respectively. In addition to Retin-A Micro~~^® ~~0.06% and Altreno~~^®, we have three other unique acne projects in earlier stages of development that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.

~~Improving Patient Access to Our Ortho Dermatologics Products~~ - We see a real opportunity to be a leader in delivering affordable prescription dermatology products. As previously discussed, we recently announced our new cash-pay prescription model, Dermatology.com. Under the recent amendment to our existing Walgreens fulfillment agreement, the program is available at all Walgreens retail pharmacy locations in the U.S., and we are working on ways to expand this program even further. There are 13 products currently available through this channel and we expect to bring the number of products available up to 15 by January 2020. We expect that e-commerce and telemedicine will also be available sometime next year.

Bolstered by new product launches in our aesthetics, psoriasis and acne product lines and the potential of other products under development, our experienced dermatology sales leadership team, our ~~increased~~ sales force and our ~~Dermatology.com~~ cash-pay prescription program, we believe we have set the groundwork ~~for~~to position the ~~potential to achieve growth in our~~ Ortho Dermatologics ~~business.~~business for future growth.

~~Continue~~

U.S. Health Care Reform

The U.S. federal and state governments continue to ~~Manage Our Capital Structure~~

~~As previously outlined, we completed a series of transactions~~propose and pass legislation designed to regulate the health care industry. In March 2010, the Patient Protection and Affordable Care Act (the “ACA”) was enacted in the U.S. The ACA contains several provisions that ~~reduced our debt levels, extended our debt maturities and improved our capital structure, providing us with additional liquidity and greater flexibility to execute~~impact our business, ~~plans. As a result of prepayments and a series of refinancing transactions, we have extended~~including: (i) an increase in the ~~maturities of a substantial portion of our long-term debt and, as a result, as~~minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the ~~date~~Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.

In addition, in 2013 federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion’s cost paid for by the federal government.

For 2019 and 2018, we incurred costs of $20 million and $36 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S. government programs (e.g., Medicare and Medicaid). For 2019 and 2018, we also incurred costs of $137 million and $90 million, respectively, on Medicare Part D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”).

On July 28, 2014, the U.S. Internal Revenue Service issued final regulations related to the branded pharmaceutical drug annual fee pursuant to the ACA. Under the final regulations, an entity’s obligation to pay the annual fee is triggered by qualifying sales in the current year, rather than the liability being triggered upon the first qualifying sale of the following year. We adopted this ~~filing, scheduled principal repayments~~guidance in the third quarter of 2014, and it did not have a material impact on our ~~debt obligations through 2021 are approximately $203 million. Our reduced debt levels and improved debt portfolio~~financial position or results of operations.

The financial impact of the ACA will ~~translate to lower repayments of principal~~be affected by certain additional developments over the next ~~five~~few years, ~~which,~~including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in ~~turn,~~new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that under the current administration, legislation will ~~permit more cash flows~~be passed by Congress repealing the ACA in whole or in part. Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.

In 2018, we faced uncertainties due to ~~be directed toward developing our core assets, identifying new product opportunities~~federal legislative and ~~repaying additional debt amounts. In addition, as a result~~administrative efforts to repeal, substantially modify or invalidate some or all of the ~~changes in our debt portfolio, approximately 80%~~provisions of ~~our debt~~the ACA. However, we believe there is ~~fixed rate debt as~~low likelihood of ~~September 30, 2019, as compared~~repeal of the ACA, given the recent failure of the Senate’s multiple attempts to ~~approximately 65% as~~repeal various combinations of ~~January 1, 2017.~~

~~We continue to monitor our capital structure and to evaluate other opportunities to simplify~~ACA provisions. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and ~~improve~~financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our ~~capital structure giving us~~business.

In 2019, the ~~ability~~U.S. Health and Human Services Administration announced a preliminary plan to ~~better focus~~allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the current administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our ~~core businesses.~~future cash flows, we cannot provide assurance as to the ultimate context, timing, effect or impact of such a plan.

In 2019, the Government of Canada (Health Canada) published in the Canadian Gazette the new pricing regulation for patented drugs. These regulations will become effective on July 1, 2020. The draft application guidelines are available with the final guidelines to be published in 2020. The new regulations will change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019; they will also require full transparency of discounts agreed with provincial bodies; and finally, will change the number and composition of reference countries used to determine if a drug’s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.

Other legislative efforts relating to drug pricing have been proposed and considered at the U.S. federal and state level. We also anticipate ~~focusing any~~that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future ~~divestiture activities on non-core assets, consistent with our duties to our shareholders~~propose and ~~other stakeholders, we will consider dispositions~~adopt legislation or policy changes or implementations affecting additional fundamental changes in ~~core areas that we believe represent attractive opportunities for~~ the Company. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.health care delivery system.

~~Managing~~

Generic Competition and Loss of Exclusivity

Certain of our products face the expiration of their patent or regulatory exclusivity in ~~2019~~2020 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in ~~2019~~2020 or in later years. Following a loss of exclusivity ("LOE") of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the loss of exclusivity or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or

through a ~~third party)~~third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.

A number of our products already face generic competition. Prior to and during ~~2019,~~2020, in the U.S., these products include, among others, Ammonul^®, Apriso^®, Benzaclin^®, Bupap^®, Cuprimine^®, Edecrin^®, Elidel^®, Glumetza^®, Istalol^®, Isuprel^®, Locoid^® Lotion, Lotemax^® Suspension, Mephyton^®, Nitropress^®, Solodyn^®, Syprine^®, ~~Virazole~~^®, Uceris^® Tablet, Virazole^®, Wellbutrin XL^®, Xenazine^®,Zegerid^® and Zovirax^® cream. In Canada, these products include, among others, Glumetza^®, ~~Sublinox~~Wellbutrin^® XL and Zovirax^® ointment.

2019 LOE Branded Products - Branded products that began facing generic competition in the U.S. during 2019 include, Apriso^®, Cuprimine^®, Lotemax^® Suspension, Solodyn^® and ~~Wellbutrin~~Zovirax^® ~~XL.~~cream. In aggregate, these products accounted for 3% of our total revenues in 2019. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.

2020 through 2024 LOE Branded Products - Based on current patent expiration dates, settlement agreements and/or competitive information, ~~our key~~we have identified branded products that ~~began facing or those which~~ we believe ~~will be~~could begin facing potential loss of exclusivity and/or generic competition in the U.S. during the years ~~2019~~2020 through ~~2023~~2024. These products and year of expected loss of exclusivity include, but are not limited to, ~~Apriso~~^®, Clindagel^®~~, Cuprimine~~^®(2020), Lotemax^® Gel ~~Lotemax~~^® ~~Suspension,~~(2021), Migranal^®(2020), MoviPrep^®(2020), Noritate^®~~, PreserVision~~^®~~, Solodyn~~^®(2020), Targretin^® Gel (2022), Xerese^®~~, Zovirax~~(2022)^® ~~cream~~ and certain other products that are subject to settlement ~~agreements. Aggregate revenues from key~~agreements which could impact their exclusivity during the years 2020 through 2024. In aggregate, these products that we believe will face potential loss of exclusivity and/or generic competition in the U.S. during: (i) 2019 represented 2% and 4%; (ii) 2020 represented 5% and 5%; (iii) 2021 represented 5% and 5%; (iv) 2022 represented less than 1% and 1%; and (v) 2023 represented 2% and 2%accounted for 3% of our ~~aggregate U.S., Mexico and Puerto Rico~~total revenues ~~for the nine months ended September 30, 2019 and the year 2018, respectively.~~in 2019. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.

2021 LOE OTC Product - PreserVision^® AREDS and PreserVision^® AREDS 2 are OTC eye vitamin formulas for those with moderate-to-advanced age-related macular degeneration. PreserVision^®products accounted for 2% of our total revenues in 2019. The PreserVision^® formulation patent expires in 2021, and whereas the Company cannot predict the magnitude or timing of the impact from its patent expiry, as this is an OTC product the impact is not expected to be as significant as the loss of exclusivity of a branded pharmaceutical product.

In addition, for a number of our products (including Uceris^®, Relistor^®, Plenvu^®, Xifaxan^® 200mg and 550mg, Bepreve^®, Bryhali^® and Jublia^®, ~~Prolensa~~^® ~~and Bryhali~~^®in the U.S. and Jublia^®in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.

Bryhali^® Lotion, 0.01% (Glenmark) - In December 2019, the Company announced that it had reached an agreement to resolve the outstanding intellectual property litigation with Glenmark Pharmaceuticals, Ltd. ("Glenmark"). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali^® in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali^® Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali^® Lotion, and all intellectual property protecting Bryhali^® Lotion remains intact.

Bryhali^® Lotion, 0.01% (Perrigo) - On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (“Perrigo”), in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA’s Orange Book for Bryhali^™ (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic halobetasol propionate lotion, for which an Abbreviated New Drug Application ("ANDA") has been filed by Perrigo. The Company has forty-five (45) days from the date of receipt of this notice to file suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims

of the Bryhali^™ Patents to trigger a 30-month stay of the approval of Perrigo ANDA for halobetasol propionate lotion. The Company intends to file within this time period.

Xifaxan^®550mg Patent Litigation (Sandoz Inc.) - In October 2019, the Company announced that it and its licensor, ~~AlfaSigma SpA~~Alfasigma had commenced litigation against Sandoz Inc. ("Sandoz"), a Novartis division, alleging patent infringement of 14 patents by Sandoz's filing of its ~~Abbreviated New Drug Application ("ANDA"~~ANDA for Xifaxan^® (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan^® (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan^® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan^® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan^® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan^® (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028.The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.

Xifaxan^®550mg Patent Litigation (Norwich Pharmaceuticals Inc.)- On March 26, 2020, The Company and its licensor Alfasigma filed suit against Norwich Pharmaceuticals Inc. (“Norwich”), alleging infringement by Norwich of one or more claims of the 23 Xifaxan^® Patents by Norwich’s filing of its ANDA for Xifaxan^® (rifaximin) 550 mg tablets. Xifaxan^® is protected by 23 patents covering the composition of matter and the use of Xifaxan^® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.

~~Apriso~~ The Company remains confident in the strength of the Xifaxan^® ~~Extended Release Capsules Patent Litigation~~ - On March 27, 2017, the Company initiated litigation against Teva Pharmaceuticals USA, Inc. ("Teva"), which alleged infringement by Teva of one or more claims of U.S. Patent No. 8,865,688, which protects the formulation for Apriso^® ~~extended-release capsules 0.375g. In July, we announced that we had agreed~~patents and will continue to ~~resolve the outstanding~~vigorously pursue these two matters and defend its intellectual ~~property litigation with Teva regarding Apriso~~^® ~~extended-release capsules 0.375g. As part of the settlement, the parties agreed to dismiss all litigation related to Apriso~~^®~~, and intellectual property protecting Apriso~~^®~~will remain intact and enforceable. In addition, the Company will grant Teva a non-exclusive license effective October 1, 2021to the intellectual property relating to Apriso~~^®in the United States (provided that Teva will be able to begin marketing prior to such date if another generic version of the product is granted approval and starts selling or distributing such generic prior to October 1, 2021). The final patent expiry on Apriso^® ~~is 2030. The Company has now resolved litigation related to Apriso~~^® ~~with two out of the four Paragraph IV filers.~~property.

Relistor^® Tablets Patent Litigation - On December 6, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc.’s ("Actavis"), which alleged infringement by Actavis of one or more claims of U.S. Patent No. 8,524,276 (the “‘276 Patent”), which protects the formulation of RELISTOR^® tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined that Actavis infringed the ‘276 Patent, expiring in March 2031.

Xifaxan^® 550mg Patent Litigation (Actavis)- On March 23, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of each of the Xifaxan^® patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan^® (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan^® (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan^® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan^® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan^® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (1) market a royalty-free generic version of Xifaxan^®tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan^®tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of

such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.

Generic Competition to Uceris^® - In July 2018, a generic competitor launched a product which will directly compete with our Uceris^® Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, ~~other~~on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic ~~competitors.~~tablets under the Court’s claim construction, while reserving its right to appeal the claim construction. The Company continues to believe that its Uceris^® Tablet-related patents are enforceable and is proceeding ~~in the ongoing litigation between the Company and the generic competitor;~~with an appeal; however, the ultimate outcome of the matter is not predictable. The ultimate impact of this generic competitor on our future revenues cannot be predicted; however, Uceris^® Tablet revenues for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ were approximately ~~$17~~$3 million and ~~$75~~$8 million, respectively, and for the full years 2019, 2018 and 2017 were approximately $20 million, $84 million and $134 million, respectively.

Generic Competition to Jublia^® - On June 6, 2018, the U.S. Patent and Trial Appeal Board (“PTAB”) completed its inter partes review for an Orange Book-listed patent covering Jublia^® and issued a written determination invalidating such patent. ~~Although~~On March 13, 2020, the ~~Company is not aware~~Court of ~~any imminent launches of a generic competitor to Jublia~~^®,Appeals for the ~~ultimate impact of~~Federal Circuit reversed this decision ~~on our future revenues cannot be predicted.~~and remanded the matter back to the PTAB for further proceedings. Jublia^® revenues for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ were approximately ~~$81~~$30 million and ~~$62~~$20 million, respectively, and for the full years 2019, 2018 and 2017 were approximately $110 million, $89 million and $96 million, respectively. The Company continues to believe that the Jublia^®related patent is valid and enforceable, ~~and, on August 7, 2018, an appeal of this decision was filed. The~~but the ultimate

outcome of this matter is not predictable. Jublia^® continues to be covered by ~~eight~~eleven remaining Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through ~~2034.~~2035. In August and September 2018, we received notices of the filing of a number of ANDAs with paragraph IV certification, and have timely filed patent infringement suits against these ANDA ~~filers.~~filers, and, in addition, we have also commenced certain patent infringement proceedings in Canada against two separate defendants.

See Note ~~19,~~18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note ~~20,~~21, "LEGAL PROCEEDINGS" of our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC and the ~~Canadian Securities Administrators~~CSA on SEDAR on February ~~20, 2019~~19, 2020 for further details regarding certain infringement proceedings.

The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company's patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company's pipeline in order to identify what we believe are the proper projects to pursue. Innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.

We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market. Revenues for our Significant Seven were greater than $150 million in 2018 and approximately $75 million in 2017. We believe the prospects for this group of products to be substantial and anticipate devoting significant marketing efforts toward their promotion.

See Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC and the ~~Canadian Securities Administrators~~CSA on SEDAR on February ~~20, 2019~~19, 2020 for additional information on our competition risks.

~~Business Trends~~Regulatory Matters

In ~~addition~~the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations, including the FDA. Currently, all of our global operations and facilities have the relevant operational certificates. Through the date of this filing, the Company's operating sites are in good compliance standing with no material noncompliance, and all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (“VAI”) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the ~~acquisition and divestiture actions previously outlined,~~issues cited in the ~~following events~~Form 483, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have ~~affected and are expected to affect our business trends:~~observed any condition that in their judgment may constitute violations of current good manufacturing practice.

~~U.S. Health Care Reform~~

SELECTED FINANCIAL INFORMATION

The ~~U.S. federal~~following table provides selected unaudited financial information for the three months ended March 31, 2020 and ~~state governments continue~~2019:



	Three Months Ended March 31,
(in millions, except per share data)	2020			2019			Change
Revenues	$	2,012		$	2,016		$	(4	)
Operating income	$	248		$	287		$	(39	)
Loss before benefit from income taxes	$	(178	)	$	(122	)	$	(56	)
Net loss attributable to Bausch Health Companies Inc.	$	(152	)	$	(52	)	$	(100	)

Basic and diluted loss per share attributable to Bausch Health Companies Inc.	$	(0.43	)	$	(0.15	)	$	(0.28	)

Financial Performance

Summary of the Three Months Ended March 31, 2020 Compared to ~~propose~~the Three Months Ended March 31, 2019

Revenue for the three months ended March 31, 2020 and ~~pass legislation designed to regulate the health care industry. In March 2010, the Patient Protection~~2019 was $2,012 million and ~~Affordable Care Act (the “ACA”)~~$2,016 million, respectively, a decrease of $4 million, or less than 1%. The decrease was ~~enacted in the U.S. The ACA contains several provisions that impact our business, including:~~primarily driven by: (i) ~~an increase in the minimum Medicaid rebate to states participating in the Medicaid program,~~higher sales deductions, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.unfavorable

~~In addition,~~effect of foreign currencies, primarily in ~~2013:~~Europe and Latin America, (iii) the impact of divestitures and discontinuations and (iv) the impacts of the COVID-19 pandemic. The decreases in our revenues were partially offset by: (i) ~~federal subsidies began~~higher gross selling prices (ii) higher volumes and (iii) the incremental product sales of our Trulance^® product, which we added to ~~be phased~~our portfolio in ~~for brand-name prescription drugs filled~~March 2019 as part of the acquisition of certain assets of Synergy. As discussed in the ~~Medicare Part D cover gap~~"Impact of COVID-19 Pandemic" section above, although volumes were higher during the three months ended March 31, 2020 as compared to the same period in 2019, we are experiencing revenue declines in our second quarter in certain businesses in connection with the COVID-19 pandemic.

Operating income for the three months ended March 31, 2020 and 2019 was $248 million and $287 million, respectively, a decrease of $39 million and reflects, among other factors:

•

an increase in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $16 million primarily due to: (i) higher gross selling prices, (ii) the incremental contribution of the sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, and (iii) lower third-party royalty costs. The increases were partially offset by higher sales deductions;

an increase in Selling, general and administrative expenses (“SG&A”) of $46 million primarily due to: (i) higher professional service costs, (ii) higher compensation expense, (iii) higher selling expenses and (iv) the impact of the acquisition of certain assets of Synergy. The increases were partially offset by the favorable impact of foreign currencies;

an increase in R&D of $5 million primarily attributable to a number of projects within our Bausch + Lomb and GI businesses;

a decrease in Amortization of intangible assets of $53 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020;

an increase in Asset impairments of $11 million, primarily related to decreases in forecasted sales of a certain product line during the three months ended March 31, 2020; and

an increase in Other expense (income), net of $26 million, primarily attributable to expenses related to Litigation and other matters during the three months ended March 31, 2020.

Operating income for the three months ended March 31, 2020 and 2019 was $248 million and $287 million, respectively, and included non-cash charges for Depreciation and amortization of intangible assets of $481 million and $532 million, Asset impairments of $14 million and $3 million and Share-based compensation of $27 million and $24 million for the three months ended March 31, 2020 and 2019, respectively.

Our Loss before benefit from income taxes for the three months ended March 31, 2020 and 2019 was $178 million and $122 million, respectively, an increase of $56 million. The increase in our Loss before benefit from income taxes is primarily attributable to: (i) the decrease in our operating results of $39 million, as previously discussed, (ii) an increase in Loss on extinguishment of debt of $17 million due to the December 2019 Financing and Refinancing Transactions, which were completed in January 2020, and (iii) an unfavorable net change in Foreign exchange and other of $13 million. The increase in our Loss before benefit from income taxes was partially offset by a decrease in Interest expense of $10 million.

Net loss attributable to Bausch Health Companies Inc. for the three months ended March 31, 2020 and 2019 was $152 million and $52 million, respectively, a decrease in our reported results of $100 million. The decrease in our results was primarily due to: (i) the increase in our Loss before benefit from income taxes of $56 million, as previously discussed and (ii) the ~~law requires the medical device industry to subsidize health care reform~~unfavorable change in ~~the form~~Benefit from income taxes of a 2.3% excise tax on U.S. sales of most medical devices. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two-year moratorium on the medical device excise tax. On January 22, 2018, with the passage of continuing appropriations through February 8, 2018 (HR 195), the moratorium on the medical device excise tax was further extended until January 1, 2020. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion’s cost paid for by the federal government.

~~For 2018 and 2017, we incurred costs of $36 million and~~ $48 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S. government programs (e.g., Medicare and Medicaid). For 2018 and 2017, we also incurred costs of $90 million and $106 million, respectively, on Medicare Part D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”).

On July 28, 2014, the U.S. Internal Revenue Service issued final regulations related to the branded pharmaceutical drug annual fee pursuant to the ACA. Under the final regulations, an entity’s obligation to pay the annual fee is triggered by qualifying sales in the current year, rather than the liability being triggered upon the first qualifying sale of the following year. We adopted this guidance in the third quarter of 2014, and it did not have a material impact on our financial position or results of operations.

The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that under the current administration, legislation will be passed by Congress repealing the ACA in whole or in part. Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.

In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate’s multiple attempts to repeal various combinations of ACA provisions. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.

Other legislative efforts relating to drug pricing have been proposed and considered at the U.S. federal and state level. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system.million.

~~SELECTED FINANCIAL INFORMATION~~RESULTS OF OPERATIONS

Our unaudited operating results for the three months ended March 31, 2020 and 2019 were as follows:



	Three Months Ended March 31,
(in millions)	2020			2019			Change
Revenues
Product sales	$	1,986		$	1,989		$	(3	)
Other revenues	26			27			(1		)
	2,012			2,016			(4		)
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	505			524			(19		)
Cost of other revenues	14			13			1
Selling, general and administrative	633			587			46
Research and development	122			117			5
Amortization of intangible assets	436			489			(53		)
Asset impairments	14			3			11
Restructuring and integration costs	4			20			(16		)
Acquisition-related contingent consideration	13			(21		)	34
Other expense (income), net	23			(3		)	26
	1,764			1,729			35
Operating income	248			287			(39		)
Interest income	7			4			3
Interest expense	(396		)	(406		)	10
Loss on extinguishment of debt	(24		)	(7		)	(17		)
Foreign exchange and other	(13		)	—			(13		)
Loss before benefit from income taxes	(178		)	(122		)	(56		)
Benefit from income taxes	26			74			(48		)
Net loss	(152		)	(48		)	(104		)
Net income attributable to noncontrolling interest	—			(4		)	4
Net loss attributable to Bausch Health Companies Inc.	$	(152	)	$	(52	)	$	(100	)

Three Months Ended March 31, 2020 Compared to the Three Months Ended March 31, 2019

Revenues

The Company’s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.

Our revenues were $2,012 million and $2,016 million for the three months ended March 31, 2020 and 2019, respectively, a decrease of $4 million, or less than 1%. The decrease was primarily driven by: (i) higher sales deductions of $67 million primarily in our Salix and Ortho Dermatologics segments, (ii) the unfavorable effect of foreign currencies of $18 million primarily in Europe and Latin America and (iii) the impact of divestitures and discontinuations of $7 million. The decreases in our revenues were partially offset by: (i) higher gross selling prices of $59 million primarily in our Salix segment, (ii) higher volumes of $15 million primarily in our Salix and Bausch + Lomb/International segments, partially offset by lower volumes in our Diversified Products segment and the impacts of the COVID-19 pandemic, (iii) the incremental product sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, of $13 million and (iv) an increase in other revenues of $1 million. As discussed in the "Impact of COVID-19 Pandemic" section above, although volumes were higher during the three months ended March 31, 2020 as compared to the same period in 2019, we are experiencing revenue declines in our second quarter in certain businesses in connection with the COVID-19 pandemic.

Our segment revenues and segment profits for the three months ended March 31, 2020 and 2019, including the impact of the COVID-19 virus on our revenues for the three months ended March 31, 2020, are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

Cash Discounts and Allowances, Chargebacks and Distribution Fees

As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales. Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. Price appreciation credits are generated when we increase a product’s wholesaler acquisition cost (“WAC”) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities.

We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate. Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended March 31, 2020 and 2019 were as follows:



	Three Months Ended March 31,
	2020				2019
(in millions)	Amount		Pct.		Amount		Pct.
Gross product sales	$	3,323	100.0	%	$	3,250	100.0	%
Provisions to reduce gross product sales to net product sales
Discounts and allowances	156		4.7	%	204		6.3	%
Returns	42		1.3	%	33		1.0	%
Rebates	602		18.0	%	533		16.4	%
Chargebacks	484		14.6	%	443		13.6	%
Distribution fees	53		1.6	%	48		1.5	%
Total provisions	1,337		40.2	%	1,261		38.8	%
Net product sales	1,986		59.8	%	1,989		61.2	%
Other revenues	26				27
Revenues	$	2,012			$	2,016

Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 40.2% and 38.8% for the three months ended March 31, 2020 and 2019, respectively. The increase in cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales was primarily driven by:

•

discounts and allowances as a percentage of gross product sales was lower primarily due to lower gross product sales and lower discount rates for our Glumetza^® AG, Syprine^® AG, Migranal^® AG and Benzamycin^® AG. The lower discounts and allowances as a percentage of gross product sales was partially offset by the impact of: (i) the release of certain generics, such as Apriso^® AG (December 2019) and (ii) higher sales of Xifaxan^®;


•	returns as a percentage of gross product sales was higher primarily due to higher return experience for a limited number of products, primarily Glumetza^® SLX, partially offset by lower returns for Solodyn^®, Nitropress^® and Xifaxan^®;

•

rebates as a percentage of gross product sales were higher primarily due the impact of: (i) increases in gross product sales for products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Xifaxan^®, Wellbutrin^® and Prolensa^®, (ii) sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, and (iii) rebates associated with our Duobrii^® product launched in June 2019, partially offset by decreases in gross product sales for products which carry higher rebate rates, such as Apriso^®, Lotemax^®Suspension, Lotemax^®Gel, Zovirax^® and Cuprimine^®. The decreases in gross product sales for these products were due in part to generic competition and the release of certain branded generics.

•

chargebacks as a percentage of gross product sales were higher primarily due to the impact of: (i) higher gross product sales of Xifaxan^®, (ii) higher chargeback rates for Xifaxan^® and Glumetza^® SLX and (iii) the release of certain generics, such as Apriso^® AG (December 2019). The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of: (i) certain branded products, such as and Nifediac^® and Retin-A Micro^® 0.06% and (ii) certain generic products, such as Glumetza^® AG, Ofloxacin and Syprine^® AG; and

•

distribution service fees as a percentage of gross product sales were higher due to the impact of: (i) higher sales of branded products, such as Xifaxan^®, (ii) sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, and (iii) sales of our Duobrii^® product launched in June 2019. The higher distribution service fees as a percentage of gross product sales were partially offset by the impact of lower gross product sales of certain branded products, such as Apriso^® as a result of its generic release and Cuprimine^®. Price appreciation credits are offset against the distribution service fees we pay wholesalers and were $4 million and $0 for the three months ended March 31, 2020 and 2019, respectively.

Expenses

Cost of Goods Sold (excluding amortization and impairments of intangible assets)

Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold excludes the amortization and impairments of intangible assets.

Cost of goods sold was $505 million and $524 million for the three months ended March 31, 2020 and 2019, respectively, a decrease of $19 million, or 4%. The decrease was primarily driven by: (i) the favorable impact of foreign currencies, (ii) lower third-party royalty costs and (iii) the impact of divestitures and discontinuations. The decrease was partially offset by: (i) product mix and (ii) the incremental costs of sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy.

Cost of goods sold as a percentage of product sales revenue was 25.4% and 26.3% for the three months ended March 31, 2020 and 2019, respectively, a decrease of 0.9 percentage points. Costs of goods sold as a percentage of Product sales revenue was favorably impacted as a result of: (i) higher gross selling prices, (ii) the favorable impact of foreign currencies on cost of goods sold and (iii) lower third-party royalty costs. These factors were partially offset by: (i) higher sales deductions and (ii) product mix.

Selling, General and Administrative Expenses

SG&A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs.

SG&A expenses were $633 million and $587 million for the three months ended March 31, 2020 and 2019, respectively, an increase of $46 million, or 8%. The increase was primarily driven by: (i) higher professional service costs, (ii) higher compensation expense, (iii) higher selling expenses and (iv) the impact of the acquisition of certain assets of Synergy. The increases were partially offset by the favorable impact of foreign currencies.

Research and Development Expenses

Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs.

R&D expenses were $122 million and $117 million for the three months ended March 31, 2020 and 2019, respectively, an increase of $5 million, or 4%, primarily attributable to a number of projects within our Bausch + Lomb and GI businesses. R&D expenses as a percentage of Product sales were approximately 6% for both the three months ended March 31, 2020 and 2019.

Amortization of Intangible Assets

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years.

Amortization of intangible assets was $436 million and $489 million for the three months ended March 31, 2020 and 2019, respectively, a decrease of $53 million. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2020. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.

See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to the Amortization of intangible assets.

Asset Impairments

Asset impairments were $14 million and $3 million for the three months ended March 31, 2020 and 2019, respectively, an increase of $11 million. Asset impairments for the three months ended March 31, 2020 were due to decreases in forecasted sales of a certain product line. Asset impairments for the three months ended March 31, 2019 were due to the discontinuance of a specific product line not aligned with the focus of the Company's core businesses.

See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to our intangible assets.

Restructuring and Integration Costs

The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.

Restructuring and integration costs were $4 million and $20 million for the three months ended March 31, 2020 and 2019, respectively, a decrease of $16 million. During the three months ended March 31, 2020, these costs included $3 million of facility closure costs and $1 million of severance costs. During the three months ended March 31, 2019, these costs included: (i) $10 million of severance costs associated with the acquisition of certain assets of Synergy, which were not essential to complete, close and report the acquisition, (ii) $6 million of other severance costs and (iii) $4 million of facility closure costs. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.

See Note 5, "RESTRUCTURING AND INTEGRATION COSTS" to our unaudited interim Consolidated Financial Statements for further details regarding these actions.

Acquisition-Related Contingent Consideration

Acquisition-related contingent consideration primarily consists of potential milestone payments and royalty obligations associated with businesses and assets we acquired in the past. These obligations are recorded in the Consolidated Balance Sheets at their estimated fair values at the acquisition date, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.

Acquisition-related contingent consideration was a loss of $13 million for the three months ended March 31, 2020, and included net fair value adjustments of $7 million and accretion for the time value of money of $6 million. Acquisition-related contingent consideration was a gain of $21 million for the three months ended March 31, 2019, and included net fair value adjustments of $27 million, which included adjustments to future royalty payments, partially offset by accretion for the time value of money of $6 million.

Other Expense (Income), Net

Other expense (income), net for the three months ended March 31, 2020 and 2019 consists of the following:



	Three Months Ended March 31,
(in millions)	2019			2018
Net gain on sale of assets	$	(1	)	$	(10	)
Acquired in-process research and development costs	1			1
Acquisition-related costs	—			8
Litigation and other matters	23			2
Other, net	—			(4		)
	$	23		$	(3	)

Non-Operating Income and Expense

Interest Expense

Interest expense primarily consists of interest payments due and amortization of debt discounts and deferred financing costs on indebtedness under our credit facilities and notes.

Interest expense was $396 million and $406 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred financing costs of $15 million and $17 million, for the three months ended March 31, 2020 and 2019, respectively. Interest expense for the three months ended March 31, 2020 decreased $10 million, or 2%, as compared to the three months ended March 31, 2019, primarily due to: (i) interest related to the Company's cross-currency swaps and (ii) lower weighted average interest rate, partially offset by higher outstanding principal balances. The weighted average stated rates of interest as of March 31, 2020 and 2019 were 6.01% and 6.38%, respectively.

Loss on Extinguishment of Debt

Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $24 million and $7 million for the three months ended March 31, 2020 and 2019, respectively. Loss on extinguishment of debt for the three months ended March 31, 2020 is primarily related to the December 2019 Financing and Refinancing Transactions, which were completed in January 2020. Loss on extinguishment of debt for the three months ended March 31, 2019 is related to a series of transactions which allowed us to refinance portions of our debt arrangements.

See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.

Foreign Exchange and Other

Foreign exchange and other was a loss of $13 million and $0 for the three months ended March 31, 2020 and 2019, respectively, an unfavorable net change of $13 million. Foreign exchange and other includes translation gains/losses on intercompany loans and third-party liabilities and the gain/loss due to the change in fair value of foreign currency exchange contracts.

Income Taxes

Benefit from income taxes was $26 million and $74 million for the three months ended March 31, 2020 and 2019, respectively, a decrease of $48 million. Our effective income tax rate for the three months ended March 31, 2020 and 2019 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) the net tax benefit related to uncertain tax positions and (b) the adjustments for book to income tax return provisions.

See Note 16, "INCOME TAXES" to our unaudited interim Consolidated Financial Statements for further details.

Reportable Segment Revenues and Profits

Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.

The following is a brief description of our segments:

•


•	The Salix segment consists of sales in the U.S. of GI products.


•	The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.


•	The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.

Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, In-process research and development costs, Restructuring and integration costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 19, "SEGMENT INFORMATION" to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Loss before benefit from income taxes.

The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended March 31, 2020 and 2019. The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended March 31, 2020 and 2019.



	Three Months Ended March 31,
	2020				2019				Change
(in millions)	Amount		Pct.		Amount		Pct.		Amount			Pct.
Segment Revenues
Bausch + Lomb/International	$	1,114	55	%	$	1,118	55	%	$	(4	)	—	%
Salix	477		24	%	445		22	%	32			7	%
Ortho Dermatologics	133		7	%	138		7	%	(5		)	(4	)%
Diversified Products	288		14	%	315		16	%	(27		)	(9	)%
Total revenues	$	2,012	100	%	$	2,016	100	%	$	(4	)	—	%

Segment Profits / Segment Profit Margins
Bausch + Lomb/International	$	325	29	%	$	319	29	%	$	6		2	%
Salix	319		67	%	288		65	%	31			11	%
Ortho Dermatologics	48		36	%	57		41	%	(9		)	(16	)%
Diversified Products	202		70	%	236		75	%	(34		)	(14	)%
Total segment profits	$	894	44	%	$	900	45	%	$	(6	)	(1	)%

Organic Revenues and Organic Growth Rates (non-GAAP)

Organic growth, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.

Organic revenue growth (non-GAAP) reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued. These adjustments are determined as follows:

Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

~~Please refer to the tables of organic revenues (non-GAAP) and organic revenue growth (non-GAAP) rates presented in the subsequent section titled “Reportable Segment Revenues and Profits” for~~

The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP).

~~The following table provides selected unaudited financial information for~~ and the ~~three and nine months ended September 30, 2019 and 2018:~~

Three Months Ended September 30, Nine Months Ended September 30,
(in millions, except per share data) 2019 2018 Change 2019 2018 Change
Revenues $ 2,209
$ 2,136
$ 73
$ 6,377
$ 6,259
$ 118
Operating income (loss) $ 329
$ 117
$ 212
$ 873
$ (2,409 ) $ 3,282
Loss before benefit from (provision for) income taxes $ (66 ) $ (300 ) $ 234
$ (367 ) $ (3,728 ) $ 3,361
Net loss attributable to Bausch Health Companies Inc. $ (49 ) $ (350 ) $ 301
$ (272 ) $ (3,804 ) $ 3,532

Basic and diluted loss per share attributable to Bausch Health Companies Inc. $ (0.14 ) $ (1.00 ) $ 0.86
$ (0.77 ) $ (10.83 ) $ 10.06

~~Financial Performance~~

~~Summary of the Three Months Ended September 30, 2019 Compared to the Three Months Ended September 30, 2018~~

Revenue for the three months ended September 30, 2019 and 2018 was $2,209 million and $2,136 million, respectively, an increase of $73 million, or 3%. The increase was primarily driven by: (i) higher gross selling prices, (ii) lower sales deductions and (iii) the incremental product ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~. The increases in our revenues were partially offset by: (i) the unfavorable effect of foreign currencies, primarily in Europe and Latin America and (ii) the impact of divestitures and discontinuations. Theperiod-over-period changes in ~~our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.~~

~~Operating income~~organic revenue (Non-GAAP) for ~~the three months ended September 30, 2019 and 2018 was $329 million and $117 million, respectively, an increase of $212 million and reflects, among other factors:~~

•

an increase in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $74 million primarily due to: (i) higher gross selling prices, (ii) net lower sales deductions, (iii) better inventory management and (iv) the incremental contribution of the ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, partially offset by: (i) the impact of divestitures and discontinuations, (ii) the unfavorable effect of foreign currencies and (iii) higher third-party royalty costs;~~

an increase in Selling, general and administrative expenses (“SG&A”) of $34 million primarily due to: (i) higher selling, advertising and promotion expenses, (ii) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC, (iii) the impact of the acquisition of certain assets of Synergy and (iv) costs in 2019 attributable to our IT infrastructure improvement projects. The increase was partially offset by: (i) lower costs related to professional services, (ii) lower compensation expense, (iii) the favorable impact of foreign currencies and (iv) the impact of divestitures and discontinuations;

~~an increase in R&D of $16 million primarily attributable to a number of projects within our Bausch + Lomb and GI businesses;~~


•	~~a decrease in Amortization of intangible assets of $183 million~~ ~~primarily due to: (i) the impact of the change in the estimated useful life of the Xifaxan~~^®~~related intangible assets made in September 2018 to reflect management's changes in assumptions and (ii) lower amortization as a result of impairments to intangible assets in prior periods~~;

a decrease in Asset impairments of $56 million, primarily related to impairments during the three months ended September 30, 2018 related to: (i) the discontinuance of specific product lines and (ii) Acquired IPR&D associated with a product no longer in development; and

an increase in Other expense (income), net of $25 million primarily attributable to a favorable adjustment of $40 million during the three months ended September 30, 2018 related to the Salix SEC litigation. This increase was partially offset by the loss on sale of assets during the three months ended September 30, 2018.

Operating income for the three months ended September 30, 2019 and 2018 was $329 million and $117 million, respectively, and included non-cash charges for Depreciation and amortization of intangible assets of $520 million and $703 million, Asset impairments of $33 million and $89 million and Share-based compensation of $26 million and $22 million for the three months ended September 30, 2019 and 2018, respectively.

Our Loss before benefit from (provision for) income taxes for the three months ended September 30, 2019 and 2018 was $66 million and $300 million, respectively, a decrease of $234 million. The decrease in our Loss before benefit from (provision for) income taxes is primarily attributable to: (i) the increase in our operating results of $212 million, as previously discussed, (ii) a decrease in Interest expense of $14 million as a result of lower principal amounts of outstanding debt partially offset by the effect of higher interest rates during the three months ended September 30, 2019 and (iii) the net change in Foreign exchange and other of $9 million.

Net loss attributable to Bausch Health Companies Inc. for the three months ended September 30, 2019 and 2018 was $49 million and $350 million, respectively, an increase in our reported results of $301 million. The increase in our results was primarily due to: (i) the decrease in our Loss before benefit from (provision for) income taxes of $234 million, as previously discussed and (ii) the favorable change in Benefit from (provision for) income taxes of $69 million.

~~Summary of the Nine Months Ended September 30, 2019 Compared to the Nine Months Ended September 30, 2018~~

Revenue for the nine months ended September 30, 2019 and 2018 was $6,377 million and $6,259 million, respectively, an increase of $118 million, or 2%. The increase was primarily driven by: (i) higher gross selling prices, (ii) lower sales deductions, (iii) higher net volumes and (iv) ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~. These increases in Revenue were partially offset by: (i) the unfavorable effect of foreign currencies, primarily in Europe, Asia and Latin America and (ii) the impact of divestitures and discontinuations. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

Operating income for the nine months ended September 30, 2019 was $873 million, as compared to Operating loss for the nine months ended September 30, 2018 of $2,409 million, an increase in our reported results of $3,282 million and reflects, among other factors:

•

an increase in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $160 million. The increase was primarily driven by: (i) higher gross selling prices, (ii) lower sales deductions, (iii) better inventory management and (iv) the incremental contribution of the ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, partially offset by: (i) the unfavorable effect of foreign currencies, (ii) the impact of divestitures and discontinuations and (iii) higher third-party royalty costs;~~

an increase in SG&A of $39 million primarily attributable to: (i) higher selling, advertising and promotion expenses, (ii) the impact of the acquisition of certain assets of Synergy, (iii) costs in 2019 attributable to our IT infrastructure improvement projects and (iv) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC. The increase was partially offset by: (i) the favorable impact of foreign currencies, (ii) lower compensation expense and (iii) lower costs related to professional services;

~~an increase in R&D of $64 million primarily attributable to a number of projects within our Bausch + Lomb and GI businesses;~~


•	~~a decrease in Amortization of intangible assets of $690 million~~ ~~primarily due to: (i) the impact of the change in the estimated useful life of the Xifaxan~~^®~~related intangible assets made in September 2018 to reflect management's changes in assumptions and (ii) lower amortization as a result of impairments to intangible assets in prior periods~~;

a decrease in Goodwill impairments of $2,213 million, as a result of impairments in 2018 to the goodwill of our: (i) Salix reporting unit upon adopting the new guidance for goodwill impairment accounting at January 1, 2018 and (ii) Ortho Dermatologics reporting unit due to unforeseen changes in business dynamics during the three months ended March 31, ~~2018;~~

~~a decrease in Asset impairments of $385 million, primarily related to the decrease in forecasted sales in 2018 for a certain product line facing generic competition;~~2020 and

an increase in Other expense (income), net of $18 million primarily attributable to a favorable adjustment of $40 million during the nine months ended September 30, 2018 related to the Salix SEC litigation. This increase was partially offset 2019 by ~~the loss on sale of assets during the nine months ended September 30, 2018.~~

Operating income for the nine months ended September 30, 2019 was $873 million and Operating loss for the nine months ended September 30, 2018 was $2,409 million, and included non-cash charges for Depreciation and amortization of intangible assets of $1,583 million and $2,273 million, Goodwill impairments of $0 and $2,213 million, Asset impairments of $49 million and $434 million and Share-based compensation of $77 million and $65 million, respectively.

Our Loss before benefit from (provision for) income taxes for the nine months ended September 30, 2019 and 2018 was $367 million and $3,728 million, respectively, a decrease of $3,361 million. The decrease in our Loss before benefit from (provision for) income taxes is primarily attributable to: (i) the increase in our operating results of $3,282 million, as previously discussed, (ii) a decrease in Interest expense of $50 million as a result of lower principal amounts of outstanding debt partially offset by the effect of higher interest rates during the nine months ended September 30, 2019 and (iii) a decrease in Loss on extinguishment of debt of $35 million. The decrease in our Loss before benefit from (provision for) income taxes was partially offset by the net change in Foreign exchange and other of $6 million.

Net loss attributable to Bausch Health Companies Inc. for the nine months ended September 30, 2019 and 2018 was $272 million and $3,804 million, respectively, an increase in our reported results of $3,532 million. The increase in our results was primarily due to: (i) the decrease in our Loss before benefit from (provision for) income taxes of $3,361 million, as previously discussed and (ii) the favorable change in Benefit from (provision for) income taxes of $175 million.

~~RESULTS OF OPERATIONS~~

~~Our unaudited operating results for the three and nine months ended September 30, 2019 and 2018 were as follows:~~segment.

Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2019 2018 Change 2019 2018 Change
Revenues
Product sales $ 2,180
$ 2,108
$ 72
$ 6,291
$ 6,173
$ 118
Other revenues 29
28
1
86
86
—
2,209
2,136
73
6,377
6,259
118
Expenses
Cost of goods sold (excluding amortization and impairments of
intangible assets) 571
573
(2 ) 1,675
1,717
(42 )
Cost of other revenues 13
9
4
40
32
8
Selling, general and administrative 648
614
34
1,886
1,847
39
Research and development 123
107
16
357
293
64
Amortization of intangible assets 475
658
(183 ) 1,452
2,142
(690 )
Goodwill impairments —
—
—
—
2,213
(2,213 )
Asset impairments 33
89
(56 ) 49
434
(385 )
Restructuring and integration costs 4
3
1
28
16
12
Acquisition-related contingent consideration 3
(19 ) 22
2
(23 ) 25
Other expense (income), net 10
(15 ) 25
15
(3 ) 18
1,880
2,019
(139 ) 5,504
8,668
(3,164 )
Operating income (loss) 329
117
212
873
(2,409 ) 3,282
Interest income 2
3
(1 ) 9
9
—
Interest expense (406 ) (420 ) 14
(1,221 ) (1,271 ) 50
Loss on extinguishment of debt —
—
—
(40 ) (75 ) 35
Foreign exchange and other 9
—
9
12
18
(6 )
Loss before benefit from (provision for) income taxes (66 ) (300 ) 234
(367 ) (3,728 ) 3,361
Benefit from (provision for) income taxes 18
(51 ) 69
101
(74 ) 175
Net loss (48 ) (351 ) 303
(266 ) (3,802 ) 3,536
Net (income) loss attributable to noncontrolling interest (1 ) 1
(2 ) (6 ) (2 ) (4 )
Net loss attributable to Bausch Health Companies Inc. $ (49 ) $ (350 ) $ 301
$ (272 ) $ (3,804 ) $ 3,532

~~Three Months Ended September 30, 2019 Compared to the Three Months Ended September 30, 2018~~

~~Revenues~~

The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.

Our revenue was $2,209 million and $2,136 million for the three months ended September 30, 2019 and 2018, respectively, an increase of $73 million, or 3%. The increase was primarily driven by: (i) higher gross selling prices of $46 million primarily in our Salix segment, (ii) lower sales deductions of $44 million primarily in our Ortho Dermatologics and Salix segments, (iii) the incremental product ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~, of $14 million and (iv) an increase in other revenues of $1 million. The increases in our revenues were partially offset by: (i) the unfavorable effect of foreign currencies, primarily in Europe and Latin America, of $15 million, (ii) the impact of divestitures and discontinuations of $13 million and (iii) lower net volumes of $4 million primarily in our Ortho Dermatologics and Diversified Products segments, partially offset by higher volumes in our Bausch + Lomb/International and Salix segments.

Our segment revenues and segment profits for the three months ended September 30, 2019 and 2018 are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

~~Cash Discounts and Allowances, Chargebacks and Distribution Fees~~

Three Months Ended September 30,
2019 2018
(in millions) Amount Pct. Amount Pct.
Gross product sales $ 3,428
100.0 % $ 3,614
100.0 %
Provisions to reduce gross product sales to net product sales
Discounts and allowances 179
5.2 % 237
6.6 %
Returns (28 ) (0.8 )% 46
1.3 %
Rebates 550
16.1 % 646
17.9 %
Chargebacks 495
14.4 % 515
14.2 %
Distribution fees 52
1.5 % 62
1.7 %
Total provisions 1,248
36.4 % 1,506
41.7 %
Net product sales 2,180
63.6 % 2,108
58.3 %
Other revenues 29
28

Revenues $ 2,209
$ 2,136

Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 36.4% and 41.7% for the three months ended September 30, 2019 and 2018, respectively. The decrease in cash discounts

~~and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales was primarily driven by:~~

•

~~discounts and allowances as a percentage of gross product sales was lower primarily due to lower gross product sales and lower discount rates for Glumetza~~^® ~~authorized generic ("AG"), Xenazine~~^® ~~AG, Migranal~~^® ~~AG and Benzamycin~~^® ~~AG. The lower discounts and allowances as a percentage of gross product sales was partially offset by the impact of: (i) the release of certain generics such as Elidel~~^® ~~AG (December 2018) and (ii) higher sales of Xifaxan~~^®;

•

Over the last several years the Company increased its focus on maximizing operational efficiencies and reducing product returns. The Company continually takes actions to address product returns including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions resulted in improved sales return experience related to current branded products and previously genericized products. As a result, for the three months ended September 30, 2019 as compared to three months ended September 30, 2018, the provision for sales returns improved by a net $74 million of which approximately $50 million was attributable to past sales primarily related to our: (i) GI business primarily related to Xifaxan^® ~~and Glumetza~~^® ~~SLX, (ii) neurology business primarily related to Wellbutrin~~^®~~, Librax~~^® ~~and Nitropress~~^® ~~and (iii) generics business primarily related to Zegerid~~^®~~AG and Glumetza~~^® ~~AG. The lower returns as a percentage of gross product sales was partially offset by the impact of higher return experience for a limited number of products, primarily Mysoline~~^® ~~and Migranal~~^®~~. See Note 3, "REVENUE RECOGNITION" to our unaudited interim Consolidated Financial Statements regarding further details related to product sales provisions;~~

•

~~rebates as a percentage of gross product sales were lower primarily due to decreases in gross product sales for products which carry higher rebate rates such as Solodyn~~^®~~, Elidel~~^®~~, Cuprimine~~^®~~, Jublia~~^® ~~and Retin-A Micro~~^® 0.06%. The decreases in gross product sales for these products were due in part to generic competition and the release of certain branded generics. The decreases in rebates as a percentage of gross product sales were partially offset by the impact of: (i) increases in gross product sales for products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Xifaxan^®~~and Apriso~~^®~~, (ii) rebates associated with our Duobrii~~^® ~~product launched in June 2019 and (iii)~~ ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~;

•

~~chargebacks as a percentage of gross product sales were higher primarily due to the impact of: (i) higher gross product sales of Xifaxan~~^®~~, (ii) higher chargeback rates for Glumetza~~^® ~~SLX and Glumetza~~^® ~~AG and (iii) the release of certain generics, such as Elidel~~^® ~~AG (December 2018). The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of: (i) certain branded products, such as Nifediac~~^® ~~and Retin-A Micro~~^® ~~0.06% and (ii) certain generic products, such as Ofloxacin, Zegerid~~^®~~and Xenazine~~^® ~~AG; and~~

•

~~distribution service fees as a percentage of gross product sales were lower primarily due to the impact of lower gross product sales of certain branded products, such as Solodyn~~^® ~~and Elidel~~^®,~~as a result of generic releases. The lower distribution service fees as a percentage of gross product sales were partially offset by the impact of: (i) higher sales of Xifaxan~~^® ~~and other branded products, (ii)~~ ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~ ~~and (iii) sales of our Duobrii~~^® ~~product launched in June 2019. No price appreciation credits were provided during the three months ended September 30, 2019 and 2018.~~

~~Expenses~~

~~Cost of Goods Sold (excluding amortization and impairments of intangible assets)~~

Cost of goods sold was $571 million and $573 million for the three months ended September 30, 2019 and 2018, respectively, a decrease of $2 million, or less than 1%. The decrease was primarily driven by: (i) better inventory management, (ii) the favorable impact of foreign currencies and (iii) the impact of divestitures and discontinuations. The decrease was partially offset by: (i) product mix, (ii) higher third-party royalty costs and (iii) the incremental costs of ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~.

Cost of goods sold as a percentage of product sales revenue was 26.2% and 27.2% for the three months ended September 30, 2019 and 2018, respectively, a decrease of 1.0 percentage points. Costs of goods sold as a percentage of Product sales revenue was favorably impacted as a result of: (i) higher gross selling prices and lower sales deductions, (ii) better inventory management and (iii) the favorable impact of foreign currencies on cost of goods sold. These factors were partially offset by: (i) product mix and (ii) higher third-party royalty costs.

~~Selling, General and Administrative Expenses~~

SG&A expenses were $648 million and $614 million for the three months ended September 30, 2019 and 2018, respectively, an increase of $34 million, or 6%. The increase was primarily driven by: (i) higher selling, advertising and promotion expenses, (ii) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC, (iii) the impact of the acquisition of certain assets of Synergy and (iv) costs in 2019 attributable to our IT infrastructure improvement projects. The increase was partially offset by: (i) lower costs related to professional services, (ii) lower compensation expense, (iii) the favorable impact of foreign currencies and (iv) the impact of divestitures and discontinuations.

~~Research and Development Expenses~~

R&D expenses were $123 million and $107 million for the three months ended September 30, 2019 and 2018, respectively, an increase of $16 million, or 15%, primarily attributable to a number of projects within our Bausch + Lomb and GI businesses. R&D expenses as a percentage of Product sales were approximately 6% and 5% for the three months ended September 30, 2019 and 2018, respectively, an increase of approximately 1 percentage point.

~~Amortization of Intangible Assets~~

~~Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years.~~

~~Amortization of intangible assets was $475 million and $658 million for the three months ended September 30, 2019 and 2018, respectively, a decrease of $183 million. The decrease was~~ ~~primarily due to: (i) the impact of the change in the estimated useful life of the Xifaxan~~^®~~related intangible assets made in September 2018 to reflect management's changes in assumptions and (ii) lower amortization as a result of impairments to intangible assets in prior periods. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.~~

~~See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to the Amortization of intangible assets.~~

~~Asset Impairments~~

Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.

Asset impairments were $33 million and $89 million for the three months ended September 30, 2019 and 2018, respectively, a decrease of $56 million. Asset impairments for the three months ended September 30, 2019 include impairments of: (i) $25 million, in aggregate, reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors and (ii) $8 million related to assets being classified as held for sale. Asset impairments for the three months ended September 30, 2018 include impairments of: (i) $61 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and revisions to forecasted sales and (ii) $28 million to Acquired IPR&D not in service related to a certain product.

~~See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to our intangible assets.~~

~~Restructuring and Integration Costs~~

Restructuring and integration costs were $4 million and $3 million for the three months ended September 30, 2019 and 2018, respectively, an increase of $1 million. During the three months ended September 30, 2019, these costs included: (i) $3 million of facility closure costs and (ii) $1 million of severance costs. During the three months ended September 30, 2018, these costs included $3 million of facility closure costs. The Company continues to evaluate opportunities to streamline its operations and

identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.

~~See Note 5, "RESTRUCTURING AND INTEGRATION COSTS" to our unaudited interim Consolidated Financial Statements for further details regarding these actions.~~

~~Acquisition-Related Contingent Consideration~~

Acquisition-related contingent consideration primarily consists of potential milestone payments and royalty obligations associated with businesses and assets we acquired in the past. These obligations are recorded in the Consolidated Balance Sheet at their estimated fair values at the acquisition date, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.

Acquisition-related contingent consideration was a loss of $3 million for the three months ended September 30, 2019, and included accretion for the time value of money of $5 million, partially offset by net fair value adjustments of $2 million. Acquisition-related contingent consideration was a gain of $19 million for the three months ended September 30, 2018, and included net fair value adjustments of $25 million, partially offset by accretion for the time value of money of $6 million.

~~Other Expense (Income), Net~~

~~Other expense (income), net for the three months ended September 30, 2019 and 2018 consists of the following:~~

Three Months Ended
September 30,
(in millions) 2019 2018
Net (gain) loss on sale of assets $ (1 ) $ 26
Litigation and other matters 9
(40 )
Other, net 2
(1 )
$ 10
$ (15 )

~~Non-Operating Income and Expense~~

~~Interest Expense~~

~~Interest expense primarily consists of interest payments due and amortization of debt discounts and deferred financing costs on indebtedness under our credit facilities and notes.~~

Interest expense was $406 million and $420 million, and included non-cash amortization and write-offs of debt discounts and deferred financing costs of $17 million and $18 million, for the three months ended September 30, 2019 and 2018, respectively. Interest expense for the three months ended September 30, 2019 decreased $14 million, or 3%, as compared to the three months ended September 30, 2018, primarily due to lower principal amounts of outstanding long-term debt, partially offset by the effect of higher interest rates. The weighted average stated rates of interest as of September 30, 2019 and 2018 were 6.39% and 6.32%, respectively.

~~Foreign Exchange and Other~~

Foreign exchange and other was a gain of $9 million and $0 for the three months ended September 30, 2019 and 2018, respectively, a favorable net change of $9 million. Foreign exchange gains/losses include translation gains/losses on intercompany loans and third-party liabilities, primarily denominated in euros.

~~Income Taxes~~

Benefit from income taxes was $18 million for the three months ended September 30, 2019 compared to a Provision for income taxes of $51 million for the three months ended September 30, 2018, an increase in the Benefit from income taxes of $69 million.

Our effective income tax rate for the three months ended September 30, 2019 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters,

~~primarily related to: (a) the net tax benefit related to uncertain tax positions and (b) the adjustments for book to income tax return provisions.~~

Our effective income tax rate for the three months ended September 30, 2018 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of: (a) the tax consequences of internal restructuring efforts, (b) the net tax benefit related to the impairment of intangibles assets previously discussed and (c) adjustments for book to income tax return provisions.

~~See Note 17, "INCOME TAXES" to our unaudited interim Consolidated Financial Statements for further details.~~

~~Reportable Segment Revenues and Profits~~

Consistent with how the Company’s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports; the Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment.

~~The following is a brief description of our segments:~~

•

~~The Bausch + Lomb/International segment~~ consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.


•	~~The Salix segment~~ ~~consists of sales in the U.S. of GI products.~~


•	~~The Ortho Dermatologics segment~~ ~~consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.~~


•	~~The Diversified Products segment~~ ~~consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.~~

Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, In-process research and development costs, Restructuring and integration costs, Acquisition-related contingent consideration costs and Other income, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 20, "SEGMENT INFORMATION" to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Loss before benefit from (provision for) income taxes.

The following table presents segment revenues, segment revenues as a percentage of total revenues, and the year-over-year changes in segment revenues for the three months ended September 30, 2019 and 2018. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for the three months ended September 30, 2019 and 2018.

Three Months Ended September 30,
2019 2018 Change
(in millions) Amount Pct. Amount Pct. Amount Pct.
Segment Revenues
Bausch + Lomb/International $ 1,175
53 % $ 1,147
54 % $ 28
2 %
Salix 551
25 % 460
22 % 91
20 %
Ortho Dermatologics 147
7 % 176
8 % (29 ) (16 )%
Diversified Products 336
15 % 353
16 % (17 ) (5 )%
Total revenues $ 2,209
100 % $ 2,136
100 % $ 73
3 %

Segment Profits / Segment Profit Margins
Bausch + Lomb/International $ 333
28 % $ 341
30 % $ (8 ) (2 )%
Salix 375
68 % 304
66 % 71
23 %
Ortho Dermatologics 58
39 % 88
50 % (30 ) (34 )%
Diversified Products 246
73 % 267
76 % (21 ) (8 )%
Total segment profits $ 1,012
46 % $ 1,000
47 % $ 12
1 %

The following table presents organic revenue (non-GAAP) and the year-over-year changes in organic revenue (non-GAAP) for the three months ended September 30, 2019 and 2018 by segment. Organic revenues (non-GAAP) and organic growth (non-GAAP) rates are defined in the previous section titled “Selected Financial Information”.


	Three Months Ended September 30, 2019									Three Months Ended September 30, 2018							Change in Organic Revenue					Three Months Ended March 31, 2020									Three Months Ended March 31, 2019							Change in Organic Revenue
	Revenue as Reported		Changes in Exchange Rates		Acquisition			Organic Revenue (Non-GAAP)		Revenue as Reported		Divestitures and Discontinuations			Organic Revenue (Non-GAAP)		Change in Organic Revenue					Revenue as Reported		Changes in Exchange Rates		Acquisition			Organic Revenue (Non-GAAP)		Revenue as Reported		Divestitures and Discontinuations			Organic Revenue (Non-GAAP)		Change in Organic Revenue
(in millions)	Revenue as Reported		Changes in Exchange Rates		Acquisition			Organic Revenue (Non-GAAP)		Revenue as Reported		Divestitures and Discontinuations			Organic Revenue (Non-GAAP)		Amount			Pct.		Revenue as Reported		Changes in Exchange Rates		Acquisition			Organic Revenue (Non-GAAP)		Revenue as Reported		Divestitures and Discontinuations			Organic Revenue (Non-GAAP)		Amount			Pct.
Bausch + Lomb/International	$	1,175	$	15	$	—		$	1,190	$	1,147	$	(9	)	$	1,138	$	52		5	%	$	1,114	$	17	$	—		$	1,131	$	1,118	$	(7	)	$	1,111	$	20		2	%
Salix	551		—		(14		)	537		460		(3		)	457		80			18	%	477		—		(13		)	464		445		—			445		19			4	%
Ortho Dermatologics	147		—		—			147		176		—			176		(29		)	(16	)%	133		1		—			134		138		—			138		(4		)	(3	)%
Diversified Products	336		—		—			336		353		(1		)	352		(16		)	(5	)%	288		—		—			288		315		—			315		(27		)	(9	)%
Total	$	2,209	$	15	$	(14	)	$	2,210	$	2,136	$	(13	)	$	2,123	$	87		4	%	$	2,012	$	18	$	(13	)	$	2,017	$	2,016	$	(7	)	$	2,009	$	8		—	%

Bausch + Lomb/International Segment:

Bausch + Lomb/International Segment Revenue

The Bausch + Lomb/International segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb/International segment revenue was ~~$1,175~~$1,114 million and ~~$1,147~~$1,118 million for the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively, ~~an increase~~a decrease of ~~$28~~$4 million, or 2%less than 1%. The ~~increase~~decrease was primarily attributable to: (i) an increase in volume of $44 million, primarily in our Global Vision Care and Global Consumer businesses, and (ii) an increase in average realized pricing of $9 million, primarily driven by increased gross selling prices in our Global Consumer and International Rx businesses, partially offset by decreases in gross selling prices in our Global Vision Care business. The increase in volume in our Global Vision Care business is primarily attributable to our Biotrue^® ~~ONEday and Ultra~~^® ~~product lines. The increase in volume our Global Consumer business is primarily attributable to Lumify~~^®~~. These increases were partially offset by:~~ (i) the unfavorable effect of foreign currencies of ~~$15~~$17 million, primarily attributable to our revenues in Europe and Latin America and (ii) the impact of divestitures and discontinuations of $9$7 million, ~~primarily~~ related to the divestiture and discontinuance of several ~~products within~~products. These decreases were partially offset by: (i) an increase in volume of $10 million and (ii) an increase in average realized pricing of $10 million, primarily driven by increases in our Global Vision Care, International Rx ~~business~~ and ~~(iii) a~~Global Consumer businesses, partially offset by the decrease in ~~other~~our Global Ophtho Rx business. The increase in volume is primarily attributable to our Global Consumer and International Rx businesses, driven by: (i) our eye vitamin franchise, which includes LUMIFY^® and (ii) increased demand as consumers prepared for the COVID-19 pandemic by ensuring they had access to essential products and prescriptions. The increased volumes in our Global Consumer and International Rx businesses were partially offset by decreased volumes in our Global Vision Care, Global Surgical and Global Ophtho Rx businesses primarily in Asia and Europe and which we believe are in part due to the precautionary measures in response to the COVID-19 pandemic as previously discussed. Our Vision Care business was most impacted by declines in contact lens use in Asia, as a result of retail store closures as well as reduced contact lens wear due to decreased social interaction.

Bausch + Lomb/International Segment Profit

The Bausch + Lomb/International segment profit for three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$333~~$325 million and ~~$341~~$319 million, respectively, ~~a decrease~~an increase of $8$6 million, or 2%. The ~~decrease~~increase was primarily driven by: (i) ~~higher selling, advertising and promotion expenses, (ii) higher R&D expenses, (iii)~~ the ~~impact of divestitures and discontinuations, (iv) higher costs related to professional services and (v) the unfavorable~~favorable effect of foreign ~~currencies.~~currencies on our contribution and (ii) the increase in average realized pricing, as previously discussed. The ~~decrease~~increase was partially offset by: (i) ~~the increases in average realized pricing and volumes, as previously discussed~~product mix and (ii) ~~better inventory management.~~higher selling expenses.

Salix Segment:

Salix Segment Revenue

The Salix segment includes the Xifaxan^® product line, which accounted for ~~72%~~79% and 69% of the Salix segment product sales and ~~18%~~19% and 15% of the Company's product sales for the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively. No other single product group represents 10% or more of the Salix segment product sales. ~~The~~ Salix segment revenue for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$551~~$477 million and ~~$460~~$445 million, respectively, an increase of ~~$91~~$32 million, or ~~20%~~7%. The increase includes: (i) an increase in ~~average realized pricing of $50 million primarily attributable to higher gross selling prices and lower sales deductions for Xifaxan~~^®~~, (ii) an increase in~~ volume of $30 million ~~primarily attributable to increased demand for Xifaxan~~^®~~, Glumetza~~^® ~~SLX~~ and ~~Plenvu~~^® ~~and (iii)~~(ii) sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, of ~~$14~~$13 million. The increase in volumes was primarily attributable to increased demand for Xifaxan^®, Relistor^® and Glumetza^® SLX, partially offset by the impact of generic competition as certain products, such as Apriso^® and Uceris^®, lost exclusivity. These increases in revenue were partially offset by a decrease in average realized pricing of $11 million primarily attributable to higher sales deductions for Glumetza^® SLX partially offset by higher gross selling prices for Xifaxan^®.

As discussed in the "Impact of COVID-19 Pandemic" section above, although volumes were higher during the three months ended March 31, 2020 as compared to the same period in 2019, we are experiencing revenue declines in our second quarter in certain businesses in connection with the COVID-19 pandemic. In response to the COVID-19 pandemic, many health care facilities and medical offices are closed and certain surgeries and elective medical procedures have been postponed, which we expect to impact the revenues of ~~divestitures~~our Salix segment during 2020. However, through the date of this filing, we believe that the COVID-19 pandemic has had only a limited impact on the demand for our Xifaxan^® products. Further, as of April 30, 2020, we have over five months’ supply of Xifaxan^® on hand and ~~discontinuations~~enough API to manufacture another five months’ supply of ~~$3 million.~~Xifaxan^® finished goods. We also have open orders for API that we currently expect will arrive on schedule. However, if we were to experience a lack of availability of API for Xifaxan^®, such disruption to our supply chain could have a significant adverse effect on our business, financial condition and results of operations.

Salix Segment Profit

The Salix segment profit for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$375~~$319 million and ~~$304~~$288 million, respectively, an increase of ~~$71~~$31 million, or ~~23%~~11%. The increase was primarily driven by a net increase in contribution as a result of: (i) the ~~increases~~increase in ~~average realized pricing and~~ volume, as previously discussed, (ii) lower third-party royalty costs and (iii) gross profit from the sales of our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy ~~and (iii) better inventory management.~~. The ~~increase~~increases in segment profit was partially offset by: (i) a decrease in average realized pricing, as previously discussed, (ii) higher selling, advertising and promotion expenses primarily related to our Trulance^® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy and ~~(ii) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC.~~(iii) higher costs related to professional services.

Ortho Dermatologics Segment:

Ortho Dermatologics Segment Revenue

The Ortho Dermatologics segment revenue for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$147~~$133 million and ~~$176~~$138 million, respectively a decrease of ~~$29~~$5 million, or ~~16%~~4%. The decrease ~~includes:~~is primarily driven by: (i) a decrease in average realized pricing of $8 million as a result of higher sales deductions in our medical dermatology products and (ii) the unfavorable effect of foreign currencies of $1 million. These decreases were partially offset by an increase in volume of ~~$52~~$4 million ~~and (ii) a decrease in other revenues of $3 million. The decrease in volume is~~ primarily due to: (i) ~~the impact of generic competition as certain products lost exclusivity, including Solodyn~~^®~~, Zovirax~~^®,~~and Elidel~~^® ~~and (ii) decreased demand for Tretinoin~~^®~~, Targretin~~^®,~~Onexton~~^®~~and Jublia~~^®~~, partially offset by the~~ increased demand of Thermage FLX^® and ~~Siliq~~(ii) the launch of Duobrii^®~~. These decreases were~~(June 2019) and partially offset by ~~an increase~~a decrease in ~~average realized pricing~~volumes due to the impact of ~~$26 million~~generic competition as ~~a result of lower sales deductions primarily attributable to Jublia~~certain products, such as Solodyn^®, ~~Targretin~~Zovirax^®and ~~Solodyn~~Elidel^®., lost exclusivity.

Ortho Dermatologics Segment Profit

The Ortho Dermatologics segment profit for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$58~~$48 million and ~~$88~~$57 million, respectively, a decrease of ~~$30~~$9 million, or ~~34%~~16%. The decrease was primarily driven ~~by: (i)~~by a decrease in contribution as a result of the decrease in revenue, as previously ~~discussed and (ii) higher selling, advertising and promotion expenses, primarily attributable to the launches of Duobrii~~^®~~, Altreno~~^® ~~and Bryhali~~^®.discussed.

Diversified Products Segment:

Diversified Products Segment Revenue

The following table displays the Diversified Products segment revenue by product and product revenues as a percentage of segment revenue for the three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019.


	Three Months Ended September 30,													Three Months Ended March 31,
	2019				2018				Change					2020				2019				Change
(in millions)	Amount		Pct.		Amount		Pct.		Amount			Pct.		Amount		Pct.		Amount		Pct.		Amount			Pct.
Wellbutrin^® Franchise	$	64	19	%	$	64	18	%	$	—		—	%	$	58	20	%	$	58	18	%	$	—		—	%
Aplenzin^®														26		9	%	16		5	%	10			63	%
Arestin^®	22		7	%	21		6	%	1			5	%	19		7	%	21		7	%	(2		)	(10	)%
Aplenzin^®	22		7	%	13		4	%	9			69	%
Diastat^® Franchise														11		4	%	6		2	%	5			83	%
Migranal^® Franchise	15		4	%	20		6	%	(5		)	(25	)%	10		3	%	12		4	%	(2		)	(17	)%
Diastat^® Franchise	12		4	%	10		3	%	2			20	%
Xenazine^® Franchise	11		3	%	12		3	%	(1		)	(8	)%
Librax^®	11		3	%	8		2	%	3			38	%
Neo/Poly/HC Otic														9		3	%	5		2	%	4			80	%
Uceris^®AG	9		3	%	6		2	%	3			50	%	9		3	%	5		2	%	4			80	%
Apriso^®														8		3	%	—		—	%	8			—	%
Ativan^®	9		3	%	15		4	%	(6		)	(40	)%	8		3	%	15		5	%	(7		)	(47	)%
Cardizem^® CD	9		3	%	6		2	%	3			50	%
Tobramycin/Dexamethasone														8		3	%	7		2	%	1			14	%
Other product revenues	142		41	%	173		49	%	(31		)	(18	)%	119		41	%	168		52	%	(49		)	(29	)%
Other revenues	10		3	%	5		1	%	5			100	%	3		1	%	2		1	%	1			50	%
Total Diversified Products revenues	$	336	100	%	$	353	100	%	$	(17	)	(5	)%	$	288	100	%	$	315	100	%	$	(27	)	(9	)%

The Diversified Products segment revenue for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$336~~$288 million and ~~$353~~$315 million, respectively, a decrease of ~~$17~~$27 million, or 5%9%. The decrease was primarily driven ~~by: (i)~~by a decrease in volume of ~~$26 million and (ii) the impact of divestitures and discontinuations of $1~~$29 million. The decrease in volume was primarily attributable toto: (i) our Neurology and Other business ~~as: (i)~~as certain products ~~lost exclusivity, including~~such as Cuprimine^®, ~~Syprine~~and Ativan^®, ~~Mephyton~~^® ~~and Xenazine~~^®lost exclusivity and (ii) ~~decreased demand~~our Dentistry business related to the postponement of ~~Ativan~~^®certain surgeries and ~~Wellbutrin~~^®.elective medical procedures in response to the COVID-19 pandemic. These decreases in volume were partially offset ~~by: (i)~~by increased demand for Aplenzin^®, a product within our Neurology and Other ~~business and (ii) increased volumes in our Generics business, primarily due to the launches of Elidel~~^® ~~AG (December 2018), Lotemax Suspension~~^®~~AG (July 2019) and Cuprimine~~^® ~~AG (May 2019).~~business. These decreases in revenue were partially offset by increases in: (i) other revenues of $1 million and (ii) average realized pricing of $5$1 million ~~and (ii) other revenues of $5 million. The increase in average realized pricing was~~ primarily ~~driven by lower sales deductions in our Neurology and Other business as a result of lower returns experience.~~attributable to higher gross selling prices.

Diversified Products Segment Profit

The Diversified Products segment profit for three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$246~~$202 million and ~~$267~~$236 million, respectively, a decrease of ~~$21~~$34 million, or 8%14% and was primarily driven by: (i) the decrease in volume, as previously discussed, and (ii) higher ~~third-party royalty costs.~~

~~Nine Months Ended September 30, 2019 Compared to the Nine Months Ended September 30, 2018~~

~~Revenues~~

~~Our revenue was $6,377 million~~general and $6,259 million for the nine months ended September 30, 2019 and 2018, respectively, an increase of $118 million, or 2%. The increase was primarily driven by: (i) higher gross selling prices of $146 million primarily in our Salix segment, (ii) lower sales deductions of $48 million primarily in our Ortho Dermatologics and Salix segments, (iii) higher volumes of $46 million primarily in our Bausch + Lomb/International and Salix segments, partially offset by lower volumes in our Ortho Dermatologics and Diversified Products segments and (iv) the incremental product ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~, of $37 million. The increases in our revenues were partially offset by: (i) the unfavorable effect of foreign currencies, primarily in Europe, Asia and Latin America, of $112 million and (ii) the impact of divestitures and discontinuations of $47 million.

Our segment revenues and segment profits for the nine months ended September 30, 2019 and 2018 are discussed in further detail in the subsequent section titled "Reportable Segment Revenues and Profits".

~~Cash Discounts and Allowances, Chargebacks and Distribution Fees~~

~~Provisions recorded to reduce gross product sales to net product sales and revenues for the nine months ended September 30, 2019 and 2018 were as follows:~~

Nine Months Ended September 30,
2019 2018
(in millions) Amount Pct. Amount Pct.
Gross product sales $ 10,151
100.0 % $ 10,641
100.0 %
Provisions to reduce gross product sales to net product sales
Discounts and allowances 585
5.8 % 643
6.0 %
Returns 50
0.5 % 209
2.0 %
Rebates 1,650
16.2 % 1,976
18.6 %
Chargebacks 1,425
14.0 % 1,462
13.7 %
Distribution fees 150
1.5 % 178
1.7 %
Total provisions 3,860
38.0 % 4,468
42.0 %
Net product sales 6,291
62.0 % 6,173
58.0 %
Other revenues 86
86

Revenues $ 6,377
$ 6,259

Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 38.0% and 42.0% for the nine months ended September 30, 2019 and 2018, respectively. Changes in cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were primarily driven by:

•

~~discounts and allowances as a percentage of gross product sales was lower primarily due to lower sales of higher discounted generics, such as Glumetza~~^® ~~AG, Xenazine~~^® ~~AG, Targretin~~^® ~~AG and Benzamycin~~^® ~~AG. The lower discounts and allowances as a percentage of gross product sales was partially offset by the impact of: (i) the release of certain generics such as Elidel~~^® ~~AG (December 2018) and (ii) higher sales of Xifaxan~~^®;

•

~~returns as a percentage of gross product sales was lower primarily due to: (i) better inventory practices and disciplines and (ii) lower gross product sales of Isuprel~~^® ~~and Mephyton~~^®, as a result of generic competition. Additionally, over the last several years the Company increased its focus on maximizing operational efficiencies and reducing product returns. The Company continually takes actions to address product returns including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions resulted in improved sales return experience related to current branded products and previously genericized products. As a result, for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018, the provision for sales returns improved by a net of $159 million of which approximately $75 million related to past sales. The Company's actual return rate experience in the current period was lower than its historical rate experience primarily in its: (i) GI business primarily related to Glumetza^® ~~SLX and Xifaxan~~^®~~, (ii) neurology business primarily related to Wellbutrin~~^® ~~and Nitropress~~^® ~~and (iii) generics business primarily related to Zegerid~~^®~~AG and Glumetza~~^® ~~AG. The lower returns as a percentage of gross product sales was partially offset by the impact of higher return experience for a limited number of products, primarily Mysoline~~^®~~. See Note 3, "REVENUE RECOGNITION" to our unaudited interim Consolidated Financial Statements regarding further details related to product sales provisions;~~

•

~~rebates as a percentage of gross product sales were lower primarily due to decreases in gross product sales of certain products which carry higher rebate rates such as Solodyn~~^®~~, Elidel~~^®~~, Jublia~~^® ~~and Retin-A Micro~~^® 0.06%. The decreases in gross product sales for these products were due in part to generic competition and the release of certain branded generics. The lower rebates as a percentage of gross product sales were partially offset by the impact of: (i) increased gross product sales of products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Xifaxan^® ~~and Apriso~~^®~~, (ii)~~ ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~ ~~and (iii) rebates associated with our Duobrii~~^® ~~product which we launched in June 2019;~~

•

~~chargebacks as a percentage of gross product sales were higher primarily due to the impact of: (i) higher gross product sales of Xifaxan~~^®~~, Glumetza~~^® ~~SLX and Syprine~~^® ~~AG, (ii) higher chargeback rates for certain products such as Glumetza~~^® ~~AG and (iii) the release of certain generics, such as Elidel~~^® ~~AG (December 2018) and Uceris~~^® ~~AG (July 2018). The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of certain generic products, such as Xenazine~~^® ~~AG and Zegerid~~^® ~~AG and certain branded products, such as Isuprel~~^® ~~and Nifediac; and~~

•

~~distribution service fees as a percentage of gross product sales were lower primarily due to lower gross product sales of Solodyn~~^®~~, Targretin~~^®~~, Elidel~~^® ~~and Isuprel~~^®~~. The lower distribution service fees as a percentage of gross product sales were partially offset by: (i) higher sales of Xifaxan~~^®~~and Apriso~~^® ~~and other branded products, (ii)~~ ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~ ~~and (iii) distribution service fees associated with our Duobrii~~^® product launched in June 2019. Price appreciation credits, which are offset against the distribution service fees we pay wholesalers, were $0 and $15 million during the nine months ended September 30, 2019 and 2018, respectively.

~~Expenses~~

~~Cost of Goods Sold (excluding amortization and impairments of intangible assets)~~

Cost of goods sold was $1,675 million and $1,717 million for the nine months ended September 30, 2019 and 2018, respectively, a decrease of $42 million, or 2%. The decrease was primarily driven by: (i) the favorable impact of foreign currencies, (ii) better inventory management and (iii) the impact of divestitures and discontinuations, partially offset by: (i) the net increase in volumes, (ii) the incremental costs of ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~ ~~and (iii) higher third-party royalty costs.~~

Cost of goods sold as a percentage of product sales revenue was 26.6% and 27.8% for the nine months ended September 30, 2019 and 2018, respectively, a decrease of 1.2 percentage points. Costs of goods sold as a percentage of Product sales revenue was favorably impacted as a result of: (i) higher gross selling prices and lower sales deductions, (ii) better inventory management and (iii) the impact of divestitures and discontinuations, which generally had lower gross margins than the balance of our product portfolio. These factors were partially offset by: (i) product mix and (ii) the amortization of acquisition accounting adjustments related to the inventories we acquired as part of the acquisition of certain assets of Synergy.

~~Selling, General and Administrative Expenses~~

SG&A expenses were $1,886 million and $1,847 million for the nine months ended September 30, 2019 and 2018, respectively, an increase of $39 million, or 2%. The increase was primarily driven by: (i) higher selling, advertising and promotion expenses, (ii) the impact of the acquisition of certain assets of Synergy, (iii) costs in 2019 attributable to our IT infrastructure improvement projects and (iv) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC. The increase was partially offset by: (i) the favorable impact of foreign currencies, (ii) lower compensation expense, (iii) lower costs related to professional services and (iv) the impact of divestitures and discontinuations;

~~Research and Development~~

R&D expenses were $357 million and $293 million for the nine months ended September 30, 2019 and 2018, respectively, an increase of $64 million, or 22%, primarily attributable to a number of projects within our Bausch + Lomb and GI businesses. R&D expenses as a percentage of Product sales were approximately 6% and 5% for the nine months ended September 30, 2019 and 2018, respectively, an increase of 1 percentage point.

~~Amortization of Intangible Assets~~

~~Amortization of intangible assets was $1,452 million and $2,142 million for the nine months ended September 30, 2019 and 2018, respectively, a decrease of $690 million, or 32%. The decrease was~~ ~~primarily due to: (i) the impact of the change in the estimated useful life of the Xifaxan~~^®~~related intangible assets made in September 2018 to reflect management's changes in assumptions and (ii) lower amortization as a result of impairments to intangible assets in prior periods. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.~~

~~Goodwill Impairments~~

~~Goodwill impairments were $0 and $2,213 million for the nine months ended September 30, 2019 and 2018, respectively.~~

~~March 31, 2018~~

In January 2017, the Financial Accounting Standards Board issued guidance which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. The Company elected to adopt this guidance effective January 1, 2018.

~~See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements for additional details regarding our goodwill impairment testing.~~

~~Asset Impairments~~

Asset impairments were $49 million and $434 million for the nine months ended September 30, 2019 and 2018, respectively, a decrease of $385 million. Asset impairments for the nine months ended September 30, 2019 include impairments of: (i) $38 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale and (iii) $3 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses. Asset impairments for the nine months ended September 30, 2018 include impairments of: (i) $341 million reflecting decreases in forecasted sales for the Uceris^® Tablet product and other product lines due to generic competition, (ii) $60 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and revisions to forecasted sales, (iii) $28 million to Acquired IPR&D not in service related to a certain product and (iv) $5 million related to assets being classified as held for sale.

~~See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to our intangible assets.~~

~~Restructuring and Integration Costs~~

Restructuring and integration costs were $28 million and $16 million for the nine months ended September 30, 2019 and 2018, respectively, an increase of $12 million. During the nine months ended September 30, 2019 these costs included: (i) $11 million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) $9 million of facility closure costs and (iii) $8 million of other severance costs. During the nine months ended September 30, 2018, these costs included: (i) $8 million of severance costs and (ii) $8 million of facility closure costs. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.

~~See Note 5, "RESTRUCTURING AND INTEGRATION COSTS" to our unaudited interim Consolidated Financial Statements for further details regarding these actions.~~

~~Acquisition-Related Contingent Consideration~~

Acquisition-related contingent consideration was a loss of $2 million for the nine months ended September 30, 2019 and included accretion for the time value of money of $16 million, partially offset by net fair value adjustments of $14 million. Acquisition-related contingent consideration was a net gain of $23 million for the nine months ended September 30, 2018, and included net fair value adjustments of $41 million, partially offset by accretion for the time value of money of $18 million.

~~See Note 6, "FAIR VALUE MEASUREMENTS" to our unaudited interim Consolidated Financial Statements for further details.~~

~~Other Expense (Income), Net~~

~~Other expense (income), net for the nine months ended September 30, 2019 and 2018 consists of the following:~~

Nine Months Ended
September 30,
(in millions) 2019 2018
Net (gain) loss on sale of assets $ (10 ) $ 26
Acquisition-related costs 8
1
Litigation and other matters 12
(30 )
Other, net 5
—
$ 15
$ (3 )

~~Non-Operating Income and Expense~~

~~Interest Expense~~

Interest expense was $1,221 million and $1,271 million and included non-cash amortization and write-offs of debt discounts and deferred financing costs of $49 million and $62 million for the nine months ended September 30, 2019 and 2018, respectively. Interest expense decreased $50 million, or 4%, primarily due to lower principal amounts of outstanding long-term debt, partially offset by the effect of higher interest rates. The weighted average stated rates of interest as of September 30, 2019 and 2018 were 6.39% and 6.32%, respectively.

~~See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.~~

~~Loss on Extinguishment of Debt~~

~~See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.~~

~~Foreign Exchange and Other~~

Foreign exchange and other was a gain of $12 million and $18 million for the nine months ended September 30, 2019 and 2018, respectively, an unfavorable net change of $6 million. Foreign exchange gains/losses include translation gains/losses on intercompany loans and third-party liabilities, primarily denominated in euros.

~~Income Taxes~~

Benefit from income taxes was $101 million for the nine months ended September 30, 2019 compared to a Provision for income taxes of $74 million for the nine months ended September 30, 2018, an increase in the Benefit from income taxes of $175 million.

Our effective income tax rate for the nine months ended September 30, 2019 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) the net tax benefit related to uncertain tax positions and (b) the adjustments for book to income tax return provisions.

Our effective income tax rate for the nine months ended September 30, 2018 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of: (a) the tax consequences of internal restructuring efforts, (b) the net tax benefit related to the impairment of intangibles assets previously discussed and (c) adjustments for book to income tax return provisions.

~~See Note 17, "INCOME TAXES" to our unaudited interim Consolidated Financial Statements for further details.~~

~~Reportable Segment Revenues and Profits~~

The following table presents segment revenues, segment revenues as a percentage of total revenues, and the year-over-year changes in segment revenues for the nine months ended September 30, 2019 and 2018. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for the nine months ended September 30, 2019 and 2018.

Nine Months Ended September 30,
2019 2018 Change
(in millions) Amount Pct. Amount Pct. Amount Pct.
Segment Revenues
Bausch + Lomb/International $ 3,501
55 % $ 3,459
56 % $ 42
1 %
Salix 1,505
24 % 1,323
21 % 182
14 %
Ortho Dermatologics 407
6 % 457
7 % (50 ) (11 )%
Diversified Products 964
15 % 1,020
16 % (56 ) (5 )%
Total revenues $ 6,377
100 % $ 6,259
100 % $ 118
2 %

Segment Profits / Segment Profit Margins
Bausch + Lomb/International $ 989
28 % $ 988
29 % $ 1
< 1%
Salix 995
66 % 868
66 % 127
15 %
Ortho Dermatologics 156
38 % 190
42 % (34 ) (18 )%
Diversified Products 714
74 % 766
75 % (52 ) (7 )%
Total segment profits $ 2,854
45 % $ 2,812
45 % $ 42
1 %

The following table presents organic revenue (non-GAAP) and the year-over-year changes in organic revenue (non-GAAP) for the nine months ended September 30, 2019 and 2018 by segment. Organic revenues (non-GAAP) and organic growth (non-GAAP) rates are defined in the previous section titled “Selected Financial Information”.

Nine Months Ended September 30, 2019 Nine Months Ended September 30, 2018
Change in
Organic Revenue

Revenue
as
Reported
Changes in Exchange Rates Acquisition Organic Revenue (Non-GAAP)
Revenue
as
Reported
Divestitures and Discontinuations Organic Revenue (Non-GAAP)
(in millions) Amount Pct.
Bausch + Lomb/International $ 3,501
$ 110
$ —
$ 3,611
$ 3,459
$ (35 ) $ 3,424
$ 187
5 %
Salix 1,505
—
(37 ) 1,468
1,323
(9 ) 1,314
154
12 %
Ortho Dermatologics 407
2
—
409
457
—
457
(48 ) (11 )%
Diversified Products 964
—
—
964
1,020
(3 ) 1,017
(53 ) (5 )%
Total $ 6,377
$ 112
$ (37 ) $ 6,452
$ 6,259
$ (47 ) $ 6,212
$ 240
4 %

~~Bausch + Lomb/International Segment:~~

~~Bausch + Lomb/International Segment Revenue~~

The Bausch + Lomb/International segment revenue was $3,501 million and $3,459 million for the nine months ended September 30, 2019 and 2018, respectively, an increase of $42 million, or 1%. The increase was primarily attributable to: (i) an increase in volume of $152 million, primarily in our Global Vision Care and Global Consumer businesses, (ii) an increase in average realized pricing of $29 million primarily driven by our International Rx and Global Ophtho Rx businesses and (iii) an increase in other revenues of $6 million. The increase in volume in our Global Vision Care business is primarily attributable to our Biotrue^® ~~ONEday and Ultra~~^® ~~product lines in the U.S. and internationally. The increase in volume in our Global Consumer business is primarily attributable to the launch of Lumify~~^® ~~(May 2018) and sales of PreserVision~~^®~~. The increase in average realized pricing in our Global Ophtho Rx business is primarily attributable to Lotemax~~^®~~, Vyzulta~~^® ~~and Prolensa~~^®. The increase was partially offset by: (i) the unfavorable effect of foreign currencies of $110 million primarily attributable to our revenues in Europe, Asia and Latin America and (ii) the impact of divestitures and discontinuations of $35 million, primarily related to the divestiture and discontinuance of several products within our International Rx business.

~~Bausch + Lomb/International Segment Profit~~

The Bausch + Lomb/International segment profit for the nine months ended September 30, 2019 and 2018 was $989 million and $988 million, respectively, an increase of $1 million, or less than 1%. The increase was primarily driven by an increase in contribution as a result of: (i) the increase in average realized pricing and volume as previously discussed and (ii) better inventory management. The increase was partially offset by: (i) higher selling, advertising and promotion expenses primarily due to the launch of Lumify^®~~, (ii) higher R&D expenses, (iii) the unfavorable effect of foreign currencies and (iv) the impact of divestitures and discontinuations.~~

~~Salix Segment:~~

~~Salix Segment Revenue~~

~~The Salix segment includes the Xifaxan~~^®product line, which accounted for 70% and 67% of the Salix segment product sales and 17% and 14% of the Company's product sales for the nine months ended September 30, 2019 and 2018, respectively. No other single product group represents 10% or more of the Salix segment product sales. The Salix segment revenue for the nine months ended September 30, 2019 and 2018 was $1,505 million and $1,323 million, respectively, an increase of $182 million, or 14%. The increase includes: (i) an increase in average realized pricing of $121 million primarily attributable to higher gross selling prices and lower sales deductions for Xifaxan^®~~, (ii)~~ ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, of $37 million and (iii) an increase in volume of $33 million primarily attributable to increased demand for Xifaxan~~^® ~~and Glumetza~~^® ~~SLX, partially offset by the decrease in demand for Uceris~~^® ~~due to loss of exclusivity. The increase in revenue was partially offset by the impact of divestitures and discontinuations of $9 million. Although Glumetza~~^® ~~SLX contributed to the increase in volumes discussed above, an accelerated shift in channel mix could lead to deteriorating average realized pricing for this product in future periods.~~

~~Salix Segment Profit~~

The Salix segment profit for the nine months ended September 30, 2019 and 2018 was $995 million and $868 million, respectively, an increase of $127 million, or 15%. The increase was primarily driven by: (i) a net increase in contribution as a result of the increase in average realized pricing, as previously discussed and (ii) gross profit from the ~~sales of our Trulance~~^® ~~product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy~~. The increase in segment profit was partially offset by: (i) higher selling, advertising and promotion expenses and (ii) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC.

~~Ortho Dermatologics Segment:~~

~~Ortho Dermatologics Segment Revenue~~

The Ortho Dermatologics segment revenue for the nine months ended September 30, 2019 and 2018 was $407 million and $457 million, respectively, a decrease of $50 million, or 11%. The decrease includes: (i) a decrease in volume of $89 million, (ii) a decrease in other revenues of $9 million and (iii) the unfavorable effect of foreign currencies of $2 million. The decrease in volume is primarily due to: (i) the impact of generic competition as certain products lost exclusivity, including Elidel^®~~, Solodyn~~^® ~~and Zovirax~~^®~~and (ii) decreased demand for Onexton~~^®~~, Targretin~~^®,~~Jublia~~^®~~, Tretinoin~~^®~~and Retin-A Micro~~^® ~~0.08%, partially offset by the increased demand of Thermage FLX~~^®~~and Siliq~~^®~~. The decrease was partially offset by an increase in average realized pricing of $50 million as a result of lower sales deductions primarily attributable to Jublia~~^®~~, Retin-A Micro~~^® ~~0.06%, and Onexton~~^®.

~~Ortho Dermatologics Segment Profit~~

The Ortho Dermatologics segment profit for the nine months ended September 30, 2019 and 2018 was $156 million and $190 million, respectively, a decrease of $34 million, or 18%. The decrease was primarily driven by a decrease in contribution as a result of the decrease in revenue, as previously discussed, partially offset by decreases in: (i) selling expenses and (ii) professional fees.

~~Diversified Products Segment:~~

~~Diversified Products Segment Revenue~~

~~The following table displays the Diversified Products segment revenue by product and product revenues as a percentage of segment revenue for the nine months ended September 30, 2019 and 2018.~~

Nine Months Ended September 30,
2019 2018 Change
(in millions) Amount Pct. Amount Pct. Amount Pct.
Wellbutrin^® Franchise
$ 183
19 % $ 193
19 % $ (10 ) (5 )%
Arestin^®
64
7 % 70
7 % (6 ) (9 )%
Aplenzin^®
59
6 % 37
4 % 22
59 %
Cuprimine^®
44
5 % 60
6 % (16 ) (27 )%
Migranal^® Franchise
40
4 % 46
5 % (6 ) (13 )%
Ativan^®
34
4 % 41
4 % (7 ) (17 )%
Uceris^®AG
29
3 % 6
1 % 23
383 %
Xenazine^®Franchise
29
3 % 41
4 % (12 ) (29 )%
Elidel^®AG
26
3 % —
— % 26
100 %
Diastat^® Franchise
25
3 % 34
3 % (9 ) (26 )%
Other product revenues 416
41 % 480
46 % (64 ) (13 )%
Other revenues 15
2 % 12
1 % 3
25 %
Total Diversified Products revenues $ 964
100 % $ 1,020
100 % $ (56 ) (5 )%

The Diversified Products segment revenue for the nine months ended September 30, 2019 and 2018 was $964 million and $1,020 million, respectively, a decrease of $56 million, or 5%. The decrease was primarily driven by: (i) a decrease in volume of $50 million, (ii) a decrease in average realized pricing of $6 million and (iii) the impact of divestitures and discontinuations of $3 million. The decrease was partially offset by an increase in other revenues of $3 million. The decrease in volume was primarily attributable to our Neurology and Other business due to: (i) the loss of exclusivity of Isuprel^®~~, Mephyton~~^®~~, Cuprimine~~^®~~, Syprine~~^®~~and Xenazine~~^®~~and (ii) lower demand for Wellbutrin~~^®~~, partially offset by increased demand for Aplenzin~~^®~~. The net decrease in volume in our Neurology and Other business was partially offset by the impact of the launches of Elidel~~^® ~~AG (December 2018) and Uceris~~^®AG (July 2018) and other increases in product volumes in our Generics business. The decrease in average realized pricing is primarily attributable to the impact of generic competition in our Generics business for Glumetza^® ~~AG, Syprine~~^® ~~AG, Targretin~~^® ~~AG, Mephyton~~^® ~~AG and Cardizem~~^® ~~AG, partially offset by an increase in average realized pricing in our Neurology and Other business.~~

~~Diversified Products Segment Profit~~

The Diversified Products segment profit for the nine months ended September 30, 2019 and 2018 was $714 million and $766 million, respectively, a decrease of $52 million, or 7% and was primarily driven by: (i) the decrease in volume, as previously discussed and (ii) higher selling, advertising and promotion expenses, partially offset by: (i) lower third-party royalty costs and (ii) better inventory management.administrative expenses.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows


	Nine Months Ended September 30,									Three Months Ended March 31,
(in millions)	2019			2018			Change			2020			2019			Change
Net loss	$	(266	)	$	(3,802	)	$	3,536		$	(152	)	$	(48	)	$	(104	)
Adjustments to reconcile net loss to net cash provided by operating activities	1,645			4,882			(3,237		)	541			459			82
Cash provided by operating activities before changes in operating assets and liabilities	1,379			1,080			299			389			411			(22		)
Changes in operating assets and liabilities	(112		)	102			(214		)	(128		)	2			(130		)
Net cash provided by operating activities	1,267			1,182			85			261			413			(152		)
Net cash used in investing activities	(334		)	(134		)	(200		)	(40		)	(203		)	163
Net cash used in financing activities	(812		)	(851		)	39			(1,521		)	(150		)	(1,371		)
Effect of exchange rate on cash and cash equivalents	(17		)	(21		)	4			(21		)	1			(22		)
Net increase in cash, cash equivalents and restricted cash	104			176			(72		)	(1,321		)	61			(1,382		)
Cash, cash equivalents and restricted cash, beginning of period	723			797			(74		)	3,244			723			2,521
Cash, cash equivalents and restricted cash, end of period	$	827		$	973		$	(146	)	$	1,923		$	784		$	1,139

Operating Activities

Net cash provided by operating activities was ~~$1,267~~$261 million and ~~$1,182~~$413 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively, ~~an increase~~a decrease of ~~$85~~$152 million. The ~~increase~~decrease was attributable to ~~the increase~~net decreases in cash from Changes in operating assets and liabilities and Cash provided by operating activities before changes in operating assets and liabilities ~~partially offset by the decrease in cash from Changes in operating assets and liabilities.~~.

Cash provided by operating activities before changes in operating assets and liabilities for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$1,379~~$389 million and ~~$1,080~~$411 million, respectively, ~~an increase~~a decrease of ~~$299~~$22 million. The ~~increase~~decrease is primarily attributable ~~to: (i)~~ ~~Payments~~to higher sales deductions and the unfavorable effect of ~~accrued legal settlements~~ ~~during 2018 not recurring~~foreign currencies, primarily in ~~2019~~Europe and ~~(ii)~~Latin American partially offset by higher ~~revenues,~~volumes, improved gross margins and cash expense reductions in ~~2019~~2020 as compared to ~~2018~~2019 as previously discussed. ~~During the nine months ended September 30, 2018,~~ ~~Payments of accrued legal settlements~~ ~~were $222 million and were primarily related to the settlements of the Solodyn Antitrust Class Actions, the Allergan Shareholder Class Actions and other matters.~~

Changes in operating assets and liabilities resulted in a net decrease in cash of ~~$112~~$128 million for the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, as compared to the net increase in cash of ~~$102~~$2 million for the ~~nine~~three months ended ~~September 30, 2018,~~March 31, 2019, a decrease of ~~$214~~$130 million. During the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, Changes in operating assets and liabilities was negatively impacted by: (i) the ~~build-up of~~increase in inventories of ~~$205~~$94 million and (ii) the timing of other payments in the ordinary course of business of $103 million, partially offset by the collection of trade receivables of ~~$110~~$69 million. For the ~~nine~~three months ended ~~September 30, 2018,~~March 31, 2019, Changes in operating assets and liabilities was positively impacted by the collection of trade receivables of $89 million offset by the increase in inventories of $68 million and the timing of payments in the ordinary course of business of ~~$107 million and the collection of trade receivables of $56~~$19 million.

Investing Activities

Net cash used in investing activities was $40 million for the three months ended March 31, 2020 and was driven by Purchases of property, plant and equipment of $72 million offset by Proceeds from sale of assets and businesses, net of costs to sell of $21 million primarily related to the receipt of a milestone payment associated with a prior divestiture and Interest settlements from cross-currency swaps of $11 million.

Net cash used in investing activities was ~~$334~~$203 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2019 and was driven ~~by: (i) Purchases of property, plant and equipment of $192 million, and (ii) Acquisition~~by the acquisition of businesses, net of cash acquired of $180 million, related to the acquisition of certain assets of ~~Synergy. Net cash used in investing activities was~~Synergy, and purchases of property, plant and equipment of $47 million, partially offset by ~~Proceeds~~proceeds from sale of assets and businesses, net of costs to sell of ~~$44~~$25 million, primarily related to the receipt of a milestone payment associated with a prior ~~year~~ divestiture.

Net cash used in investing activities was $134 million for the nine months ended September 30, 2018 and was driven by: (i) Purchases of property, plant and equipment of $95 million and (ii) Payments for intangible and other assets previously acquired of $76 million.

Financing Activities

Net cash used in financing activities was ~~$812~~$1,521 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and was primarily driven by the repayments of debt of $1,459 million which consisted of: (i) $1,240 million of May 2023 Unsecured Notes, which was previously financed as part of the December 2019 Financing and Refinancing Transactions, which were completed in January 2020, (ii) $100 million of 5.50% Senior Unsecured Notes due March 2023, (iii) $103 million of our June 2025 Term Loan B Facility (as defined below) and (iv) the repurchase and retirement of outstanding senior unsecured notes with an aggregate par value of $17 million in the open market, for an aggregate cost of $16 million. Issuance of long-term debt, net of discounts of $(3) million primarily represents the payment of fees and expenses associated with the December 2019 Financing and Refinancing Transactions.

Net cash used in financing activities was $150 million for the three months ended March 31, 2019 and was primarily driven by the net reduction in our debt portfolio. Repayments of debt for the ~~nine~~three months ended ~~September 30,~~March 31, 2019 were ~~$3,956~~$1,621 million and consisted of: (i) repayments of principal amounts due under our Senior Notes of ~~$3,000~~$1,318 million, (ii) repayments of term loans under our Senior Secured Credit Facilities of ~~$631~~$228 million and (iii) repayments of our revolving credit facility of ~~$325~~$75 million. Net proceeds from the issuances of long-term debt for the ~~nine~~three months ended ~~September 30,~~March 31, 2019 was ~~$3,238~~$1,514 million and included the net proceeds of: (i) ~~$1,018~~$1,021 million from the issuance of $1,000 million in principal amount of January 2027 Unsecured Notes and (ii) ~~$740 million from the issuance of $750 million in principal amount of January 2028 Unsecured Notes, (iii)~~

~~$740 million from the issuance of $750 million in principal amount of May 2029 Unsecured Notes, (iv) $492~~$494 million from the issuance of $500 million in principal amount of August 2027 Secured ~~Notes and (v) $250 million of borrowings under our revolving credit facilities.~~ Notes. Net proceeds from the issuances of long-term debt is ~~net of $2~~reduced by $1 million ~~in payments we made in 2019~~ for issuance costs paid in 2019 associated with long-term debt issued in previous years. ~~Payments of financing~~Debt extinguishment costs ~~associated with~~ paid for the refinancing of certain debt was ~~$26~~$1 million.

Net cash used in financing activities was $851 million for the nine months ended September 30, 2018 and was primarily driven by the net reduction in our debt portfolio. Repayments of debt for the nine months ended September 30, 2018 were $8,200 million and consisted of: (i) repayments of term loans under our Senior Secured Credit Facilities of $3,635 million, (ii) repayments of principal amounts due under our Senior Notes of $3,640 million, (iii) refinancing $500 million of outstanding amounts under our 2020 Revolving Credit Facility with our 2023 Revolving Credit Facility and (iv) repayments of our revolving credit facilities of $425 million. ~~Net proceeds from the issuances of long-term debt~~ for the nine months ended September 30, 2018 was $7,471 million and included: (i) the net proceeds of: (a) $4,508 million from the issuance of $4,565 million in principal amount of June 2025 Term Loan B Facility, (b) $1,481 million from the issuance of $1,500 million in principal amount of 9.25% Senior Unsecured Notes due April 2026 and (c) $739 million from the issuance of $750 million in principal amount of January 2027 Unsecured Notes, (ii) refinancing $500 million of outstanding amounts under our revolving credit facility set to expire in April 2020 with our 2023 Revolving Credit Facility and (iii) $250 million of borrowings under our revolving credit facilities. ~~Net proceeds from the issuances of long-term debt~~ ~~is net of $7 million in payments we made in 2018 for issuance costs associated with certain senior unsecured notes issued during the second half of 2017.~~ ~~Payments of financing costs~~ ~~associated with the refinancing of certain debt was $62 million.~~

See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for additional information regarding the financing activities described above.

Liquidity and Debt

Future Sources of Liquidity

Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the ~~next~~ twelve ~~months.~~months following the issuance of this Form 10-Q.

The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities. We believe our existing cash and cash generated from operations will be sufficient to service our debt obligations in the years ~~2019~~2020 and ~~2020.~~2021.

Proposed Refinancing Transactions - In February 2020, we announced intentions to opportunistically amend and refinance the Company’s Restated Credit Agreement, in order to extend and reprice our term loans and revolving credit facility and make certain other amendments to the terms of the facilities in connection therewith. We also announced our intention to issue $3,250 million of secured debt securities. The proceeds of the credit agreement refinancing and the offering of the new secured debt securities, along with cash on hand, were to be used to redeem certain outstanding senior secured notes, refinance our outstanding term loans under our Restated Credit Agreement (as defined below) and to pay related fees, premiums and expenses. However, in March 2020, as a result of challenging market conditions, we decided not to pursue these opportunities. We will continue to monitor market conditions and consider opportunistic refinancing transactions from time to time.

Long-term Debt

Long-term debt, net of unamortized premiums, discounts and issuance costs was ~~$23,566~~$24,428 million and ~~$24,305~~$25,895 million as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, respectively. Aggregate contractual principal amounts due under our debt obligations were ~~$23,841~~$24,701 million and ~~$24,632~~$26,188 million as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, respectively, a decrease of ~~$791~~$1,487 million during the ~~nine~~three months ended ~~September 30, 2019.~~March 31, 2020. The decrease was primarily driven by the debt repayments previously discussed under "Cash Flows - Financing Activities".

~~Debt~~Our prepayment and refinancings of debt over the last four years translate into lower repayments ~~- During~~ of principal over the ~~nine months ended September 30, 2019,~~next four years, which, in turn, we ~~repaid approximately $700 million of long-term~~believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt net of borrowings under our 2023 Revolving Credit Facility. Repayments of long-term debt during the nine months ended September 30, 2019 included: (i) $462 million of our June 2025 Term Loan B Facility, (ii) $169 million of our November 2025 Term Loan B Facility and (iii) $75 million, net of borrowings, of our 2023 Revolving Credit Facility. In addition to theseamounts. The mandatory scheduled principal repayments during October 2019, we redeemed $100 million aggregate principal amount of our May 2023 Unsecured Notes and had drawn net borrowings of $200 million under our 2023 Revolving Credit Facility primarily used for the payment of interest due in October 2019 and other short-term capital needs.

~~Refinancing~~ - In March and May 2019, we accessed the credit markets and completed a series of transactions, whereby we extended $3,000 million in aggregate maturities of certain debt obligations due to mature in December 2021 through May 2023, out to January 2027 through May 2029.

On March 8, 2019, we issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of August 2027 Secured Notes in a private placement. A portion of the net proceeds of the January 2027 Unsecured Notes and August 2027 Secured Notes were used to: (i) repurchase the remaining $700 million outstanding principal amount of December 2021 Unsecured Notes, (ii) repurchase $584 million of May 2023 Unsecured Notes, (iii) repurchase $216 million of March 2023 Unsecured Notes and (iv) pay all fees and expenses associated with these transactions.

On May 23, 2019, we issued: (i) $750 million aggregate principal amount of January 2028 Unsecured Notes and (ii) $750 million aggregate principal amount of May 2029 Unsecured Notes in a private placement. The net proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions.

~~Maturities and mandatory payments~~ of our debt obligations as of ~~September 30, 2019 compared with those as~~May 7, 2020, the date of ~~December 31, 2018~~this filing, were as ~~follows:~~follows and reflects repurchases of our senior unsecured notes in the open market of $8 million, in aggregate, in April 2020:

(in millions) September 30,
2019
December 31,
2018
2019 $ 100

$ 228
2020 —

303
2021 203

1,003
2022 1,553

1,553
2023 3,788

6,348
2024 2,303

2,303
2025 10,632
10,632
2026 - 2029 5,262

2,262
Gross maturities $ 23,841
$ 24,632



(in millions)
2020		2021		2022		2023		2024		2025		2026		2027		2028		2029		2030		Total
$	—	$	—	$	1,553	$	2,443	$	2,303	$	10,632	$	1,500	$	2,250	$	2,012	$	750	$	1,250	$	24,693

~~During October 2019, we redeemed $100 million aggregate principal amount of~~See Note 10, "FINANCING ARRANGEMENTS" to our ~~outstanding May 2023 Unsecured Notes~~audited Consolidated Financial Statements and ~~had drawn net borrowings of $200 million under our 2023 Revolving Credit Facility primarily used~~“Management's Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt” for ~~the payment of interest due in October 2019 and other short-term capital needs. These transactions are not reflected in the table above.~~further details.

Senior Secured Credit Facilities

Agreement”) with a syndicate of financial institutions and investors as lenders. As of January 1, 2018, the Third Amended Credit Agreement, as amended, provided for: (i) $1,500 million of revolving credit facilities, which included a sublimit for the issuance of standby and commercial letters of credit and a sublimit for swing line loans and (ii) a series of tranche B term loans maturing on April 1, 2022 (the "Series F Tranche B Term Loan Facility").

~~On June 1, 2018, the Company entered into a Restatement Agreement in respect of a Fourth Amended and Restated Credit and Guaranty Agreement (the “Restated Credit Agreement”).~~

~~On November 27, 2018, the Company entered into the First Incremental Amendment to the~~The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which ~~provided~~matures on the ~~November~~earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the “June 2025 Term Loan B ~~Facility of $1,500 million.~~

~~As of September 30, 2019,~~Facility”) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company ~~had no outstanding borrowings, $170 million of issued~~ and ~~outstanding letters of credit and remaining availability of $1,055 million~~BHA are borrowers under ~~its~~the 2023 Revolving Credit ~~Facility.~~Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.

Current Description of Senior Secured Credit Facilities

Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar

deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.

As of ~~September 30, 2019,~~March 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were ~~5.04%~~3.61% and ~~4.79%~~3.36% per annum, respectively.

The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings. As of ~~September 30, 2019,~~March 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was ~~5.04%~~3.36% per annum. As of March 31, 2020, the Company had no outstanding borrowings, $168 million of issued and outstanding letters of credit and remaining availability of $1,057 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.

Senior Secured Notes

~~5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions~~

On March 8, 2019, we issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of August 2027 Secured Notes, respectively, in a private placement, a portion of the net proceeds of which, and cash on hand, were used to: (i) repurchase $584 million of May 2023 Unsecured Notes, (ii) repurchase $518 million of December 2021 Unsecured Notes, (iii) repurchase $216 million of March 2023 Unsecured Notes and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.

The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. We may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, we may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.

Senior Unsecured Notes

The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of ~~$2,628~~$2,562 million and total liabilities of ~~$1,077~~$1,034 million as of ~~September 30, 2019,~~March 31, 2020, and revenues of ~~$1,071~~$329 million and operating income of ~~$93~~$21 million for the ~~nine~~three months ended ~~September 30, 2019.~~March 31, 2020.

~~8.50% Senior Unsecured Notes due 2027 - March 2019 Refinancing Transactions~~

As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as the Company's existing January 2027 Unsecured Notes.

~~7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions~~

On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of January 2028 Unsecured Notes and (ii) $750 million aggregate principal amount of May 2029 Unsecured Notes, respectively, in a private placement, the net proceeds of which, and cash on hand, were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions. Interest on the January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30.

Covenant Compliance

Any inability to comply with the ~~financial maintenance covenant~~covenants under the terms of our Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant

additional costs. In addition, the lenders under our Restated Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.

During 2017 ~~2018 and~~ through the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, the Company completed several actions which included using cash flows from operations to repay debt and refinancing debt with ~~near term~~near-term maturities. These actions have reduced the Company’s debt balance and positively affected the Company’s ability to comply with the financial maintenance covenant. As of ~~September 30, 2019,~~March 31, 2020, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast as adjusted for the ~~next twelve months from~~potential impacts of the ~~date of issuance of this Form 10-Q,~~COVID-19 pandemic, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations ~~over that same period.~~for at least the twelve months following the date of issuance of this Form 10-Q.

The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company’s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.

Weighted Average Interest Rate

The weighted average stated rate of interest of the Company's outstanding debt as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 was ~~6.39%~~6.01% and ~~6.23%~~6.21%, respectively.

See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.

Credit Ratings

As of ~~November 4, 2019,~~May 7, 2020, the credit ratings and outlook from Moody's, Standard & Poor's and Fitch for certain outstanding obligations of the Company were as follows:



Rating Agency	Corporate Rating	Senior Secured Rating	Senior Unsecured Rating	Outlook
Moody’s	B2	Ba2	B3	Stable
Standard & Poor’s	BB+	~~BB-~~BB	B-B	Stable
Fitch	B	BB	B	Stable

Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.

Future Cash Requirements

A substantial portion of our cash requirements for the remainder of ~~2019~~2020 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring and integration, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions.

In addition to our working capital requirements, as of ~~September 30, 2019,~~March 31, 2020, we expect our primary cash requirements during the remainder of ~~2019~~2020 to be as follows:

•

Debt service—We expect to make principal and interest payments of approximately ~~$561~~$1,164 million during the remainder of ~~2019, which includes the $100 million principal payment of our May 2023 Unsecured Notes paid in October 2019.~~2020. As a result of prepayments and a series of refinancing transactions we have reduced and extended the maturities of a substantial portion of our long-term debt. As of the date of this filing, there are no scheduled principal repayments of our debt obligations through ~~2021 are approximately $203 million.~~2021. We may elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay amounts under our 2023 Revolving Credit Facility to meet business needs;


•	IT Infrastructure Investment—We expect to make payments of approximately ~~$30~~$35 million for licensing, maintenance and other costs associated with our IT infrastructure improvement projects during the remainder of ~~2019;~~2020;


•	Capital expenditures—We expect to make payments of approximately ~~$85~~$200 million for property, plant and equipment during the remainder of ~~2019;~~2020;


•	Contingent consideration payments—We expect to make contingent consideration and other approval/sales-based milestone payments of approximately ~~$10~~$30 million during the remainder of ~~2019;~~2020;


•	Restructuring and integration payments—We expect to make payments of approximately $4$6 million during the remainder of ~~2019~~2020 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through ~~September 30, 2019;~~March 31, 2020; and


•	Benefit obligations—We expect to make payments under our pension and postretirement obligations of approximately $3$13 million during the remainder of ~~2019.~~2020.

•

U.S. Securities Litigation Settlement—As more fully discussed in Note 18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements, in December 2019, we announced that we had agreed to resolve the U.S. Securities Litigation for $1,210 million, subject to final court approval. Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. This settlement, once approved by the court, will resolve the most significant of the Company's remaining legacy legal matters and eliminate a material uncertainty regarding our Company. As of March 31, 2020, Restricted cash includes $1,010 million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to final court

approval. On January 27, 2020 the court preliminarily approved the settlement and scheduled the final settlement approval hearing for May 27, 2020. The balance of the settlement will be paid in accordance with the payment schedule outlined in the settlement agreement.

We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate redundant processes and expenses. These cost savings programs may include, but are not limited to: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.

In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. See Note ~~19,~~18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.

OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. The following table summarizes our contractual obligations related to our long-term debt, including interest, as of ~~September 30, 2019:~~March 31, 2020:


(in millions)	Total		Remainder of 2019		2020		2021 and 2022		2023 and 2024		Thereafter		Total		Remainder of 2020		2021		2022 and 2023		2024 and 2025		Thereafter
Long-term debt obligations, including interest	$	32,634	$	561	$	1,495	$	4,661	$	8,495	$	17,422	$	33,419	$	1,164	$	1,472	$	6,774	$	15,122	$	8,887

There have been no other material changes to the contractual obligations disclosed in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Off-Balance Sheet Arrangements and Contractual Obligations” included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC on February ~~20, 2019.~~19, 2020.

OUTSTANDING SHARE DATA

Our common shares trade on the New York Stock Exchange and the Toronto Stock Exchange under the symbol “BHC”.

At ~~October 31, 2019,~~April 30, 2020, we had ~~352,431,217~~354,727,444 issued and outstanding common shares. In addition, as of ~~October 31, 2019,~~April 30, 2020, we had outstanding ~~7,165,906~~9,191,569 stock options and ~~6,103,681~~6,227,030 time-based restricted share units that each represent the right of a holder to receive one of the Company’s common shares, and ~~2,031,619~~2,287,525 performance-based restricted share units that represent the right of a holder to receive a number of the Company's common shares up to a specified maximum. A maximum of ~~4,065,209~~4,300,999 common shares could be issued upon vesting of the performance-based restricted share units outstanding.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management’s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates” included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC on February ~~20, 2019,~~19, 2020, and determined that there were no significant changes in our critical accounting policies in the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, except ~~for~~for: (i) estimates and assumptions regarding the nature, timing and extent that the COVID-19 pandemic will possibly have on the Company's operations and cash flows as disclosed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our unaudited interim Consolidated Financial Statements, (ii) the impact that the COVID-19 pandemic has on the Company’s assessment of goodwill as disclosed in Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements and (iii) recently adopted accounting guidance as discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our unaudited interim Consolidated Financial ~~Statements and the application of the derivative and hedging accounting guidance to the derivative instruments entered into during the three months ended September 30, 2019.~~

~~Derivative Instruments~~

Derivative instruments are measured at fair value at each reporting date and the accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.

The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value of the Company’s cross-currency swaps are carried as an asset or liability within the Consolidated Balance Sheets. The net change in the fair value of the Company’s cross-currency swaps are reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective. The Company uses the spot method of assessing hedge effectiveness and no portion of the cross-currency swaps were ineffective for the three and nine month periods ended September 30, 2019. The Company elects to record amounts excluded from the assessment of effectiveness in Interest expense in the Consolidated Statements of Operations. Settlements of the Company’s cross-currency swaps will be reported as investing activities in the Consolidated Statement of Cash Flows.Statements.

NEW ACCOUNTING STANDARDS

Adoption of New Accounting Guidance

Information regarding recently issued accounting guidance is contained in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" of notes to the unaudited interim Consolidated Financial Statements.

FORWARD-LOOKING STATEMENTS

Caution regarding forward-looking information and statements and “Safe-Harbor” statements under the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws:

These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our ~~products, including the Significant Seven;~~products; anticipated growth in our Ortho Dermatologics business; expected R&D and marketing ~~spend, including in connection with the promotion of the Significant Seven;~~spend; our expected primary cash and working capital requirements for ~~2019~~2020 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement (the "Restated Credit Agreement"), and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; ~~and~~ our impairment assessments, including the assumptions used therein and the results ~~thereof.~~thereof; and the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and the Company’s planned actions and responses to this pandemic.

assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the following:

the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);

actions by the FDA or other regulatory authorities with respect to our products or facilities;

our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;

any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;

any delay in the filing of any future financial statements or other filings and any default under the terms of our senior notes indentures or Restated Credit Agreement as a result of such delays;

any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;

any reductions in, or changes in the assumptions used in, our forecasts for fiscal year ~~2019~~2020 or beyond, including as a result of the impacts of COVID-19 on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;

•

our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;

our ability to retain, motivate and recruit executives and other key employees;

our ability to implement effective succession planning for our executives and key employees;

•

the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;

the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;

the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;

our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;

the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);

adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do business;

the impact of the United States-Mexico-Canada Agreement (“USMCA”) and any potential changes to other trade agreements;

the final outcome and impact of Brexit negotiations;

the trade conflict between the United States and China;

•

our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the recent filing by ~~Sandoz~~Norwich Pharmaceuticals Inc. (“Norwich”) of its ~~ANDA~~Abbreviated New Drug Application (“ANDA”) for Xifaxan^® (rifaximin) 550 mg tablets and the Company’s related lawsuit filed against Norwich in connection therewith);

our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;

the disruption of delivery of our products and the routine flow of manufactured goods;

interest rate risks associated with our floating rate debt borrowings;

our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreens;


•	~~our ability to effectively promote our own products and those of our co-promotion partners, such as Doptelet~~^® ~~(Dova Pharmaceuticals, Inc.);~~ our ability to effectively promote our own products and those of our co-promotion partners;

the acceptance and success of our new cash-pay prescription program for certain of our Ortho Dermatologics branded products;

our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;

the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;

and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of others;

the results of continuing safety and efficacy studies by industry and government agencies;

the seasonality of sales of certain of our products;


•	declines in the pricing and sales volume of certain of our products ~~or the products that we co-promote (such as Doptelet~~^®) that are distributed or marketed by third parties, over which we have no or limited control;

illegal distribution or sale of counterfeit versions of our products;

interruptions, breakdowns or breaches in our information technology systems; and

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Other than as indicated below under “— Interest Rate Risk”, and under 1A. “Risk Factors” of Part II of this Form 10-Q, there have been no material changes to our exposures to market risks as disclosed in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Quantitative and Qualitative Disclosures About Market Risks” included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC on February ~~20, 2019.~~

19, 2020.

Interest Rate Risk

As of ~~September 30, 2019,~~March 31, 2020, we had ~~$16,962~~$18,005 million and ~~$5,244~~$5,041 million principal amount of issued fixed rate debt and variable rate debt, respectively, that requires U.S. dollar repayment, as well as €1,500 million principal amount of issued fixed rate debt that requires repayment in euros. The estimated fair value of our issued fixed rate debt as of ~~September 30, 2019,~~March 31, 2020, including the foreign currency-denominated debt, ~~denominated in euros,~~ was ~~$19,745~~$19,654 million. If interest rates were to increase by 100 basis-points, the ~~estimated~~ fair value of our issued fixed rate debt ~~as of September 30, 2019~~ would decrease by approximately ~~$388~~$755 million. If interest rates were to decrease by 100 basis-points, the ~~estimated~~ fair value of our issued fixed rate debt ~~as of September 30, 2019~~ would increase by approximately ~~$261~~$667 million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates,

based on 3-month LIBOR, would have an annualized pre-tax effect of approximately ~~$52~~$50 million in our Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of our disclosure controls and procedures as of ~~September 30, 2019.~~March 31, 2020. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of ~~September 30, 2019.~~March 31, 2020.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal controls over financial reporting that occurred during the three months ended ~~September 30, 2019~~March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

For information concerning legal proceedings, reference is made to Note ~~19,~~18, "LEGAL PROCEEDINGS" of notes to the unaudited interim Consolidated Financial Statements included elsewhere in this Form 10-Q.

Item 1A. Risk Factors

~~There~~Except as set forth below, there have been no material changes to the risk factors as disclosed in Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC on February ~~20, 2019.~~19, 2020. The following risk factor sets forth are additional risks affecting the Company from those originally presented in the Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019:

Risk Relating to COVID-19

The ongoing COVID-19 pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and/or the associated economic impact of the pandemic and the reactions to it, could adversely and materially impact our business, financial condition, cash flows and results of operations.

In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread to other parts of the world, including the United States, Canada and Europe, and was declared a global pandemic by the World Health Organization on March 11, 2020. The pandemic and the rapidly evolving reaction of governments, private sector participants and the public in an effort to contain the spread of COVID-19 and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce generally, including disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, travel and elective surgery.

The extent and duration of the pandemic, the reactions of governments, private sector participants and the public to that pandemic and the associated disruption to business and commerce generally, and the extent to which these may impact our business, financial condition, cash flows and results of operations in particular, will depend on future developments which are highly uncertain and many of which are outside our control and cannot be predicted with confidence. Such developments include the ultimate geographic spread and duration of the pandemic, new information which may emerge concerning the severity of COVID-19, the effectiveness and intensity of measures to contain COVID-19 and/or address its impacts, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on our business, financial condition, cash flows and results of operations and may exacerbate other risk factors disclosed in Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020.

As a result of these factors, we may experience disruptions that could materially impact our business, financial condition, cash flows and results of operations. For example, we may experience:

•material closures or disruptions to our manufacturing sites (including Milan, Bothell, Washington USA and our two sites in China);

•lack of availability of active pharmaceutical ingredients, or API, and intermediates, or other supply chain disruptions, including for some of our key products;

•alternative working arrangements, including personnel working remotely and additional cleaning or sterilization protocols at our production facilities, which could negatively impact our business should such arrangements remain for an extended period of time;

•interruption or delays in the operations of the FDA, the EMA and other regulatory authorities, which may impact review and approval timelines for our planned trials and launches;

•delays or difficulties in enrolling patients in our clinical trials;

•delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

•diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

•interruption or postponement of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;

•limitations on employee resources that would otherwise be focused on our business and operations, such as the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;

•delays in or postponements of our clinical trial programs as a result of “stay at home” orders affecting our research facilities or the closure of such research facilities, which may impact the timing, approval and launch of the affected clinical trial programs;

•deferral of elective or elective medical procedures and of doctor and dentist visits, and reduced usage of contact lens, which may reduce demand for certain of the Company’s products, including our contact lens products and certain branded pharmaceutical products in our eye care, dermatology, GI and dentistry businesses; and

•adverse effects on the regional economies in which we operate which could reduce demand for certain of the Company’s products.

As a result of the impact of COVID-19, we have experienced delays in and postponement of our clinical trial programs and reduced demand for certain of our products due to the deferral of elective medical procedures and of doctor and dentist visits, and we expect to continue to experience those effects as a result of the pandemic, the reactions of governments, private sector participants and the public to the pandemic and the associated disruption to business and commerce generally.

Developments such as those described above, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.

As a result, we expect that our consolidated results in 2020 and possibly beyond will be negatively impacted by COVID-19 and this impact may be material. In particular, if management’s assumptions regarding the global impact of the COVID-19 pandemic are incorrect, including our expectation of the absence of a significant second wave of mandated shutdowns, stay-at-home orders and office closures in the fall, our actual results could differ materially from those described in these and other forward-looking statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no purchases of equity securities by the Company during the three months ended ~~September 30, 2019.~~March 31, 2020.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits



10.1	Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 28, 2020, originally filed as Exhibit A to the Company's Management Proxy Circular and Proxy Statement on Schedule 14A filed on March 16, 2020, which is incorporated by reference herein.†
31.1*	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certificate of the Chief Executive Officer of Bausch Health Companies Inc. pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.


†	Management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	Bausch Health Companies Inc. (Registrant)

Date: ~~November 4, 2019~~May 7, 2020	/s/ JOSEPH C. PAPA
	Joseph C. Papa Chief Executive Officer (Principal Executive Officer and Chairman of the Board)


Date: ~~November 4, 2019~~May 7, 2020	/s/ PAUL S. HERENDEEN
	Paul S. Herendeen Executive Vice President and Chief Financial Officer (Principal Financial Officer)

INDEX TO EXHIBITS



Exhibit Number	Exhibit Description
10.1	Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 28, 2020, originally filed as Exhibit A to the Company's Management Proxy Circular and Proxy Statement on Schedule 14A filed on March 16, 2020, which is incorporated by reference herein.†
31.1*	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certificate of the Chief Executive Officer of Bausch Health Companies Inc. pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.


†	Management contract or compensatory plan or arrangement.

9183



(in millions)	Bausch + Lomb/ International			Branded Rx			U.S. Diversified Products			Salix		Ortho Dermatologics		Diversified Products			Total
Balance, January 1, 2018	$	6,016		$	6,631		$	2,946		$	—	$	—	$	—		$	15,593
Impairment of the Salix and Ortho Dermatologics reporting units	—			(2,213		)	—			—		—		—			(2,213		)
Realignment of Global Solta reporting unit goodwill	(82		)	115			(33		)	—		—		—			—
Goodwill reclassified to assets held for sale and subsequently disposed	(2		)	—			—			—		—		—			(2		)
Realignment of segment goodwill	—			(4,533		)	(2,913		)	3,156		1,267		3,023			—
Impairment of the Dentistry reporting unit	—			—			—			—		—		(109		)	(109		)
Foreign exchange and other	(127		)	—			—			—		—		—			(127		)
Balance, December 31, 2018	5,805			—			—			3,156		1,267		2,914			13,142
Acquisition of certain assets of Synergy	—			—			—			3		—		—			3
Goodwill reclassified to assets held for sale (Note 4)	(18		)	—			—			—		—		—			(18		)
Foreign exchange and other	(75		)	—			—			—		—		—			(75		)
Balance, September 30, 2019	$	5,712		$	—		$	—		$	3,159	$	1,267	$	2,914		$	13,052



(in millions)
Right-of-use assets included in:
Other non-current assets	$	263
Lease liabilities included in:
Accrued and other current liabilities	$	49
Other non-current liabilities	235
Total lease liabilities	$	284



(dollars in millions)
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities	$	56
Right-of-use assets obtained in exchange for new operating lease liabilities	$	28
Weighted-average remaining lease term	8.5 years
Weighted-average discount rate	6.2		%